var title_f30_41_31376="Gastric MALT lymphoma Endosc";
var content_f30_41_31376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Gastric marginal zone (MALT) lymphoma endoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing a superficial ulceration with mucosal thickening in the incisura with surrounding erythema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John K. Kwon, MD and Harry Anastopoulus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31376=[""].join("\n");
var outline_f30_41_31376=null;
var title_f30_41_31377="Patient information: Dupuytrenâ€™s contracture (The Basics)";
var content_f30_41_31377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16651\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/19/37170\">",
"         Dupuytren's contracture",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/11/7347\">",
"         Patient information: Hand pain (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dupuytren&rsquo;s contracture (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dupuytrens-contracture-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28679209\">",
"      <span class=\"h1\">",
"       What is Dupuytren&rsquo;s contracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dupuytren&rsquo;s contracture is a condition that affects 1 or both hands. It causes the tissue under the skin on the palm to thicken. Over time, this can affect the finger muscles and how the fingers move.",
"     </p>",
"     <p>",
"      Dupuytren&rsquo;s contracture usually gets worse slowly over many years. Most often, it involves the ring finger and little finger.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28679224\">",
"      <span class=\"h1\">",
"       What are the symptoms of Dupuytren&rsquo;s contracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Early on, the tissue under the skin on the palm of the hand becomes thick. This is usually painless.",
"     </p>",
"     <p>",
"      Later on, people can have other symptoms that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hard bumps (called &ldquo;nodules&rdquo;) under the skin on the palm",
"       </li>",
"       <li>",
"        Bands of thick tissue under the skin on the palm",
"       </li>",
"       <li>",
"        Finger joint stiffness",
"       </li>",
"       <li>",
"        Trouble straightening 1 or more fingers all the way (",
"        <a class=\"graphic graphic_picture graphicRef60082 \" href=\"UTD.htm?36/19/37170\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people have mild symptoms and can use their hand without difficulty. Other people have severe symptoms and have trouble using their hand for everyday activities and tasks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28679239\">",
"      <span class=\"h1\">",
"       Is there a test for Dupuytren&rsquo;s contracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28679254\">",
"      <span class=\"h1\">",
"       How is Dupuytren&rsquo;s contracture treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dupuytren&rsquo;s contracture is treated in different ways, depending on how severe the symptoms are. Treatment can&rsquo;t stop the condition from getting worse, but it can help reduce symptoms.",
"     </p>",
"     <p>",
"      If your symptoms are mild, you can treat your condition on your own by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stretching your fingers &ndash; Place your hand on a table, palm side down. Then slowly lift your palm up, while you keep your fingers flat on the table. Hold this position for 10 to 20 seconds. Lower your hand back to the table and repeat the movement 4 more times. Do this stretch 2 times a day. Your doctor might recommend that you massage your palms with lanolin cream before you stretch.",
"       </li>",
"       <li>",
"        Avoiding a tight grip &ndash; You can cushion tool handles and other items you need to grip by putting tape on them. You can also use padded gloves when you grab or hold heavy objects.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your symptoms are severe, your doctor will talk with you about treatments to help your fingers move and straighten. All of the treatments involve removing or breaking apart the thick tissue (or bands of tissue) under the skin.",
"     </p>",
"     <p>",
"      The different treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery &ndash; A doctor can do surgery to remove or break apart the thick tissue.",
"       </li>",
"       <li>",
"        A procedure &ndash; A doctor can stick a needle in your palm to break apart the thick tissue.",
"       </li>",
"       <li>",
"        Medicine &ndash; You can get a shot of medicine in your palm. The medicine softens and breaks up the thick tissue.",
"       </li>",
"       <li>",
"        Radiation &ndash; You can get high doses of X-rays beamed into your hand.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To decide which treatment is right for you, talk with your doctor about the benefits and downsides of each option.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28679269\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=see_link\">",
"       Patient information: Hand pain (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?30/41/31377?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16651 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31377=[""].join("\n");
var outline_f30_41_31377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28679209\">",
"      What is Dupuytren&rsquo;s contracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28679224\">",
"      What are the symptoms of Dupuytren&rsquo;s contracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28679239\">",
"      Is there a test for Dupuytren&rsquo;s contracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28679254\">",
"      How is Dupuytren&rsquo;s contracture treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28679269\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16651\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/19/37170\">",
"      Dupuytren's contracture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_41_31378="Sucrose: Drug information";
var content_f30_41_31378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sucrose: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/13/43218?source=see_link\">",
"    see \"Sucrose: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13265422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sweet-Ease&reg; [OTC];",
"     </li>",
"     <li>",
"      TootSweet&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13265425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Nonopioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13266058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/13/43218?source=see_link\">",
"      see \"Sucrose: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Short-term analgesia:",
"     </b>",
"     Infants prior to vaccine administration: Oral: 2 mL of 24% solution administered 1-2 minutes prior to vaccine administration has been used; others have shown 10 mL of 25% effective in infants receiving their 2-month vaccinations (Reis, 2003). For older infants, higher concentration of solution for analgesic effect: 2 mL of 50% or 75% solution has been shown effective (Harrison, 2010; Shah, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13265444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sweet-Ease&reg; Preserved: 24% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     TootSweet&trade;: 24% (0.5 mL, 1 mL, 2 mL, 12 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, oral [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sweet-Ease Natural&reg;: 24% (15 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13265423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13265442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For single oral use only. May be administered directly into baby&rsquo;s mouth or via a pacifier dipped into solution. Do not reuse or sterilize; dispose of any remaining product after use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13265426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provide short-term analgesia in infants during immunization administration",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13265431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Bradycardia (self-limiting)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Oxygen desaturation or brief apnea in premature neonates (spontaneous resolution)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13265427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sucrose, corn, corn products, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13265428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal disorders: Patients should have a functioning gastrointestinal tract; avoid use in patients with gastrointestinal tract abnormalities (eg, esophageal atresia or tracheal esophageal fistula); while necrotizing enterocolitis (NEC) has not been reported with sucrose administration, risk:benefit assessment should be considered in patients at high risk for NEC.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates: Efficacy in unstable or extremely low birth weight, premature neonates has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Avoid use in patients at risk for aspiration; sucrose should not be used for patients requiring ongoing analgesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Storage: Concentration of some products has been shown to increase (up to 40%) when stored over a 6-month period.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13265436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exact mechanism is not known; it has been proposed that sucrose induces endogenous opioid release.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13265438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Maximum effect: 2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 3-5 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Blass EM and Hoffmeyer LB, \"Sucrose as an Analgesic for Newborn Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1991, 87(2):215-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31378/abstract-text/1987534/pubmed\" id=\"1987534\" target=\"_blank\">",
"        1987534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harrison D, Stevens B, Bueno M, et al, \"Efficacy of Sweet Solutions for Analgesia in Infants Between 1 and 12 Months of Age: A Systematic Review,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2010, 95(6):406-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31378/abstract-text/20463370/pubmed\" id=\"20463370\" target=\"_blank\">",
"        20463370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnston CC, Stremler R, Horton L, et al, \"Effect of Repeated Doses of Sucrose During Heel Stick Procedure in Preterm Neonates,\"",
"      <i>",
"       Biol Neonate",
"      </i>",
"      , 1999, 75(3):160-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31378/abstract-text/9925903/pubmed\" id=\"9925903\" target=\"_blank\">",
"        9925903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reis EC, Roth EK, Syphan JL, et al, \"Effective Pain Reduction for Multiple Immunization Injections in Young Infants,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2003, 157(11):1115-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31378/abstract-text/14609903/pubmed\" id=\"14609903\" target=\"_blank\">",
"        14609903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shah V, Taddio A, Rieder MJ, et al, \"Effectiveness and Tolerability of Pharmacologic and Combined Interventions for Reducing Injection Pain During Routine Childhood Immunizations: Systematic Review and Meta-Analyses,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2009, 31(Suppl 2):104-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31378/abstract-text/19781433/pubmed\" id=\"19781433\" target=\"_blank\">",
"        19781433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens B, Yamada J, and Ohlsson A, \"Sucrose for Analgesia in Newborn Infants Undergoing Painful Procedures,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2010, (1):CD001069.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31378/abstract-text/20091512/pubmed\" id=\"20091512\" target=\"_blank\">",
"        20091512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17089 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31378=[""].join("\n");
var outline_f30_41_31378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265422\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265425\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13266058\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265444\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265423\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265442\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265426\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265431\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265427\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265428\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265436\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265438\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17089\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17089|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/13/43218?source=related_link\">",
"      Sucrose: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_41_31379="Lymphomatoid papulosis histo 2";
var content_f30_41_31379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Wedge-shaped infiltrate of lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 195px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADDAgEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6L8XeJI/DcGns2n32oTX119khgs/K3l/KklJJkdFACxN39Kxf+E8u/wDoSvEv/f2w/wDkql+Jf/IQ8Ff9hl//AEgvK5/TrC51e78WXl74p1XSrHSrwQrHaxWvlxxCzgmZiZIHYnMjnr0xxQI3/wDhPbv/AKErxL/39sP/AJKpf+E8u/8AoSvEn/f2w/8AkquK+F15p/xI0y8vNB8ZeMIRaTCGWG7t9OSQZUFWwtuw2nnHP8J4rf8AA95can4J8P399J5t3dafbzzPtC7naNWY4GAMknpxQBrf8J5d/wDQleJf+/th/wDJVH/CeXf/AEJXiT/v7Yf/ACVUoFOxQFyD/hO7v/oSvEn/AH9sP/kql/4Tu8/6EnxL/wB/bD/5KqcClxQFyv8A8J3ef9CV4k/7+2H/AMlUf8J3ef8AQk+JP+/th/8AJVWAOcY5NY2ueJtG0RvL1C/gSf8A54q25/yGcfjTjFydoq7HFSk7JGj/AMJ1ef8AQk+Jf+/th/8AJVH/AAnV5/0JXiT/AL+2H/yVXE33xIhRf9D0i7YEcSXDLEp+g5P8qyE+IGt3xKW8FlauxCoEUyEk8dW6flXTHB1pK9rHSsHWerVj03/hOrz/AKEnxJ/39sP/AJKpkvj+4iGZfBviJB/tT6eP/bqvMtSuvEkWm3F5NrDXMkCF3gi+QMAM/LjGeKyP7a14wfaZ4ZYrWba3Kg49s9RnPGe4rSGBlJXUkUsI+564/wAS9jAP4S8QAnp+/wBP/wDkqkHxNBOP+ET1/P8A130//wCSq8ji8SXbXsUE0UMUSsWwMncB7+uKd/bqSLLGN+zzCwCuSpHH+FX/AGfIf1XuetR/E1ZGIj8K66SO32jT/wD5Kq0nj65kGY/BniJx6rNp5/ldV4a2vXG9C0cboDkMetXbjWGtVjGHCFdxJfDL+A4NEsumtmL6t2Z7MfHl2OvgrxL+Mth/8lUn/Ce3f/QleJP+/th/8lV4+3iu/tnjZXuFXOMKxOR7djWlF401+3L+attKMBhHcRFGA/3lP9KyeBqoSwk3senf8J7df9CV4k/7+2H/AMlUf8J7df8AQleJP+/th/8AJVchZeNJzbrNfaNIqnGRbTB2A9drAGtvR/Eek6xI0Njex/aR1t5v3cg/4Cev4ZrnnRqQ1aMZUZx3Rqf8J7df9CV4k/7+2H/yVR/wnt1/0JXiT/v7Yf8AyVUhXBwRzSEVkZjP+E+uv+hK8Sf9/LD/AOSqT/hPrr/oSvEv/fyw/wDkqn4pNtADf+E/uf8AoS/En/fyw/8Akqk/4WBc/wDQl+JP+/lh/wDJVOK0wrQIX/hYNx/0JfiT/v5Yf/JNJ/wsK4/6EzxJ/wB/LD/5JppWmlaYEh+Ic/8A0JniT/v5Yf8AyTU2mfEBLvXNN0y68O63pz6hK8MM9ybVo96xPLg+XO7D5Y27dcVSK1mTjHjTwR/2FJf/AEgu6BnU+IPGi6Tr8mkW+havqlzHaxXcjWZt1REkeRVBMsyEnMT9Ae1U/wDhPrr/AKErxJ/38sP/AJKqlqf/ACVPWf8AsC6d/wCj72uGjvp7TQPAcuoeIPGN9rHiizjmht9Nh0wKJPJSRxmWJQo+fjLHpQI9G/4T26/6ErxJ/wB/bD/5Ko/4T26/6ErxJ/39sP8A5KrhbO8Oo+C7XxTofifxJLENVtLKS01K3slB3XkUMiN5cAPR2wVfr3rvcUwuM/4T26/6ErxL/wB/LD/5Kpf+E8u/+hK8Sf8Af2w/+SqkApcUguRf8J5d/wDQleJf+/th/wDJVH/Cd3f/AEJXiT/v7Yf/ACVUuOadigLkH/Cd3f8A0JXiT/v7Yf8AyVR/wnd3/wBCV4k/7+2H/wAlVNilxQFyD/hO7v8A6ErxJ/39sP8A5Ko/4Tu7/wChK8Sf9/bD/wCSqnPA5OPrTDJGOrr+dAXI/wDhO7v/AKErxJ/39sP/AJKo/wCE7u/+hK8Sf9/bD/5KqGXVbCK4ED3cInPSPcNx/CqeseIbPSrcz3AzEGCFt6gBj0Bz60gNL/hPLv8A6ErxJ/39sP8A5Ko/4Ty7/wChK8Sf9/bD/wCSq5JfiBpkigobcnzPKCm7jU5HU9eMUn/CxdCW8a2uLhYnVGkJ3Z+UEAnAGQMnvQtR6nXf8J5d/wDQleJf+/th/wDJVJ/wnt3/ANCV4k/7+2H/AMlVgaR438OaxEZNO1SGZAxQsOACOuc1q2WraffmcWd3HN5D+VLsOdj+h96LgWv+E9uv+hK8Sf8Af2w/+SqP+E+uv+hK8Sf9/LD/AOSqUOjch1I+tLjPuKAG/wDCfXX/AEJXiT/v5Yf/ACVR/wAJ9df9CV4k/wC/lh/8lU7FG2gBn/Cf3P8A0JfiT/v5Yf8AyVR/wn91/wBCX4k/7+WH/wAlU/FIVoAYfiBcjr4L8Sf9/LD/AOSqX/hYFz/0JfiX/v5Yf/JVG2kK0XAP+FgXH/Ql+JP+/lh/8lUn/Cwbj/oS/Ev/AH8sP/kmjbTCtMB//Cwp/wDoTPEn/fyw/wDkmk/4WHP/ANCZ4l/7+WH/AMk1GRTStAE3/CxJv+hM8S/9/LD/AOSa1fCXi+LxHqGoWJ0nUtMurKKGZ0vfJO9JTIFKmKRx1ifOcdqwWXijwAMfELxN/wBgvTf/AEbe0Aei0UUUAcR8Sv8AkI+Cv+wy/wD6QXlcfqOgaz4o8KfEjQ/DtzaWt3f6xFBJNcsyqsJsbPzMbVJJK5XHuea7H4k/8hLwT/2GX/8ASC8rK1Lwj4b1O8kvNS8P6ReXcmN89xZRyO2AAMsVJOAAPoKBPcq+BPhlqHgf4hS6lpWqLd+H7vTIrO6iutiTiWEBYmVYo1QqEAXnnkk5pfhmP+LceFP+wTaf+iVpf+EC8H/9CpoH/guh/wDia6C1t4bS2it7WGOG3iQRxxRqFVFAwFAHAAA4AoC5IBk0oWlpwoAaBWfr2s2OhWP2rUZdinISNeXkPoo71z3ijx9YaU8lrpyi/v1OGCtiKM+jN3PsK8j1bVb7VtWNxqExuLt/lA6BR2VR/CK78NgJ1tZ6I7sPgpVPenojpvEHizxDr8b/AGR00jSz91I3JmkH+246fQVm6alvaaRNCoTzZXPmOBzIvvnJz7021kb7KsErFBt6OM4x3zViOAGV0A27hzzXqRpxguWKsjsuoLlirIyJllci3RGktuoy5yqg55pLOV47qV0Ykg8jbjAqa+8yC6lVUMkh+Xg8fh6GmpBIrM6PgS8lCpBVvSrtrc7FJeztJ9C1ZXE13NhmIJDIV3Z4NWonms7maNH3ocr1yPrg1Bp+nrBIJj5jSM29hu6rnnHp7Vo3zJe6hNNFGYI5fmjjY5IGP8mpdr2WxxztzabGK8fnJtG8MWPK9Bx3pbS0BRyh+TA4wME/hWhNFwVcHgAggfp9KkhCRKgOwZ6DOPoTVudloS720IdLghN4zShPLVckE8H0+tZdxtn1CYRgCLcflIJArYuIo3YoVCNgHbjByfQetVGtXAdQzk56DjP1pRlrdhFdUPvLeaCNWkmieFTujwOjdc//AFqtLcJd6lBNL8wTCyIcYCqMke+Tzms+ffduC7Zi4Q7e3tUTxPEpCs6DnAYfeFLkTWr1Kv3L97qskuoCZEdVdsoMgnA4zx/Wuc1O4hvdSeD7NLKUO4FEJYe4I5FakYD4Vgq5OQCOp+van2xe0RxC3zyNueTHJI6DP0q4xjDZBB8mpe0HxZ4h0iVbeKSW/iTg2N8CZFH+y/3hx65r0rw54x0jXdkUUrWt6Rza3Pytn0U9G/CvNVuC+p/aJ9itsSNN3sTnOKry20F3aalPDAZZ3uAYMY4UEZIz755rirYWnV6WfkRUo06urVn3PdWXnkc00A45Fed+F/Fdzo8iab4kmDxADZcFtxjB6ZPdfc9K9HQh0VlIZWGQQcgivIrUZUnaR5tWlKk7MjK96QrUxWmlayMyErTStTEUhFAiuVrKuhjxn4I/7Csv/pBd1tFayL0Y8Y+CP+wrL/6QXdMC1qf/ACVPWT/1BtO/9H31ce3ga/8AFvgn4QX9nZ6NqFro+mQy3NjqkjJHcB7aIAcRSDgjPK+ldjqP/JU9Z/7A2nf+j76s0eA/CH/QqaB/4Lof/iadg6mbH4S1Dwd8Lriy1O5gke48SWN3Fa2pZoLKN9QttsERYAlVx6Dr09e2xWDa+CvC1rcxXFr4a0SC4hcSRyx2ESsjA5DAhcggjOa6CkJiAdqcBQBSigYgFKcAc8Cg4AJJwB1Jrzj4qeNrbRbWGz8+6ha6R2EluoL7U5YgnjPt1xmmlcDt73U4LWN5GwETq7HAzXNXviiZ9ci020G52RmZlACJg8hiT156CvGdb+IaixljEpZLlkkiUf6vG7AJzyoYkZ5rlhcaxd3t5dalM1jqJ3xyKAyxrgYJcjP+yQeh609FsUoN7nr0/wAQb4+PbXSIlja2kUuxKnJUrwQx4+9xiovEPxD0yK5a2uLkxSxzeUG2sFZjzjK84HGSOteY+DrsyXp1HUZ5mnjt3KMcEOyKOAf1I79eKw/E9gkfiO8nhmlaOQfaY9soZUyv165HX0pa2uWoK5qf8JJdWHi2bVGnkuC8rZtZycyrliuW6AjOAPQ1ykd/eXt5d6pd6hcpK02ZUWYgjJ4UDOWAHHHStLUtKhtoUugyG3ZFllRAS6ll9c8jIzVGW1ku7GL7LGfOI2u0g2kZAPHb2/Kp1NUkh15YJeS3dy0dvH5m2WNkkx5Z/iCjJySeo65rbTQ9S1cCLw/pt3JoiJ5ssqkEs2OTJIMZJOflJ4rPjFnNarHJpjWd1EAyzIW2zIoyyuezH+8OMcYrp/DDazol4q20scSySZn05jvCR43KxTr3P600JorziPTfDy6FaX0fm30DTXUzR42hPuwL/tYH68mtzwNrkmh+BLpWna33zloBLISWCAbz65HHHTtXHavcrL4nkntnWWIOyiV1O4r/AHmHUDnj6Vc1W7/tW30a3mYSR2KyOWVRvLM2SC2cHPFFxON0ep+EPGkd1c29rZNK8s0UzsGYFWYDO4enf0FdRoPja2vLfMxNrJH8hErBWds8YTqcjnPSvH9Du4YrzUFaCVmv4GtF2x/MN3QHHofTvUfhe3ZNe0+2NwPtLssA89GVyFHRcg9AO2M5qkS4LU+kLTWEkhEpkVkOMZ4OK04biOUDacE+teFeIvFtxZ3Ooafa252QOgMm7BiIGSV49P5V1/hHX21KXbt8nhnC+YGyoOASOuT3GOOKWlzNxaVz03bSbazjfC2VDI42t0B7/StGCaO4jDRsCKTTRNxCtNK1MRmkK0hkJFNK1MRTcUAQlaay1OV5phHXNMRAVpngQY+Ifib/ALBem/8Ao29qwRUPgcY+IniX/sFab/6OvaYz0GiiikBxPxJ/5CXgn/sNP/6QXlT1B8Sf+Ql4K/7DL/8ApBeVPTJYvejvRRnAOSAOuTQAMyopZyFUDJLHAA968m8f+PheCbS9DnaO1I2z3icF+eVQ+nv3q34+8UNq1nPp+hOTp8bKL68XgMpYKUjJ+915PauX1jRbN4pQkaooCLGVPzZXP3vrxmvUweGhFqdb5L/M9TCYZJ881r2I7jTLSFFiWNwuwrvVuox970z3rJt7KR71S6pIq879wwy9jj3/AJ1t6bautjBbztvaJdrNnIGeg9qeLJIllRdykdi33j7mvSVXlur3O7m01ZDHuLp5bJsUEMuMk57Va2ZidcOUI28fLj6H+tTwRKybEVMNg5UccDnPp7VYljWaLC/u2XHzKc5Gf/11i6mpjOzKUiMHLOr7FUDei84PHWkjlLfezjOBubn61ccBnYtzztwnUiqr7IVE4iXI4YZ5ye3tQncFLZDkZpBjLAMSFYjG0DvQFW5UIUKDt36dQTTtxaBUIj3I2GAJAJPehSPLjCtjoSGbt/LNGpLstiPLuxG1BtJP07fiKRVi+RGLDB4OOWpIguSH2OynPzMcsPUCiYPtJ2yln6AjpVW6DIzueU5wyoD87fLz/UkcUKGjhdk+6eFBBIOfX/Chc+aUnVgzrjHoB0PsakKsnzODtBz8oJy3TOKYehI8PygQvtZTkknGc+1Upod5UoBlcnnoT6HParJfKR4Xbk8sfT196keJVJbd8uMMTkfj796lNoS0dzJWxliaSRUd2kJ+YdvUD6UZa3ALhyuCWwMnpx+PatJERQwL5wNw3H1681HcEMp3Lx1Cg4yQOn86vnfUuyb8jKt1mn8yM7lLIcsB8yj1GenpU1kIreJba1WVHXfudnznuMVdEMarJs+YbCfkGCV9Oe9JDDHFCZSwCffZvSrckyXLQytRe5luYjsL5i2k9B17mun8I+KZ/DNxFZX0n2jS3AJVSWMBPdPUeo/KqSqhVd33QN2cdR61n3rQx20r3KmRRzGSMYY8DNROMasfZyWgK1SPJNHvdvPDdW8dxayJNBIu5JEOQw9qeRXh3gjxjJoFxNHPL9o0zfiVEOQp7yR/1HevcLeaK5t4p7dxJDKodHHRgehrwsThpYeVnt0Z5teg6MrdAIppFSkUhFcxzkJFY+oDHjDwR/2FZf8A033dbZFY2pD/AIrDwP8A9haX/wBN93TAm1H/AJKnrX/YG07/ANH31adZmo/8lT1n/sC6d/6Pvq0QaYmP/Gim5pwoAXvWfq2px2ETE/NJgkCnX19HbLgHfKTtWNTyxNcRqI1i58SJZPYPKzQOzM7bYQeqqze5wK0p0+bVib7DtT8RTXbxQWPmSSykhFHIZsZA9uh615l441e71fS106Oza6vJA7Q5TKrjGHJ7ZyR/+uu+1fUPD2j2N5Pd6feafqflsktpbOWQOVIJDD+EjIBGDg9K8/h0XVbzT3t1uj/YZtFYxId0V0fviJWJ3LImACf9npVu3QqK6s8917RGj1VrbSFlkmgtgbnYpIjIxkAc+o56Zq74QutNl06K11m6vorxWeSHM21ZspgRueoGOM9uPaupGl6NcaXdva3clxKQgVpkLTRMSM4x1KMACx45GK5i58LHT7V9TuHimYs4lHm7yzL/ABr7Env0xnpWTi+hsmmM0iw1pLJtTsHWwt1k/dbkyhTOMjPp09DnrWvf21nBaT311rKvLHZcHyiiOOBtGfvbjwTwAaztW1CbTGhshdXEemiJbgpNArvOCThgM4GAx6nnritqxvLfXvDUGm3Kw2tr5zW6SPEXcg84Unpn72DnkHFCt0Btj/DjWEmkS7LS4k0OzLJMl64UIxXhQ6/eBPIxz2rGe/tNT0/TtHs9Km0yyM5uBKY2lJABO1AOSCQcnPANZVta3UtzJo93eKdKs5gf3L5VznGFHViR+RPavQL64t30dVs7mMLJOn2RI22BkGRwAdyMFB3MDjkdaSuxt2OfFzD5HDBUtlTypSwcDcR8mGxuK8DA9KsXlreRyxXV35CmW38s3VxKfNI4+4mM8EkEnOCRnFR3lsLIXdtLax29nblTFeWSCTz8DBjViQWUHgkDPUnrWlZXN7d+HZxqtpbskFg3kzGJo5BKSf3ZOcE8j5RgkEnnFAbalHRLuJru3tr21sJZJkYvcTEYES/wMeMOewJGcVkAWFv50lk000IY+TAyhwijI3EjrycY/WtG80lltr+CSIyR2aLNdHfkWyTAANsH38McFSeOKl0W2Sw02OS4ngkuSxb7PPw0EMY+UAdDnOcLnpRZjuYuhXxske3voZDmTAlkkdQgOR93vg4PXtU9hNLaX25pA00cg8lGcgtjq+O2Rjv9a6uCxQ3k0cdrFKUhWUyy/OqA45JJGWyoyO2elLe21iupM0+nW8iRx+cW3bUMYGCy4/iPTn0Jx0osHPdnIz3AuLqdprlZCZvOKlsEEgAnJ53e1esfDSygsRLeYH2iXEbRoT8q9cHP8R4zzXC6roMItorrR7NvMuGP+j+Yz4+UFTk8gYI/rTtOe+0Nmdr1vN+RpVikDcsPl6cHOOmc8U9hS95WR7FrGrw21zCtw8aAoWRS4UE+hzwvTv1q/omoRxpAImzvUMMDgA5xmvCPE0N/dsdNe2dbp503ZY4wSOWq/pPiXUrSBrXQ5o5Wgkci4kUt5wX5TGgIG3B7ntTuZunpofSVndR3UeVI3DqKnxXnXgjVJNQsopWdBch9snlNlQ2Mkfzrv7ScTKVYjzF4PvUOPVEbaEjCkIqQikxUgRMuRTWWpcUhFMCErVbwUMfEbxL/ANgrTf8A0dfVdNVPBn/JRvEv/YK03/0dfUxnfUUUUgOI+JX/ACEfBX/YZf8A9ILyps1D8S/+Qj4K/wCw0/8A6QXlYPi3xXaeGPsf2yC4lN0zBfKjLY2jJzirhCU3yxV2Cg5ytHcv+I/ENl4ftopb7zXkmfy4YIELySNjOAo9u9cL4k8R23iybT9Jge/tbGRmGoARmNkfbmONm7ZPWqPheCbU9RuvE19LL59xJLGIZhzbpkbNo7HA59jXUb3kYxiAJMw5Gf8AWEdPxxXfGnCg+8l+D/4H5noQoxpvuznrXTI9P082GRNYbdqh+G3H72e2DwfrUM4WELFKDnlR9fStWaJl8wquXDblHXHrVO0sWu3JKsE+YsANwx61tGpf3pM6W9LkMNuqxbyuELDpnn2qOWCNpmDswZBuLHoB2H1q1cQzo8kVu0kUXTk88fX8aryhhKdsgJIyxHPmHsQaqMru9xX6EUrhYcjBVmAyAcde/sajRnWRlOQV+8AOCPQY6U6VwsSPLIZCPlUA4GCegHTNII5Iztw8TZ3Bc4OT3+larVD+FaksLqhchBNG/VDkYpHSJBJEqAR5xtY9D/hxTiAkSsuUCnKqByxJ7fnVW5dFGFPyn5Qd3GPX86aV3chakjqEtw4kAUfLvI+U8/y5HWq6wiUIEJ2kEMnXPcE1HI6y3ASaEeUqqVfd3HPHt05pzzZk3QqyuxCOucKvfluapXNOUsoUb5Svy5XgcH3YflUKWx2DBO1uTycn6fzpYZd8pRFJQYBYv/npVhpXDhWjIPVGwCDT1Rm207DfKE/mLtJBALbh05zyRzn270pSMXS7ZGA9QTz9P84p0TNlmVWjYtyHGQR9B2pGMazZVwwxghRggZwCf61NwuwkiUNuBctjhVOAwx0P+HtVOZmd1UFdh4wy8oABwy98561cdTIMyKoyPlxxk5qLyyMSMcls4JP3WH8xQmVEljVcGNlAJ+VkPQY9PY02W3UukyIchsncc/kO5/limoGVDvUquQrlT0z049KuWrp9mBbDdUGeduO4/wDr0pNrUV7a3IUhDOWMe2Qt8wbvSzxxqyoyjLkjHUEemKmSRRIqBiqrzu65NIp/eZ2jd0B/XrU3d7skpPC6S9MKOMHgZ9qq6kJJrO4WLcGkQKqgZJyRwfar1w4H38leoA5I+vpU1rGXO7aAg5+bjB9q0UuX3mF7O6MxNMjg02GyRoY/MAjd8Y+TO5tp9etdN8NNeWy1Gfw/dO6WrMX09pupGeVz6elUJYy87SbQ0nl7AoAwPoPf+lLe6BbXlncXeqTMJoodyeTn9xgZ+UDkkmsajjVi4VOv5jlapFxmeu0hrm/h9r8XiDw5by+Yz3duqw3O8YO8Dr9DXSmvFnBwk4y3R5U4OEnFjCKxNT/5G/wP/wBhaX/033dbhGaxNUH/ABV/gf8A7C0v/pvu6kkfqZ/4unrP/YG07/0fe1oZrN1YgfFLWSTgf2Np/wD6PvauySpFEZJDtQDJJqkJk4rF16/u0SS302JpLngADqSemOw+pqib281fUJLeyWSK1jTMk7KQisei+5I9OnetDSrZNNF+Y7jzvMYS75JNzM2OQfRfQCtVHk1lv2IvfY56403UrdFvr/7NCDtSX96cR+rjPPGAcZ60678fJLbyWWh2815qhQRxuQFjEx9c8nA+c8Yx3qPxxqslsbTNzLBMZF2+XF5iouRliuDnGR+lcPpmj3Gi3wkjvYog86iMtbt5mOpAJOWVyOWPIyQMVT9/4hpJambr/n2VjPHqSJLdeVNd3lyYiFcFivmgLwf4RzWPa6lPo+n215eBWjktGFtDBcKiKR3weQD3f0zXU65qeqyTXUFxYG3SPc4WNCYXkkIwrMMhOMfL17VxXiq50rSNancW8NxrJhW3MsOI4ElC4w0bHJwAPk6E9aT01LTOzN1qEukQfY5FvpXtldmgfZHZgHJjIxknDHP0z6GvLdXmSyN9pdxdSXNjGiS2sccndlB2E9lGST+B6V0nhhprE64NWnuLrVBunbYdu35s7iOgXGORxg4ArDsdZuZvF2lXmh29utxFJjyA+DuJGSQx+6V46881EnsaRVjZGkQ6zd21zZW0DwXJhTTg0gAchQrdBzIpX5sjn8qsWukTjXriwiZv7Vs5AmWJ/eOhIIEf3dvJwcY44JORWvp9jYS+IdQtrfMJspyI3twQIZP9YZto74O3IPQDg1B4cK6l4zgur+6vUnuZFt9SkimKpc7RuJSQdMBSxZeOSM807C5jjJtCvNY1+I4VXhkWN/s5BCuCeTjueeMc9vSutnU/8JCoFymn3FpEsjw26DzrOPIBljTAO88ZU9uagh0uz8ParcvDeXbRrcNf6f5jN5crFhgygDgDgDksS3arGp+KIL3xFql/4khl+zWshJuILT98QyBVR3OCqn5hz6A4zipSG5XZDFq81w95ZeIbWW68RwP9ohu3I+SBPmd3UdWYYDDqOKpQTXCWmoQre6jNoqFZZSzpcSKMcMoDDGegYngdu1bvifwdqug+FT4qt5bfUoZ5A8Mdm4EMFq+DGZJGG6RVyBwPcms2WK+0y8sDHEtlKkDvcWlwBJCEJYKWyP3pJyRgDaWGaW4Jqx0Emo6ZeaTeXujWV1BqLxWtrc6bJZ+dAd5GJVKsC3K5+Y/UHNQGJbqU32oa9ctr0N0IIbb7OkDPAVIKuCCsWNpGQePqareEprCH+yrC/uZbi0uZfMuEQhkwkbb3dl5UqQrHnucDmues9OKL/aUeuJcW7tJalbR33RtgkbCw+ZAMEE9S2ODTu7Bomauv3mmDR7mG0mt49XgvFRY7qYojQNl/lUjDdMbgefxrorWykudFN5qUl4s7MyNE0EbQvbMwZjgHHBGF64A5Fc/caX5tjYzW7Wv2doo1uY3yZYnVsxTbTwocqOhIzweKfqct5drDbXDPAlwoSXJ3LaPhvnKHnkBuhI5GM00uoD5rm3t1t4U229xKWKK8+PtEeflKkcEN3/GsTxDe/wBk+LLWPZD8oE0iCQKsSkcxtxg/KcDOTWxpthdJElrKumlYgpM5IP7nduzGPcEcE98DvWvqcFrpd9v0yCSJ97bbZovNadwD94tk7cEdvTnii10HNZmTYRCPR5rr7a08szvbRxzIxGQDiQEnACqcc9fY1jaTpqWVx9s86X7PZRv8m0+bIzDhgDwpI6A84HNdDZRpJdaRNPfWt1YTtK8ywRmMJxjG0dNrEr1zjNU9e1GxtdXtS89wZIA7GMYUrxtC+x9GPTn1FJrQakd38I4hh/kVFQLG7JIGEjjJYk9cjpyP0r0FJNhWWJx5oLNs9V+tch4NjFtpf2tTEk9xGXuD/CX7HA7hMZrV0a6tL0t5MknlXDCMGVdqx8fKQD1PHNNIyludnYXcV7apPC25G/Q9xU+K5rT7ifS7lYb6Hy0l+ZmTlVbpuHsa6UcjNROPKwTExSEU40hqQI2FU/Bv/JR/Ev8A2CtN/wDR19V4iqXg3/ko/iX/ALBOm/8Ao6+pjO9ooopAeWftAQXVzpHhiGwumtLl9YIWZW2kD7FdZAPYkZGfeuKk0jUbs6Z/xOZjFbTLP5dymZhjjGR3wcHjmu++NzBLbwkScD+2iM/9uV1XKJLwq9BtJJ64rtw9RwhZdzvwqfJp3LkztyjH5D94KeT9fWoYi2I3cFJAcghyD1pio8u3zDtUYweAT9PSpY1PlplSpHTb29x+FDdjeySsMuvL8pjIzKuS+7u7E9fUVXtvLceYilYQCoK8BxjnHr1/CrkMjQu6rOpm2DOFGQuegPUdKhnPlhFUbFYcylvug84A7ngc00+gJmO8ki2Sk5ZipB3DcQfembgIvN+YIpVN2Mgfl7UX90kURiRpN0n3vm4DHqcDv7VBZmJYGQqDk/KeeP8APvXbG/LchW5iaLymtX8xiOgU8Y9eP89KW5lj8tpQSQhUDjPOOQfUUROjqViGC5Eitnr+B+tNa8+0MsSeYLiMMxUDCyDHqO/BzSb1uaLUR2aYuwIUkfIOwOagYA24KIP3ZPyoAQB05q3CkItFkWQ74OSjKQrqc84Hf3qnPJPDLMd5duAxxwFq4yvohrcpS7zeoQYi5BD+YvBPYHHb6VJcRSxxfIuQp+ZeB+Ax1+lWZd0kIlMUcTsgG1Gzggn5QepyOfwqLBEiMgZWK5LE457Aj+tbRlccpNbkIu28xp2CCDZnJHDc8D2HNXPME0cbqcc7vlOePb0rPuollgliY4kZMBxkEH1wOetJFM5sEjt2VJVHBPyknHOB2ptc2xVlZNGis7zMWuJVJ6mRRjf+HrU8MpEceVYjqAON2T29BjsapW8ryBCeFACnYcc49DUygIFLja2AzBPm46DJ/Ss5R6MhlhPM42YYZyEGCfSo3t8bY/mIBJZQ2cHGeT2FP2s0iqu+Jhw208gD1qSQpH5rgEbyACMkUk9TNvlRXkhSRAF4c9Sx4I7VKVHlKYpC+w8uVxz9O4pyzORsAOM7ST29OKdg/LtB2LjPp+tPbcTm3uiGfHmna2SF4GzOB7CjTiYwDkYKnrU7pjKE7Vx3IBx7VRuZZoGhSEhoRztx3z1pb6IuFpKxcIVpFUxjBPZf5j/GtHTo2XKyKDgZA7fSqtnGrkiZ9m31ONuec881btnkkeWSTaIgSEf1P+znr0rCpLoJRZMlusUpZV4Y4bceQf6cU+GA3NjcRO7xlyUZoztZgOwPai0ZZUnkjm+cEAxsh3Fs8jPbFXIomi3lRyzHcCehNYOTRO+xzv2mTwLq0urwQ2a6LeeTBPBHkOhA4Zex9/avUNO1Sw1SJpNNvILpFxuMThtufX0rjp7ayvNhvrWGUoCAJF3FQfY9+BWFqSPoGqf8JLowmZkwt5aLgJPAOuB/eA5BonCOIt/N+fYirSVXXr+Z6yaxNV/5G7wP/wBhaX/033dalpcR3drDcwNuimRZEJHYjIrK1T/kbvA//YWl/wDTfd15x55Fr08cHxQ1h5W2gaLp5z/23vapXkp1uWCG0VzaL888rZVR6KD3Y+g6d6Txfbef8VtSaQI0EeiWJMbZw7efebQR3HWpmmCRska4QtuwOPwA7CtoaJNbmcnqXTciKPyIAERBtTafugcY/Squ7a52LtLEnjgZ9x7+tV5JclfmBIGeP8/rTUlJU4JH8WScE+2KpRJuVb5mEsUMem290JnYkuSmwn7zb88flzXFN4g+1yTG2sN9xZCW3mkWTiLaQMocbW7HB+tdzcR+bGQ67o2YEqBtJGMYJ9PpXLq/2SPyotkVkHIjhgXIJB5BJPO7PQcgiqsCZyNzqt3quozW5t82Bs5Ga4SZo33N2b0OMkYHBHYGqOr2CvbGRreKw6yG5liWVlZdo+fB4DAkgc9eaZ8Q5zD4ltxpmo+XqN2iMoiRSPPLYCllPLEDuDk4BrM1WzXRb61urSxvbKS7CnUIJ8qtsQTkuOqggfhzUJ2NUtjUnS409tZktr2W/nvLWNWlS3CkRIRyP9nAwAvAJrO8G2fhx9RN69hLFA26QwTPnBcjyxu644/E8cYzXqNlHYL4Wgi0+8tUvNxvrF2Kq7EDd9n+X+HA7HHQ9axtC8N26NdSXWjyWejLAGaKSJWJkcbzGST+8RXYbRxkkjPFDjqClZGFaalYaXqep/2mwjtbeKYySMu97tlYBYcjA2KGAKhjzWNfSz6faXFvJfLFqdwIo2KYMdsHYFdkYwdynAAGSAQe1dPcWepxWc9q2iTalpyst7dZhURBnUiMRs2cAgjeOoCgdKTSfCVx4sntJbqzW6lgl3PrP2YQr+7+X7PjIy3v044zxQxplbTLqPRkvdO0nU45LsxmG4Goqpt4iScOjuT/ABjg9ST7A151fpqvi/xRbeFtMuTPdXUuye6luHcTHAJMnbKkHn16HGK6j46Wa6LFF/wjcDnQ5YDbXF3BDmOSfzd0mZO54Az07Z4rkvhlrmpeG7z+19I03UpJo4ZLVpYoPMQyPgRoxPAXI571m3fQaR9J65pGneHvhdH4Ji1WIXcll5NsLnJa6w4LYXP3ScjrwD7V5XeRfZJFubVrh7bTv9HkMUwSTB3ZSNnz8mScnnJHFYeq31xr/iGDW9c1iKHUJoWaG3hkd0t+FzHGVyEZvmIHt0Oa15fFUs9xHPPFI0VuqrbakbRyXt2XBjeMAIX+98w6EHiqjotSbPoGtCVLxfK0u3mnulje+tQ8arKzkFGGw/NIBj9a2rpdN1KZra7in05IoPNh06UhEKhtx2MowckDjgnJ461QsLf+1NOuZ9Mvzd2llalUaGKLfMA2BC0RUEYAyCM7hzniqei288OlNGR4iliu1l+zwMirBIOWZ9xLMiLj7vUnkUynqRJcC4Se0gt3ufIkjaaWOUlkQHCKAflBQHbtBPTvVzVF029Fr5moWt39lcQ3LWcbboZS2/zto/1mFUKQvfpXN+M9US10qwsrJXW8tFjuJLjywq3BckuDwCpGMjPuK1b/AFxdDm0TVYYHkutYthJBNIFWJdpxui2/OhGcEN9ehxSb1sPfU1oLp9T8zT7q4FvZNJ/opeFogwLHa0oI3dDkdhg8VR1Qz2dva3lvZvkFI7iKKQSywr8wAyMnaw+g5AHQ02/u/EUuraVFbgXOlXQhePUIIWfYGbYWbI+f5icpz+FbeiyaVqV1q2l6hpV5NcaKWWbV4LhI55Jt+1sRkj90p2sAORindC2M6K/urSxgh1SKRJwZA9rMylt55DN3Hy4zjsDVPw4GvtajcLb20jiMu+AzTSbjxjtwQcZ6dav6nd6tDbJYaVcyTLfqoXzrRle4m6loywJIwvJzjHHpWnodvpwa1ay+xXenQzbri9RsvPcr94PjJCk55PGAKTV9Bp2R2M99HaXsumzwXZn3BjhMeWhx0x0Bxyam0Gcx6jLZO8qtkkJIuUO47iVOOvb2xVXW7m5ks5hKJ5rlnDvAAA7nqqqw4C98fnWz4ajjaIyxy3MxlJlYSyD92Sf4e5QHI/WqaMrnR3Ecl7ZsI5QScEbm6gdQPT60trdy2xSOdco38WelJCQsa4OAOmO1OdYpUVJS2FcP8p5OO341HkwNNHSRcowYeoNLWKubCTdFOjox5jbAYnrx9BWurh1DKcg1Mlb0GncU9apeDv8Ako/iX/sE6b/6OvquH3qn4N/5KP4k/wCwTpv/AKOvqRR3tFFFIDzX435Fr4T28t/bJx9fsV1XJh8Fcld75APqfQV1XxyOLPwmSxUDWs5H/XldVx8PMmdrfKuQzd/T6muil8J34a/J8y0i5U5RAflDbTznvUpK7CAowVDbgcAEnPTvwKqqQWBlG6Y/KuM9eoz9e9SH96eNwLfeVcHnpkj0qjdruKk0UAeTOQ3II6YzjjPYZ/E1iX2spd6bmOBkXByW/gHTPH06VryBPmhKtkA5G3II9cdMdsCsfVNIllkcWqtE0m1nXnZ9FzwR/LpW1Fwv7wnHrE57zjsCSOT5WHUj+PPp7itXS2MqIVUqCNoBGcgd/f1pYvD90L1GYxC3VQSzNnd2K4Hf8e9bMVs1rOk8h3DBUKB098HsK66teFrRYkupmeSZLlNm1wedw5ViOpz6062WeGYyl8zNJjYw4YHv6MBgg/WprFltdhbywCcyxoudpLdce/8AWoR5sEcjmOZwp4yclM8E/Q+nrWcptuxpBNbiwzRxQEWxMFwCNjrzjGT0PQdsemKikmuJ0lyFV5B91On1CjsaaIm8xcMSAWb2BPenLBHuEjSlZGBwpGOfr6fSqXKncWttSMeXIp81WZgu4qWIz6H8DUUtxbrGFIkaR/m37gMY6Z6gj6U/e0oCyswdBtaQjBIHI/8A1U26svlS4kXETHaMMPTg8dPoe9aXXVjg1fXUryTyiKeTTIZZrXZtuLhELFFx8wx1Azzk+1Q3EMEUJdLrzJQV8lIxxJCR/rAx688YNWj5lvDNDYvPAsi+U7xEjzQP4ZBnB6/XmpXEbxwWvlBihAKROFWFT3GBlj7VUZuL02NXZobpohIe4u0mVVx5ax4Us/Yn+Z9c09piAXVfLkYk/L8oPcCq92YPtBTdKWd8IJSWx7HHX1I7dKEt/P5Mk0ckf0Ib3HpnNVo/eZnt1LNpKZcu07lnHzRuMc/1q4sMoeNwhXI+UHo3581RJ8l4UTDErhvr1JJ6dKsogb5I3DLsyJB19OntUttkTSWpPbKPtAjZvL2nP3cgfX0GamEgiiZSqt65XJJ5/T61C2+KIT798ajaCmM+/wCXWqcks7XEbebKiqejHhvfFZ8vMxKzRYe42w/dOGGdxUE5qs8TGZJipAHykZzk/wBKhR1inkVsuRngN1OO9WLItcTxs8m1M84rVJRVwba0RZgvhMPLSMsYtyq4X72Ov5V0SKssDQlQ+4CPcBwB1AArAn094ppBaKxi4dWB3ZPII/Gty3t3igEW4s6KN+4Z+bqFPrx/KuGs4tKxUrXuizgxIAHK7TkkfNx/Q+9HmRn5nyCeckd/ejzOVAVgrHJZh949vr3z0NDnaI5EbA/iyOGP0rnuT6iPjYWVmdfvZzVbULVNS024sp5GhhnXYZEbawH1NTyrsUMquoXjbnkZ9/1qFdxfcmGU9S54/wDr1cJNaroV0Ocv9SvfBP2C807Ub++sCwjks5/3kbRgdVOMqR29a9Ae8g1HxB8P7y0ffbz6lJJG3qDp93WLB5juyzOrDPYYwPx7Vy/gPWYf+FpaJoFiyyadDq8tzblTwhNjdiRV/wBncQfzq60Pawc0tY7vuc1enzR5uqO38aNt+KWpncV/4kljz/23vKqxzKXKkkjBJGev+etL4+z/AMLVveQF/sax4Pc+feYqssrBFYs2GzjjGcVhTXunlz3LqyHYFIXjpkct9fahJPlAyGDHA47iq4Eu6PcqiFuio33vU/59KVXB2nBUhyq7lIJx0JHqaqxJOymc5UNt6oc4AOeRjt65qne2Md3FKllLHDd3JG2STmKDBG5lXjAxn8SKk1INPanYgjGOTEcOCOgHYVwReHWr6ew26lez2gHnxzKVTcT8pC8Egeo4J+maW+hSIPiT8PtGs57IaRdXlvf3d2s0kuQVgTpJMSB8pxgDHc1reOrnUZZ7C5WHUBbWReKedlVPtW2M7N4PJUjksRtycVNfWun6i8v9kBpcE2zrJDujhboW4ODjsPerUehSp4eayEENzqO79452oCiYIXa5JPHA7VPLYrmOM0i2uNQsodTtL26trNx5UsXl/NbkgEkHpjK7hg+1ehePGtda8D/Y0nkOFhuZRNG3+rRchjnAwSB1Pf1xXMy2jT263Vxe6jZWKFXmt3jErS4bhETrk454yeMVoeLNU1C8tNWfT08u2kZImiljZpYRxuLKB06HZ+ZptCuc/q+uanaaFBYajbT6fpksML/ZpIwY7hN6gKrEgxdQDk+nIpb+WOy1a+iurC5bw5qMsItk83MMkgbDRRncUZi3U5XgZ5qWy1LxJq1tJdJ/YuIYprW0uptRVHKKcnCYcYO0HDDIIxUK+IruzuLJ/GU2n6zDpka3W1LZkdCw+Vo1QFWbBJJOBj3BqSzc8J+NtAtPtPhrURMmhxL5ca31v8ucfNHkZVh6Dr35rV8U/EG38P8Ah2z/AOET0iK4s5ZRYglfIig+UnhMfvMDPA/E1wz6TN/Yuj6vb6lPJpN3dGaO3gjWSAqo+YsW2lGIUqACBkCui8eeJZNbTw1H4ftopbB993PaTQuLpYl+XhFB+TDc+uOeKTSbA5KxvLaR7u+8Y6fcw+GLa086G0sCQs7xykRuxTpnoM/Q8CtTwrcaz8YNM125ku3sfLufsttblgkNrbsu7gKMmTIX5j1qG70zWY9I1qO01C0t4L0KbrTY0IdGX5hFGDww2/eK4BzgVpeHNR1L7RF4S0mwutIuriNZLqSGBPMKlMG43A7VXIAKE7/mwOaHHqFzAubHXtJ8PW8OoSQ2k812VigtpAbjahO6eTYoC5VFAHGeuCTWHPq9nqFylv8A2hqEeopIslnJLK2yaZT80ciBcqW6ADgcZ6mtbXYAni3UdG0qaXUdYlmJZ7VE8srEqtHDJkBQSQx3A7hjHNbGlDUYPFK3d1FYyyRgz3MskioY5BDt8yNuoIBwC3zHr2ppPoO9tzmbrwtc+Oda1CeSbT9KsroC6Sa8jcts3YZUwPvKVwQemRxzXoHh/SNB0TSlkBu9X15ttqmp3q48reu0CAHIXjoMZOOTRdafPrHh7VNUiudQvbaNVFrKZj5ioi/vBEMbeTnkg5xVS8sbmbxHpVlql4yyWlqt2EKB2udxyrFlIUhRjJxgUuVbicmyDQrfTvD+yG2tZf8ARRLafanmlkkhc/Mw+TCrnPbnmug+HlnoaeKr64e2s47wxRZZlHl/MMrsJ/i4yfeuevbtraDV47K5RFt5Y5thn2tMFUfcGMYwckEgnpyK5XUBqviSwfTdJs7TT7K5Y2yeU43LjLYlXqN5GQxxgZxVSstAV2eo+Mr3whox1PVdPvJY9dtk8jzrN2kFuZM4UnlI93IDdjWdoiQWPhuK+htJNPivVWV47mFI8IvygMwxu9csB1zTdDSDw94Wj07UNPjmn1HTJIWsbNfNijVQfnO45CZI6k8txiq11JqVxpGnavPMt/Iwjt44RB8lv8oQuQwOcjjngVMRvax14tLc3dt5W9RYtuijMu4YYcFux4YkY7Vo6Dpp02zW2knNzKrMxnbgkFsgY7KBgYFQ2Ni9mwE2V8pViBYbflA+QY7kdM+grXB2heqknndz9abIH7jnDDkdyaTzCT0PTJyOn41EcMcj5c8+xNJ5mWPTHYA0rAWz5VykaTQxyKDkEjlT/eB9aro9zYrnessan5gBj9KRHI68eoXg1IDuUq744K5xnHoaNvQLmqjrIiupyrDIqt4N/wCSj+Jf+wVpv/o6+qnpErws1nMPmXLIQcgj2q34LOfiN4l/7BWm/wDo6+rOS5XYtHf0UUVIzzT44/8AHp4S6DGtZ5/68rquEaRmSSbdIIScfOQSf930rv8A40MVh8JFV3H+2G4zj/lxu+9cBI6QXccM2Wx87Z/iOMcD0Ht+NdNFe6duDqWbgy0hHlxLKQejBz39CB24qyJFLFshVyR0wR2H1qlDvhm2B2dCvmJJIQp64wT/AI9qnDsgYIu8Y57YPckjGeOKbOyUbvQk89cOFwPKGT3AI9u/4darJdsYpg+4YLOwQEvs7nHU56DFTW7SeXny4U5wEVtx9c/j70ZaYb/IMUvJOGyVwM9e3bIpCVkRRpbyW5mtp3SLJzGVKkEcsSD0bHergKvboVkPklQ7EDAx1we4GO9QPFHKySZEM4YOJEUFm4wV69wOlSX8oaVLi1QLlORwAv0B9uxqnrsK7ejKM0JKSSxps2qZCqKfmxyceo71UgkWbBAVskjd2ZeuCex9KuX9y1hMwnZ4oWf92+07YiVBAHtnnNRSmCK4WSOYSCXKMQMgPtzuPY1cWzR6x1KC7GuUW5Z4IHA/e7NxCg4IwPyoUPHIA8bi3ZjsZ06gcZUHv9KnmmUiaTbuUYBTzNuSe4B6j2xxUFxeF4EtSFeCFmkhcnDljxj2FdEW3o0ZS096JAq+arTB0iCnK9889Of6VGkiRxHEMvy4CgYwo7k+tSwIFnBRfMXbgAH5cnrxTUYOs0ZSR++SeUXvx3HT861Wmgr3d7B57xtCJANpwFJ469N3vTpzuQtI6KUXOEXK/n6UkYh8s+dvYsu6PyxhlHoxPXPWmXMLbN+n3bruABR4wDjPKleefccEU762LjZPch8jzpI0X94SuQyyAEjHP6jrWhbRRfZWaRRAUz5rmQgA9hz7c1lXHmxyiILEGjUNIhjAYY44buMVpXEyXelxRxM7IMly4wSx747Y9c0220kupVRdyN4WIAgePCkbRGSytkdz+PWrYgBVhzGV+Xk4IB6/SqFvJsMaySEBAdoOMj2z/jWkpjZk2gjjP7392uc8/N36UTbitTLeVkPiieaI2ts/kqiZIxyef8aoXMTmdBMxIAGFY+38/arlwXCq0ZMW18pIDj8+2e361AjhDPOkMbL5bKxkBfYf7yn17VEJO9ypL3dDPnj8+UJFgGI5cgcqMcZ/WtHQ7Ey/aIop4Y5IgDslOCfz61Jp9mL9nFsVimjiMjhly0gH8PHt+VXm0/yLcyYCSTA4ttxzGQR8pY+2adWqknEyTdS0Uy9aKQhDNulWIBkxtxnof/r02ISS3QkkuHigjAKruyMkc4Pcn36daYSqJ5sqclmKBV3Ow7Dk55/pVnekltsK5jI5TA4BHTHr/wDXrgbd7m3LoTtJgvlhGRyWI+Yenbr7003Ee4AGPyW+X7xO/wB8dvemZRG/esFkIB5OfMAH8wKczM8kakAocMJFcAAj2/XNQQ7Iax+0bSjoYh0KuWyMcZ/liq+p30GlWks1yV8tVyUUYye2B3J9KS8uRZxOyjdsBY7F5Y+gFcOlvqGuzxR30bRR3UxlJVOYol4CknoT1wMe9dVGkp+9J2SLUevQINT1vxfLcWds0Wk6VGMTzR/PIf8AZDep746Vq+APB1t4e+J3g+7tr2WcPeTxbHQDGbK5Ocj/AHa1bmOCBItPtokhhUjKqvy49MjvV3QhIPH3gzeVA/tGYYGev2G6p18Q3BxhpHsTXjam33NH4gAj4qXrjH/IHsEHHQme8x+FVIXMaSMV8xChIZvl2nPHB7E0/wCJVwsXxWu4WIBl0SzKkyBBkTXh5PpVW3zKjLBt80YR1Y5UtjgMfTkVzU17iPDn8RaTKxhGUxlcYY/dLk8AjOR9asbvMmwofzH7Z3bD3xntULStJsdFTK/K4Htxg5649aQq7EuDnGD8wyoHfB9KZJMA0kiCMjc27Gw4DAHOCexPb1qK1tUivZ7pmlMsqkNDkHyz25Hsfxp7RywyOSkkuDHwpAPJI4zz7kenSrJ2QtunYbB8ikHK+owfqf1qWUNtY1hARI4xt4VAAMc5/WmeQC7zBzKskm0szcgDI5z/AAnofpU6x4nbY7Sxg/cz8w9Qzd+1Eqp5bkujqGwWABcY45HY9falcDnrq+0yzuJIZ5YLQxsoENwSr5bncvHKn+HnPBrC8QSQaZpQ1tY8W8peOWTzty4HCsy53Nkjbjrj1rqjDCZpdpikeRhwzBuRjBGenGOB0rC0+PyxeXclxZQCSYyLNdELHboWC42H+InOAOp9KdgMbZ4al+x6vH4jsIdOEgUzRo1rF5q8bCgHzkA8ZGOuTWT4huX8RahdXMwj07TLF49ISGxun8uSNnBDh04IcNx6dOprT1/T9Lsh5OmaRPd6jFOFuooSHaAyMWiIQ8YJXkdBnPYVu+Bm0nRp9Xh1AXCW2oOWW5nVvssITJMG4gKrqct/U4qH3ZS8jm7rQLOTwNHpqanerHBqrtKl1HJ50T4IEQXp8wH3RkEDI5ra8M6fZz3X9oXVzdw2cSRg+TGI3QOwwjtuLbQVC4XkZ5rmPGaaLFcW8lt4gl8VR3t1lraOczywkZZJVVSB8vQjuOKsXMN3pt60dvcJqWiIUljn8t1kkLxbXeNFz5h5HoAQO4pproGu5qeINPgj8Ra1e3+na1a/Z1LWZs28wRvuHzFgSQGyOei1pT2OseGfD63unXOoXsjwsbeW0hHmRKSGCsjcMS2ck+mazLTxDLpt9Anha1Fjb38TRXZ1SYviSJQoYkkhWK9mxnBJp2vHVtU13QUuryKzsJIBLJcCYx2sG3J81l3Z+YkADjIpp6X6CsdNp3h21W2nu/FNwq3FmEuEhtJBbJa7lz5zqhALsc5ZuOMCvPrjStHjuotLl1WCJbiCUEP5rXMspIbeHGRt6c4PoOtbWpIiTT6hpyWmq6MYodOubr7JLKbgb8vtyT5iKMHPOD3rF1fxXZaHP5Q0q5W001lEl0JlMtrHcdGjVRjZwCADjLHOKV7D3NDw54j1bQ9AttA0+BYYUmlke/vZDMVUcspiGGXnHGDjI681oaayaZJBBe3y6tqsVo0vmo+97ZXbmGPHDDncfQgDgVjaQdU1vxJ5WphX0jSHeWa+mcT3D/IrKruMAqwIOR7+ldJaQQlp9QHk+dcAmGC3XcXPK+ZlsNjkE4x75pxSeoSdjB8QW0dlp97eatpg/s67kVLm5lm88zgY27VUrg8NwPftVKO3igC3qaja3EOrWottPv4ZlSFHUnemwgEuF439c5xzVvxJ4Wu7iytYbe5M/wBujit/suzdsz3KN8q4UHJGD71vaB4f0LRfAUVv40W11p+PsVsI9zrHuwqQrweXJJPqeamW9io7GfqGtadqd1oj6Wlml4IiFiZHm8/KlRbv3AJH8XQgVteG/teo6Rdaff6dBpthIzRrbKx3RHjcOD0zyDnd3NUPC+gaNqBt4dK0qS0jtLmQG7VvLlZFzlTx84BwMtyGziu4htYFlaSKBFDHCpjhF9vXnkmmncUtNB+kWX9mabDZ72lKDBZmJ3ehGScCruWILbfkAKgnrkdjmoQPLCyfKcep9f1FJmNSg3Sbm7nkk/yA96CScNlmwy4JPTpSkjG4EMvvjmofmKsVxjvjqOabCVxLMz7IkO1iwz+VKwEqfvMZX5ccAEgE01JeQrLIGHGZO1Rx3ZvL4Q2tvNCkXzGTP3lHPA7ZPFVFuHlkk8obi2CA4K9+QfSq5QL8jtFc2k6MMB9rcHkHpj1rW8E/8lG8Tf8AYK03/wBHXtYN0ytd6VDIxDSzMwC9GCjJrd8DnPxE8S/9grTf/R17WdTZFo9BooorIo8/+LkQnfwfGTjdrLjI7f6Bd1x2s6a0bIwhjdYiGVgmNwxgjOevPFdt8U/+PvwZ/wBhl/8A0gu6o3ECzxBWAO07lycYP1rWnNxZEtHdbnDTHM5yCkjkR5Y7lIB5H6VLbv8AvgrPLE27k4wTn17Y/I9zTtThlUBCypIqncD3zkDOOmT+dVk3GKUKoi2MElKLnJwM56n0PPFdElpc9ihU9rC/Ytw5MIeQIjlSMI27Az27ZHWlkCxSOUbzBGnIKl+Sf588ZpghEO4xM6xuQ4QPzyPvZHA5pY0EbqxuPs6MPmRgOWPqe/Bz1qGjVrqiaK2EJbyxjcdwDJgg9/oR2oADuV2tNIwDq+4BSueh9TkfrSiEZZnyySEllUkKOMk465pY4V80BHwEYYjCDLk9se/rSJv3M++85rlrS5WNlcbYHB+ZRnJB7EAZFRSW8jwXEMCJ5bMY4hnDHrtP1yD+nStRdPSZFit84RvMJ6AHrjPUc55pixSrJA+7BcqSUGd+CRwfXvmr5tFYUWlexmXDWYvDGZRDF90FwQS2OeByAD3qvFKmo74oEBwCQGYkn8+aitbeS5165luHUwlWM8jfLtzkDgDOc8mrcNidJtZI7eaGecKN0mRluBwMdBz0znit0kut2VJJLQorALchDIPNDdM5wfenW0Y/eiSIKpB3uzfKF7cdcnGPxqzb26PCssjqXJCsc7V56cd6kjUzKItzCUNhSg4x6+/+egqnMlavQpurSPLLcMkL7c7cbfbaPQ+5rORtgkWNlDE/Luft3I4rT1OWKLMMSRnym6yru3t/eIpkcSzW5AChi33gcFjjn6VpTbtdlSlFbIpSFFumaWX9+FCphCV+rHv3qeK4WF1VoI2i2AnJJVwe+e9MXIuEkiPyI3HzAndjoR6fzqUqgDb1Chj8uwcKO+PQc1aS2JnO6AoZUBdlbYMRuWznvj0OPWiyyjD7S3loqHjbkSf7Ptn1qe1jieAt9rKSFSkaAgAt128ggZx17VasrK3uYvtEkj/IOCG2lG9HB6fhmiVSMbxZi4u3MAkjjuZINPY3EGPO2S8iMLzjP14qbSLlftFvMUdYUmwYnA+RuflUjqDweaa6SWYRpHhXzQIkRTl9oOTx2Ge59alAx9pliQna37pVHfAGQT19B+dc02uhtTjzQaYmm2s0NxK4ctbXKYVox+7kBO4rnqCOlaaSOEkDMxThWRWJ289yO/T8KVoL2GKyVoVW3WMfPAd2Wz8ytngD39qjACv91VQZJXuP857VhOXO7kRSSK5JR0WIxGQsFxHwGXngA/8A16eQ5UEHyznpt2+YOnHv6H1o1KBUFtJCkcQRRlHyxduxHb2/Gi3maeABY9gIOGY9iOePrxU+Zs3dcyGtIWRJSrmWIttc8Koxg59zQsskcwjkAYk5ORgAjuO2ee3FTxRqsybmAEi8yA5wR1OD1qte3D21mJjIqqny7h1bJwCPQ+n/ANamtdA5lsQStFcR7grSKrsgxxuwcHB9vX2qzaxDbHcRswMoKhGGD9c1q6Pa2QFzHZKY2K7RGzltgx29Ock471mol2nN2cqsmwFRlVBOAAe5q+a+iOZ1XqmSadp1zJePmLc4P+t3fIp/DrWy1rFB4z8EOqIsrapNuZeAf9Au+1XlxY28cMS7znGGIByepNUHu45/G/glI+capNz64sLsVzTk5a9Djq1pVHdnGfGq/tbP43WAu7WS436TbYCxlwB510Dux2+bp3rbnmgS7i8iMxHYrEJESG/uuBwCP6VZ+Jmmzan4/wBWitliaUaTpx+dNxUfaL35kORhhgEGuPsbuay8UyWdpb6vLkAzO5w24cPsByAoGCTnvV0pK1jmkrnUqfmidEYndkRk7S+c5Jz34OPpU80iRwvDGSYnYDPJ3Z5II7VcWK1lkhlmuYisrkRxTYHzgYwv0Genqagl2Nq0ojn8xIk2vEIypD4HQ/3cdcd6pNMixHFjfE8ql9gONxxkdgR69KfYIWtvNkRUhmdmWIgg4/hyp6EHNPlgMdsEURzngM8zEMBjKkcetDlZJA64SZwDKXXJc4x/ieKNw2Ejct8wYqcAKewYcY+lSmR1kklEaSSvw4Zfvpj7oP8AWkiZI1jdzuiUF3LjduUZPAH9KN5mKSCOTMqqQuQOo4xz+JpMCvqlgFNnLp1qqqz7EeNR/oykfMNvfJ4OK4fVPCN3c+IZLe8aXVdNmt9wMs3MRVh8qkDgsO5APy9c13hVY3luHjZ544/LVVyM4Occ8ZPqKztUv7+G4ghtII4klcNNJK4CiIDiPjBJJJ5HpSt0KucjpIkEE11PcRWqxGTFykjPcNhyFXGMMu35eQWyTzUUV1Daay6smp30U2IJVggBjCsc7CGJDDDfMevvXQ395eaXpEdzd2wvVhXZc3MYWNivZwjdugIz71T0vWoNS1qCLxBYXIEtp9sjhjwsLZkOxHU/NvAGcHjinfoGr1ONs/DttoN0qyo1i8N28ltbO4drVZM7XXblmUjOD0z16ZrY0Dxjreo6s+tW8Gm+TgQ/ZQm5vl48oSDnqASp4Ga2Z4zJ4nhuLTQHiiLvNJcuUcF0zhQgPcHO7t0rS8NaJbafKuj/AGizTUZd8ixooOyIDJQRjABUnuM81Nh3OO0Dwxrc+sf8SW5s7bTZZZ/Nt7y6U3GxyNzGMZ3DluuOOK66w8OaZ4aW5ufEOsabHpirgQtjYdvCNIDnoMfKvGetZGpSp4X1azltTpLXcimO7METXRMYbJQbeVJXnnjisH4jaqsK3mr6dZGSzuCbZbfyQqbtxUMJFGf3mOB3IqnaO7DVnYxeMvD+kmbSYdPu/LtkMkl3GiJbCPjMygsAEJYDoOTXNXQ0LV7nTtfhER0i8k+y3dtdLuhuDuAiLMv+rIPTIH1xXH+NtI8QRaYukC0ubqK4QT3Tx2wjEDquGQlDgAYUEE8kZr0Dwzp2p+FdF0//AITGWEw6nKYmtEUMiARjy8k9GIXnrz71Ketgasro5Bbm08C+Lr3TwiXg1B2jutPsS8j2UScoobHzOST7AV6J4fubDxD4UttVtEefDrbXEAk3NDIOBz1YfdOMisTxR4Tj1jxC/iC2bynazCOm4w7pkOAd4IwGACt6Ctzw3pNn4btxZWXmT212xnKoBuef+JuPvAe/sKcVJMG1uR+Grqa58UNM0GbUymHzFBBLjO7r1H+0P5V2F1pjzX0syRWj3KR4Rp4twP8Ad56jHJ44qnp8ay7JkdNkUiqBnOF6Ae3PetuSTc0ke4qmMKc9DjNOd0xIxtNSW30yCzleMzopMkqKR5jEk9Pc1ZjwUZvNwqjaSo4/Hv7UwqC+07nbOSqnAOPU1NCMh3kZo8cALxnPah6C6jVkDZWNQrAAbt2RjP8AXvR5iALtcKM8847/AKCmqRgbHId+MHA6eopwZsF0MaY+XDdyOn4UDI33Mkpcxhj3jP5cdamjQTQR+crMFO4o4wu7196hgj3urspcD7xX39D3xV63KTLmNWQpwFPWlJ2BFKzDNqt5OQywR24iBxgEk54+lZ81pqc9wtpaEQwu4LXaOC8Keu3ux5HfArYkLksBnk52noBntTXK6Zp0r7WknkO4Rp95ieij/PrScn06jSNCG3hAiKhXERJjbj5eMHFS+BP+Sh+Jf+wVpv8A6Ova8ug1jUbzWo7PSppbdhIWnj2Dy5CeSoHcLgc8HrXofwruzfeMvEE5IbdpWnDcFIDYmvhkA9sis5KxaPUaKKKgZwnxR5vPBf8A2GX/APSC7qLFTfFD/j98F/8AYZf/ANILumU0SzD17RF1IGQMRKF2gAcMM5wfWuTliFvdzRKCQWKlVkBJYADrzgY7GvSQK5LX0K61mzYJMydEA5YjkkdWIAzjv7V00ZOXus1oV3SfkYtpEsEUUc7PLCo8tAQNywZ/iI4OGOPwq+4RMLEIWb7vyvh0xztGR6/15qjbszTvaFolWOUuvUJJkbWIx3yc4ODV+L9whjRopAG3EzADbnnBb0x0zVSVj2HK+pEypK5MhKkoPlRyFbnqR04OASaI7JoriV4p5VIXeVbP7vAz8v8As/yxjpVm62xW8himRXc/ewD8uf19qj8uYKs8yNIFBR/4SO4OO2M+uO3NSCk7aMVW2RJsSS4yMl4gobb0zt7j37ZokiWJQMpBCMEOSfunvg9Gzx2FWSQsLrszGIxlMgh17np+f1FVreeOVWnhjItYzuOM4PqcdDzSXcz1auQTXwiiljgK3HmdN3BX0/EYrLmj/tC5jlTEEGVVohwqN+HUGp9Znjjn+zq8UKCTdnBOcDBx9ck/4VJe3H9mWZhSIgYLcgfd/vH1b+VdMVypOK1YlrcrXKufNQRIsEL7Y3fqXx90Dvn9KtW0bPCG3CBzgeYpzux97rx65+lNsZmcq0kf7wriMu25emfwPqfSn6jNCzxwIWkEKBsL/Cp6HHfv17Chp35QUtLIo2gE0U8tysfkFCjTSH5lPqP9qqkjWrSpHFvVIxncwKgsfTPUe9TTK900ThwYI2Oxc8Hp/h+tV7mJwxl3Ts3KYznCn09s11QhfcjmV9GEjRIHZQzzSD5tpx+Ge1IkBntGnYtjIAGfxI/lVNZ5rK5aK6MIXON3Qlf72PStzT2iigltbj5oCwcNjKg4xke9XUXJHQpXbuzFljDCJtpCo3z4OCeMDj61veH5srNDLGJHj+dGVsksBgqD9DmsWRLaEyRwIZYsklnB3bvYZ59qkt5VS5DxyAeWwJ78+/5U6kPaQsS27m7PatDqZYIzsUAG0AbTjJJ6nH1rQtGjW3WWc+WVdUEs3ynr19ACeg61FYTC+sjcRLG0ckZBCgllz95M+p6j2rTtp2itWt5ILeQnlEc8M46ZOOAePcV5km72Y5zfLaJqyrEIvImztHHzHpnoSe3pmsq7gkIZ0JKI4JGPvDsQalvxdqgW/uVkLHd5UUeFx75OTz3piWkUCqhLvGF8wHO4ykkk/TGentWaVjmprls77lJ0lOI4Shd2wGJ3AHHHPen3FuYRFueKZQcyFBjB7nt+NMljUwboY4Arn5gxwDzgEY5B608sYxGk0m5mO0FjzjucDuBTOnXdFKS5EdtsSFgGLcyAgj3X3qo4juDdY8yJbQqFkkcbGc9ePYfqRTtRdp9Rlt4fLlijIeWR3P7tM5+6e5xkn8O9TSoGlDJEzIoHlgHAKjuT39a1S5fU2jZ2sZ6zSZMtsGfkfOjccfiM1qaVFePbCG4nfYxLJvHCnrjHX8adIfNgaVGaQqN6hh8oH4U0FIlS4ZHVwCGIblkPr9PWobuhzlzxtbU09RZsxxFmDRKOM54xznvUOlhofF/giEBPJ/tOZ129v9Au+KpLKzhyweTYoHsV9c1a0fUPtvjHwWrxJHKmqzD5DkECwusc/jUzi+Q8yvD2aSOh1wZ+Ker/APYF0/8A9H3tcz8RY7i205NS0+WSG9g+WIxRqxdiw+Vs8lD3UdRXT61/yVPV/wDsDaf/AOj72rEsKyxlXHXoe6nHUeh96513OV7nnPh2O5S/SPxDbPdmFxMly4VI7dm+8qAnJGcZJ6CuuaV/MN5eTSRZJS1iyNvI64H3vXmse9s4dNhmgubtooUOUa5iDCUYBPzZyyg889xSWHi2yvEugzQi4RRBDvPyvIchWAPAyffp+Fb35iGaAyzFyVaTYSygbckkDI9v6VNJFMIFMZQovzKOqnB5B7jJ4qOKKFrZTdSMzIMs0ecSNweg569u9Oj+YozqqMoJIUnGD0HP/wCuqZJMrpNZv5O7ZPDuilGQyse2KVV3ouJNp2iMRkDg/wB4kcnj14qEShhcLGzI8UPlM65Xyt3QjPHXNThNrOxI2rt5IyScdc/zqbWHcVoy7blJR24UBwwP+1+NZ+q263VoIrpi0TsFjXADF88Yb+XpWiYgTnCDy8b1zgkd8e/tWfPDNbA3MMx2RrkRTQ7okfB+Zf7h5AyKQHFaprOtR6vbW6WM66XcOyJcmRRtcHGMEH0I7ZyD70+/vLS31VptUvLe31O9jQxoinzGOTtjzjBwx6gk885xVq2u9QtPDl3repxy/bZnaOG3ZneOMM2EUY5wTzketU7e0vbPWEstTiuIbYwme4v515nL8eXGnVdv8OP507hY6NLW2gkhtdNDo8uJpzISxaYnOfZQQSQODmsnULXTLXUGuZLvy2kHM4ISVgRyrkjJU84/Dp1qSK7ih8qSSZ9NtIICIbV0LKOoy56k8fdzgCsjw8z6oqnWLiKPUNVQG3hkiz5NqDtBRMfK3H3ic03oJFS5h0+30S5Ph640+0guZRJMZ12+UMZcrwDgqAQOvcVjtaPod7BqElzFBplx/olvNBIBFGcFo2BJ5dCMHcMjOc81Y+IcsF//AGXaz39tdG4V4nu7UeZcweVksXQfIMAE54Kj61W8b2emeJvhtoE/w0nEln4e8ya4tijNcx5xl3Xn5iQT6enSs5SSNIrQu+CLG+1D4fQa55AvNZlut6hQ0ZcrlcEgkNk5Yk47HBqTxPPqusX72OroIbmyGFk8veZ2dc/KW+VcnADY/KrfgXX9f1PUZbSTbc2mlaTCZiqLCjTHBXDYwQVwcdsGsDUA3ie8NzbuXaaSRVtb5gfL2nluCAp2qwDDpjp3qugl8R2vwzfU73QHtNdi2SWQCkylSw56MozgAjknrzXU2dqVuJbg7kaM7FZAMqme3oCe1ecaFqUPhrSft9xexSSSXQMVushkdoSvIQ5zLnAxn6n39M0y8h1K0iurWZZLeZRIHX+Mnkd+MdCO3Sqi9LEyWty1aoxm5ESyKoZ2X5cjH3h+NaeAJkzs2bQ2COmPQ1Bp7R+SIuBkcbgDnJ4Bqw7RtNgIrsnfHT1qJO7GtijcQRFmZCjLjkkcg56DtVdUfcF24HRVz/SrQRpAzqSAD8pC8EnqaQlcR7FwNvzMRyTTTsBWMRzJHkkI4HQ7tw5wTjmlZVLYdgM8DHcmpJHdlLPIQi8jeeeuKfB5Hzm4RcgBwhxhSOjUwKh2NEHOAqnaBu+Xd7etTQyR24kmjeWResxdvuegA/pTLhQl1GFjjkljIlA8wKAwHGR6c9RVgTyx3hR7djBNnaipkEgA7s+nWhjQCWOWdEYoJDk7SMMmOpOe1R6q84Cy22wgME3Ejge3r9KmubaS6lUmOSMMmS3mDhsfdI/wqjqrzJJ5QiKQrFt85jkFv9le/uamKu9Aegujm0uoYptPgto4ACRHtAeNs8njkZ9K2fh8CPiB4lBwD/Zem9On+uva477bdw37PZafDBEY/K+0eYC7N3YpgA7cV0XwkkuX8Z+JBeTrcyLpmmjz1UKso8y8ORjjqSPwqJxsVE9VooorMo4b4n/8f3gv/sMv/wCkF5TcU74nf8f3gv8A7DL/APpBeUgFNESIbhSFEiAl16DPHPrWDqNlJdXZZ08r5d2M5z/n2rphUN5CJYGXGSRj0yPTNaQnysW2xw9zY2yskSS+ZMzL0AzkkjGPp39qS9BYtJL97KxCNFHK5OWPscfhV2+tUhu4le4kllwdhBJUEAjDcdwcH1qO+0ry7Vot7s4jEieZ0XBHyjHbAxmuqTWjueng6rVlNhbxeTDApYh1Rg235QT656j2HtTI7cqsiTCUxKoHmSDdI/cZOMcHt0xTrMedbRpOzZRjHnvlT19e/wDOr62iPdW6M0pnZWERL/I4H38gdB7ms3vqbzqcm5C6Oq+aJcTdmIAGAOFwOKx7y0eXUZZrRnhuCNojHCk4yMDuD681vpBJFLKEZGBP3V2kAYIAOPeovINy0UkiqXJP1we2B3JB54x1ojNxd0SpJ7nOQaPdRXkUt9bgxRplEVss7HoT2AH61q3tit/bxeduOBsZgcZAA9uMEYq7D+7YxOcSGRHi3k4IGSN3cEHj0NPV5J4iWBjl3biCOFJ6ZHofwqpVZSafYW+5m+VHbq8ayqI2bBwgLHd1UY9cVBepBAAbWF8M7BUb5mwegP0rXZRGS7bUKghmxyDjrg+nuabLbSKIyrl2iKurkBNzDsR0x7DuaIz1uxXscgjGSSFkwAy8YBxx3H51HdSqCiFwXL4OOOO5q34ta2stYjit4fs6RRCRSGOH3Zzx2PbHtVW1Ks6umyRiQjbkI3cjKgdicYzXpx1ip20M1tzMZb2UmqXkUEUfnS4aNF3gkqOoJNa+jRz+UiO6PKihfm4wAMZ/pmsu6kQX04t3EIByiA4MZ/uE9fatbRLiOZVSUx5BzsYkDaevI78Gor3cLlpv5EF7bx2dwJgC1vK/OP4G7r/Ig96hnQXl+ZVhuHDbgPLjCqMYBJA+79T1rpWhSSB9oJjcBlDcEc8fy6dqkmhfy2EMxhk6guvyuR6j6CueOIsrPcGrO5n6Zatbw7kVYZN251PKkDkMpHetaNVSQPk73IOx8Egjkc/rXOW9jeQ3Eg1C5lMpHmRi3YHPb5iRj/CunskMtyLaY+XcYI343ZK8EEjis6y6p3M3LuVbmwdWhntJQ7vKCkj8BQcnHsfTNTQTF9NihmjUyY2tJjbk7vT1OMmpFZ4kePzEkQfK3owJyBUZSRRIjvvEmTs37wuew9sfr0rD1Nb8ys+mxBICIyDG4IB3b/mK9uB3AyaRAPs5VtwjDEEBeAB29+an8kS28iBnQYwCo5/+v3qSMlLV8eaFiIjQsAVZ+hGO2B/OhjctDKubYRXriFUdr5RGxcHawH3Uz2HJ69fwpgykAEabdjcoeMAccHP/ANatK+iVoZlJDrHh8Y+7j+ZqnPIGtlc+bu3YOE3ZHXkfnVJ3NISukV40KDETHyEYja/IAPOfzoeDbGxjBYkABXGAT246EVJL5srpJAZSm3DrJGFC47gdaabpEZo5VaP5tp2KSoJ549Vpl+90I44Mx5AIQnEiZBGfbPam+Hk2ePvB2MhBqM2xSOg+w3VWi5kQttySCMj1zUOibl+IHg1TgA6jMSB2P2G6qZ35WZV9acrnXawM/FPWP+wLp/8A6Pvat4xVTV/+Sp6x/wBgbT//AEfe1dXg8jNcy2PIZg6/r8WmNbia0ee0llFvJKBkRufugjByDzyOlchq+l3NvrWg2CXH+g3epre3rSoru5BzEiAjCgYAY4GeO9dTa2ktheNBPHdv5sLhrqMBlIWQsA2ejNux07Vzd3pOraKmmy28dzrNgkLtPaMoJiSNf3ZjZvmEucHb0JBq1ZMDp9US2j1N43LFtyTCOPcW3Dp9T0x2xTbiVHmkJJRt5J3Dhs9R7YrL0+1m06ztxcG91W9uIGeS4uWCmyVTu2E84PzAYyclfSttptOukuJntnH2U4mlI27GwDuHOOuOa1Tt5kNCxLKIS67AuMMzIcsD0+uO4psAMaQ/Z40ZQ3c4x7nPHqf5VNayGeSZ9xlUhdhGOnc+/r+NRzLJHJI8u5AWCL6McUuthFO/hu54EgsLqKCbeJJJpE8wBB1AXoT6VV0Ndft4TDqV3DIVOVu+TLISx4KgYA246VqQqcEBQFAJbGcA0sbKWBcnnDYXoMdM9/y/GmK46PyXtYzZTS+SW+XOGRz1B98CqUtrHFNNcsWL7CfMmOcY5B9gOtW4R5Dh5FC9gD15OMD+Wan2R4kAZtzNny2OVUYx19anYe55x8RRcXPgeSy1WZoZb4xr9paTakTlvl2qo+6MZIz05rgtU8R6vHc3dhBJpqCGKeIrnzpF2INy+aQGXIDMrfoa99lVRJGJF3OH3KhCkLkcMfwrh/iRpEGmeCdd1PS44UuYZVvpBMu2OUAhWRsYJBBGBnnaKUr9BxfQ4bxFDaW3hbwZY6pqLrqmtCWdr2wVJWRCFVY2VQN5xgZGMtk1xfg3W77wZqWoTW8V3F4piugrCUFN1t/GjREYZjnpjI6g1Pp+uRy2MD2otR9nl+1NKqmIgmPa0apnBJBIzxjAq74MutNtviJ4fvphJcQufLea8cSPav8AdSXIOCoG0d+RWXXQ2a0PVJIoIdc0G6t1msLieIfbIApBYcjDA9gxX3H6Vla1Yt4X1N49LtUInJuIRcReZFC2C0rAZG7qwI7DBFdD4ZuH1TXNfj1FFGoW966zBuJdmAF5BwRwCD3z7V2BtEd7ceQlykecNMQSuRtOPXiuh7GF7M8h8XW5s9ItvEUVpbjTLC5S5htCobzZioUxxuv/ACyBGfXPWu1+Geo/2vokE40+Gxtw+BBH8wL4Bc8DHJOfzrqbfSbS2Wf7JAImlRlZ4zggNwdvYflVexMentaaVaWTw2ca+XH5S/IgBP54P86kbd0akgEh8xQmJBtGDw5A9varls0e1UjZdu3nBxg/SopG2R7PkKhgqnGNufanSK0u6XzSEB7NjJxyMdj9aT1BFWUGASYhjeJGypzuLHvx2IzUWzazAzPhicYP3j2P4CrG5ml3LGiIWJUsAMdPTnmo3jBRkU/LnkM27Iz29BTQMgIXOJAMnrjnI/oKjkMaNN5aMwACg9M+wPf8KtMyc8OkzLu3bSCBnrnp+FNIjQPtKEB8kdACeelNMRDcvGttEqW8ahXy/mKc4I6Dv+dRieS3gdop5IVRyHWcZ57Yz0Gasxgm42qSOCTu4I9z6c1BdBC8zhl5wJMDcGGOaa7BfqNuRcLDFBfTeY7DzSRxzntjqKgiZhBJuUSRxfMwlYEJmroUJEBNceZKynycDcuOo5/Ssy0U2SzTEZeRR57BCd/bgd6a2AXT47CG3i85ZmlmuS4dyGIcDGeOACO1bHwt+yDxz4nTT5EeGPTtPQ7GyFYTXuR/9asTVroWdjcXCGTCD5dke45/3R29a1vhEwk8Wa9KI4kMmk6c58rIUkzXvODyKyqrr3Lieq0UUViWcN8Tv+P/AMF/9hp//SC8oFL8Tf8Aj/8ABf8A2GX/APSC8pKpEsWnCmilFAiJ7SF1cbFUt/EBzTL2MmFViB3ZA4HGPQ1aFBGev1FNNjTs7nPtEGdoZAcj5ztU9/p3q1HZwtDMyD95Khid2B6c4z7c9qgdJ47oFm/fMRyegGef04qxa+Y+JY38wEHER7EdM/l1rZ7bmnNJrmtocwbK40meKeQGW58gqkMMbv53zYKjHGejAnpXUyokGmI12r3BRQrsEBc5OMnHTGecVNHP++RZYJIGZeMncPcHHSqd1b6g92JI7iPy4SXhjcYyxHG5h2HIx6H1FEp89uYtycrX0I3+yQ3wspiglkUrCN43vxnIHbvgn0qpd+Usj4UzNAw3Kh+YnvuHrg8iodItWi1KG+htWW8QNbXqSg5O5twdGbsufyOKtX2nW2nok9mpSSISMkHmbRMSdzZJ7fyFU4xTsaxnyyVyBFWQMy7ZIycsAcdO+055x2FEVtGIymVMDKVDEbcA9iP5/hUEUMayrLFI2WRpEY5bfk+vcentU8eJrhswkmUEF2JbdxyM8/lxSaOl7abHK+Kv3uoiIhC0cCkZGdwJJwT7f1pLvXoltkXTIILWGSHy7lNpYyEMCoDdQeDzXRT6NZXsxu7w3IVVCzRx4B2r1weuQOSPSvO1vBANQsraSRbGeQAAqCXQH5cn19xXqYdRqxS/lMlaWnY2dY0+J5bjUbe5hlsWMYaSM8oX/wBnq2OeevFXpNOFgY9T0yUzQWh8uYNwzKR/rlH908cdeDXO6ZPFHGbW4nlh0m6P+kIqgEgE4Iz6Hr+Neo+HEEmnrA237PbKsKRhtyTrw3mbSNwzmjESlSSW6/T/ADFOTha5WkAe3xGw8zbmLd90nGRz270+NfPCBxiYDBB+baODjHfmrDw/Z3fG8ozEKo5xjsB6j+lHkM7Nvd+cEgHHA9Pr3rzLlRkmroinhFwpixz94vnBUZznJ+lRzSt9j1O9s55raeBlMkX3onZiDlT6HPTsal1SwkvLOSK3lMBfnzD0znp9O1WF0ecWohe4K28hWSZCvBZf9rsOnHeqi4pasiUkty3eQ2d3buCkTyqgcFeChxweKx7VRBJ5vmSttVcRkbsPnpkdsfzFakkscUMlsisWdNzNswCTxn39MVQuYy/lHexk3bdiR4+U+/6ZrOPYdK6VnswulWd5JonRZCxGFypVOuTnjOc81BBawiW5ulLm5un8xnMhMfGBhR2JxQWDEo5Rtwypzxx7HntUsSmGSEOVeNVOAQPmb39MCq1SsaONlYjkj3RuygZyxU54Ge5qGPzBbl3B8llCgjnHHX39aszojFmZdrY4cdz2+vbNV23xZIdUUY2JG3ynHUn1oQ1qivJIYrYeb85XBYqp5z046irHy3MTC5m2yk+WG6KR746GnIq42s6Ng5TyxkE9c4qKZhGuIiwQnojYOfr/AEp+hW78yhfp5LK7wB3IywGMkDqRg9aj0BFHxA8GOjOQdQm++QTj7DdYq5JIEhG1Vhk3DaU5cj0NUdCLt8SPBxOCq6hOGwOjfYrrj8qc17jLqX9jK52mr/8AJU9Y/wCwLp//AKPvauA1T1f/AJKprH/YF0//ANH3tXM1yI8Zi9uagu7Vbnadzh0UhQGIUk/3h3xxU9OH1pgYzNINOmhvGjtbt3YAxEHzMdGUds9OazdLlnTRbeaS2jt47nZIYLlgDGrH+M9Mcnjrziugu7KK5YSRyGGdGB8yPBPBzgjuKZcadHJGwPlmQnfmXLKW9Svp7U0xGXZKiTXFpZRN5ULIQWyo+bk7fb0FaUplFyyNJhTwAR1U/wBc1DYs1jcy2zRSR22R5MjHcpGB/F29gfSr/wBohizl/mGPkAyRmncLEMMQa0IZQhxgDoce9MhtV8sqjlC5ySx6c9B/jV1HSUBhtYHoaaZBLFuRsICdxfg8cfzpXaCxX+wsyohYMA25i3Xj0qvP+7lHlndyQQG/X/69WmlZYy0jBE3FWcD5l46Y/rSXCNBbxuAHKHOTxke/vVJvqJoqfuyp+Us3U4ABPpzXn3x6nki8ATQwxtI091EuwgkOBlgD7cZ98V6JNJ5ksJymZA25m+U7u2F9Pesfx0IW8IaxFqMkhjS2YpJBGJZFJG35QR3zQ9hLc+YvBmheHtfsdSjvddjsdSkcmzkYmOFMDP7wYxh+gxyMc9auW+jWlrp9vHrl8keneYkFzqFghYruJY9QC+OmRwMDrnNcU1nJHAzIkchy27a4PXGDj8uld1oOrNCs9ncam97o2jWMt1a+ZCU8uZ1C4UNkgbmxycdxUxSZszp/gTrUlx4s1DTZri7nlQM3nTv8jW6DCKy9d2TnOehxXvUMK28aKvyknJUA4B7D2xXzR8K9ZTUfiPYiw0y00pb+5YSeW7yN9mCBTbjJ5GVDbuDkdcV9N7dh2gc5wWbqeelXF6GU1rcjYMdu4YwSRnr+NWINwXftGG6HOcChirtuYAuU4AzwBxz70+O3xMHSZiMAMhGQoxxt9Ce/XoKbZKRahUBnjkbIUAhs4IzUNxbxsWm3hpOfYFe49M+9TJAcMzuAGHzEjr/hSTFAPk3YVDtQ8KcHmp66FFLMg3sNob7qlhwPr6/Wi4ZOEyIzjnA681KYty71JZh0GducDn+lRxK0jmOJ8OSOGPI9cnuKoQpBMSrI5+8doXgE4yaqYVm3hSyn7pT7xx1X6/WpYHEkUZQPErMcRsPnzzwR2qMjY+c8k9+567f600hMJ0CvuhYs+3ErE9x0GO9VgTsDJkc7MH1+lT3CsF270lkU5P8As56L71FJG4SQjGzuR156Z9KaEyGJjDgpEJS3OG6Benf+VE8pSNonZGWNiVZM7lB9asfZkmtmVZAoY7Qr56+g5qW2stjqs8czEIGHPyqc9Pr3p8yWo0mYmpzSQ2LKl69uZiFjdcNgkdDxxn1rf+GFs9n4x1y3lkaV49H01S7HJP76+6mq00EErtEzbvOBDJ254zx0q/8ADy3W18deIIELEJpGmrljkn99e96xqO5pE9HooorIo4b4nf8AH/4L/wCw0/8A6QXlJmp/iZY6lcr4cudJ0y41JrDUzcTQW8kSP5ZtbiLI810U/NInGc1h/avEP/Qka9/4EWH/AMk00xM1hS5rI+1+If8AoSNe/wDAiw/+SaX7X4h/6EjXv/Aiw/8AkmncVjYFLWOLzxB/0I+vf+BGn/8AyTSi98QZ/wCRH1//AMCNP/8Akmi4WLeorCqB5IwxzgnPIrJtbjbI7rAYo4yWAdhmotQ/4Sa6kTZ4N12JA3zFZ9P3Mvp/x8+tRXEHiF5FeLwVryBQCqm5sMZ/8CelbQcUtWNyklZGg+os8ixqrNIRk/Lw349u1WvtQEZMjjKthsDiudFt4pUnZ4M1oA5JH2mw7nP/AD81Ktt4k2KG8F66MEkhbqwGc/8AbzTbh0NI0opayNl47W7srq2kGYpyfNweQT1Oe3QVeltoZo0Mi+YVBCs3J5GCR7kelc1FH4mUoG8E62BzvK3ViMjtx9pq1bz+KYPl/wCEM1uRB90NcWAI/wDJmobXRlSjFfCzQvoSYgWhBMRAiKdQMcZ9MVkrm1aWWRQquxOcfMj+hPXFWBeeK+f+KH1gk9/tNj/L7TUv2nX3X954F1wkjBH2iwI/9KaFNIqFVwVnqZRjS/8A3N5mOCXO9CDhyONynqD6Z7Vy3ijw3BpkYnsHnYQkAxPjD8clPUjuPxrsZ4df8uT7N4L19WfOUe5sCnPt9pqo9l4jnuLOS48E67m3BZTHeWCYbgA4+0c8e9dVHE+zd09OxbqpPmj9xzOiaDPLBp89nbpf3l9BITb3MZSGFMYDlj1PoKZoy67b27ahZ3FulxcTi23zyDcoiBySW6Jx+ldvbw61bzSyQeCNehLtuyk+n/LxjgG6wOKztWsfEVzZypa+AdWSQI8ESveWOwI+Nzn/AEjO/qMfrzWqxyk2pbPuSq13qXfDwjMF/cpejUbE7UiVlYMjYyQfXJJOR7c1pW1qkk5IwGDAbj1UYzx9a5vwrp3irRdLmsn8G60ys2UZLmx+X8Dc+5+lbllN4itkP/FE68zccfarDH/pTXLVnHmfKwc0r2ZrfYYldnchlPG08Zb+lRykRKYo2ZtoxhzuGPTHrVVbzxAp3f8ACFeICckjNxp+MHt/x81RZvEp3Y8Fa4c8/Nc2HXOf+fmslJdWTCV37zLke+WNDtwx+cfNn379DUFw7RqWRRtbAJZuQO5ApsbeIVAz4H1w/wCz9psMdOn/AB8802Z/EclsY/8AhBdXLYJBM9hjPb/l59KpTRsqsUyNo08xFUbAXLBmGQODgg04xyO0hIUL/Djr+XpTWXxI0YDeCNayVAOLiwxx6f6TTfL8SAADwVrhA9biw/8Akmnzov20e5LEkjLucoRg5C557DHp71Xnt83C42/K/I4+Y44we2OlTRL4iXzN/gfW/mIxi4sB0/7eagNp4iZwzeDdfGw5Tbc2H6/6TTU13BVo33GSlJIfMzlRxsXgr64x1pryySxYkQEbdwbIznpz/SlSy8RozMfBmuvIerG5sMn2/wCPnpQlt4nGAfA+roqnotzYnd9f9Ip88e5XtoIqwwyy3TxoqOpQDoSx/Kp7DT4rTx34KkjUqzahKp5/6cLvNaEg8RrbFLXwXrkUp6t52n8/+TNM0TTfEt54u8MT33hvULC1sbyW4uLi4ntWUA2k8YwI5nYktIowB79qmdRSi7GFXFOa5VojV1j/AJKnq/8A2BtP/wDR97Vyqfiqz1q38f3mpWHh+/1SyudMtLcSWs1suySOW5ZgwllQ9JUIIBHWq/2nxD/0JGvf+BFh/wDJNYJnIatOFZH2nxF/0JGvf+BNh/8AJNO+1eIf+hI17/wJsP8A5JouFjWVVUkhQCepHeszVbu2trhVlaZp5B8saZ5AB6f57U0XfiH/AKEjXv8AwIsP/kmqmrP4nu7CWG08IeILS4bBSdZ9PJQg56G55+lNOzCxYtLmL7TIkreSigFfN+7JngDngdOnWuc1fxSstrdro86KouVt/Mjh8xVyuW56k8joCBtqHxBpnjPV7dIJPCeuiA5eaP7dYgSNn7o/f/KuB9eTUGm+FdbsUkUeCNbkyVdQbqwAVgMEj/SPfj6CrTiB2NpfWXlMIroMgUDeVwWIHJ445xnFaEcsUwVB+83DOCOg9awY7fWhgP4G1zYn3FWfTxg/+BNSZ8QgDb4H11cDoLmw/wDkmpfKLU3JVXzCz8xlcHHOSfUVMhWaNAV3o3r7VhRXHiWIFU8D62E6AC5sOBj/AK+acbvxQ3XwVragYPFxYZ/9KaWgGhJBNHKoBSRAcCSQfMAeoB/KqpQFCJDIAGwznjjofwyBQL7xGQQ/gfXj2/4+bD/5Jpj3PiBsEeCNfUgYG25sBj/yZp8wrHlHiz4QjWL26uLDUH02K8lEjSMQIpFJyAAMEMDn61H40+Hut3nguWWBFudcjtTplzFK2DNEki+S0O3gHgZB7dea9RkbxQzSAeEdfMbMGUNNp52Y64zc9+ntU8l14m8hY4PBWux7ccfabA59s/aaG10Grnhfwr8FXlx46XV9Xg+zx2lrEIEgzE4ZcRgsAeOVIPPOc8177dSbJInlZQfLG9OQA3vxmucTS9fs7i8m03wTrySXEqztJLeWJZnznBP2n7voO1bMlx4jkuFdvBGuFejD7RYcj/wJqk0tRO7NNbaTzF+bcOfucYH9amg3Kpb7keSSCMN+FUPt2vA8eB9fA/6+NP8A/kqke+8QMv8AyJGv7scf6Rp/H/kzU81x2LslxwVO5lIJ5H86rJ8yg7iVPKlCf84qikviQBwfBmv/ADHj/SNP4/8AJmgz+JdqY8E65uydzfaLAcY7D7T1qroVjTED7BIxUSInyDfziqrI/mCb5ST2Y8oB2B7jk1WEniENk+Ctfbjvc2Ax2/5+ajL+IyMnwPrm7H/PzYYzj/r5pqSCxbd2dMssZyAMEcofUn0ovBbxRbrp4/s0P7ySdiFHUc/0zVRW8RAEnwPrhcj/AJ+bDGe//Lz0qc3PiFo2jPgXWvLIxtM+nkEfT7TQ5oXKya+C/a9sO0ed8xbgKRjqD3NNjt9pZlRSBgMQwxwOOPaolk11V2jwPrwGAP8AX6fx9P8ASaYr+IIYVSHwTr5xnO66sOQfX/SaXOth8pNieW8eGMwxwPt2bxubp8xHPWrV4ZLe3AhhLLnBK5YgdzjrmsCBPFserRTnwXq7WwUhgbmw3g9sf6SBWwb3xB/0JGv/APgTYf8AyTSctRpE1rZxPGkssR8wnePM+8voD9PSp/BP/JRfEv8A2CtN/wDR19VH7X4g/wChH17/AMCbD/5JrR8A2erf8JXr2p6not3pVvcWVlbQrdSwO0jRyXLOQIpHAAEqdSO/pUN3GjvaKKKkYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CD30 immunostaining.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31379=[""].join("\n");
var outline_f30_41_31379=null;
var title_f30_41_31380="Ioxilan: Drug information";
var content_f30_41_31380=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ioxilan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/13/4308?source=see_link\">",
"    see \"Ioxilan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11563664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxilan&reg; 300;",
"     </li>",
"     <li>",
"      Oxilan&reg; 350",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2980446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oxilan&reg; 300;",
"     </li>",
"     <li>",
"      Oxilan&reg; 350",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iodinated Contrast Media;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Nonionic, Low Osmolality)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Coronary arteriography and left ventriculography:",
"     </b>",
"     Intra-arterial: For visualization of coronary arteries and left ventricle, ioxilan injection with a concentration of 350 mg iodine/mL is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Usual injection volumes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Left and right coronary: 2-10 mL (0.7-3.5 g iodine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Left ventricle: 25-50 mL (8.75-17.5 g iodine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Total doses should not exceed 250 mL; the injection rate of ioxilan should approximate the flow rate in the vessel injected",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cerebral arteriography:",
"     </b>",
"     Intra-arterial: For evaluation of arterial lesions of the brain, a concentration of 300 mg iodine/mL is indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recommended doses: 8-12 mL (2.4-3.6 g iodine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Total dose should not exceed 150 mL",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Use caution in severe impairment and in setting of combined renal and hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in patients with combined hepatic and renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxilan&reg; 300: 62% (50 mL, 100 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium, sodium 0.2 mg (0.01 mEq)/mL; provides organically-bound iodine 300 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxilan&reg; 350: 73% (50 mL, 100 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium, sodium 0.2 mg (0.01 mEq)/mL; provides organically-bound iodine 350 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F184065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients should be adequately hydrated prior to and following intravascular administration of ioxilan. If during administration a reaction occurs, the injection should be immediately stopped.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intra-arterial: Ioxilan 300 mgI/mL is indicated for cerebral arteriography. Ioxilan 350 mgI/mL is indicated for coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intravenous: Both products are indicated for excretory urography and contrast-enhanced computed tomographic (CECT) imaging of the head and body",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina (1%), hypertension (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4%), fever (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Bradycardia, chills, diarrhea, dizziness, hypotension, injection site hematomas, rash, urticaria, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ioxilan or any component of the formulation; ioxilan injection is not indicated for intrathecal use",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: May cause serious and potentially fatal anaphylactoid reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contrast dye/iodine hypersensitivity: Use with caution in patients with history of previous reaction to contrast dye or iodine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events: Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, especially those with concomitant renal dysfunction or when using both oral and IV contrast agents in close proximity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple myeloma: Use with caution in patients with multiple myeloma; may worsen renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma: Use with extreme caution in patients with known or suspected pheochromocytoma. Dose injected should be kept to a minimum to minimize exposure; monitor blood pressure closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; clearance is reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell disease: Use with caution in patients with sickle cell disease; may promote sickling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid disease; thyroid storm has been reported in patients with history of hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients with age-related renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration: For I.V. or intra-arterial use only.",
"     <b>",
"      [U.S. Boxed Warning]: May be fatal if given intrathecally.",
"     </b>",
"     Avoid extravasation, especially in patients with severe arterial or venous disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      In vitro",
"     </i>",
"     clotting: Clotting has been reported when blood remains in contact with syringes containing ioxilan; use of plastic syringes in place of glass syringes has been reported to decrease, but not eliminate, the likelihood of",
"     <i>",
"      in vitro",
"     </i>",
"     clotting.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Contrast Media (Non-ionic) may enhance the potential for allergic or hypersensitivity reactions to Aldesleukin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal harm was not observed in animal studies. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9732469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F184061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to and 24-48 hours after intravascular administration: Thyroid function tests, renal function tests, blood counts, serum electrolytes, and urinalysis should be monitored for and blood pressure, heart rate, electrocardiogram, and temperature should be monitored throughout the procedure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Oxilan 300 (CA);",
"     </li>",
"     <li>",
"      Oxilan 350 (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ioxilan is a nonionic, water soluble, triiodinated x-ray contrast agent for intravascular injection. Intravascular injection of a radiopaque diagnostic agent opacifies those vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion. Guidelines for Diagnostic Imaging During Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 104(3):647-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31380/abstract-text/15339791/pubmed\" id=\"15339791\" target=\"_blank\">",
"        15339791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31380/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2009, 74(4):728-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31380/abstract-text/19830793/pubmed\" id=\"19830793\" target=\"_blank\">",
"        19830793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):584-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31380/abstract-text/17692741/pubmed\" id=\"17692741\" target=\"_blank\">",
"        17692741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/41/31380/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8989 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31380=[""].join("\n");
var outline_f30_41_31380=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708951\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11563664\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980446\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184082\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184075\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184076\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962292\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962293\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184063\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184049\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184065\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184064\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174555\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184080\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184067\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184052\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299537\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184055\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184058\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184069\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184077\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9732469\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184061\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869387\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184051\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8989|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/13/4308?source=related_link\">",
"      Ioxilan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_41_31381="Grover's disease (transient and persistent acantholytic dermatosis)";
var content_f30_41_31381=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Grover's disease (transient and persistent acantholytic dermatosis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31381/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31381/contributors\">",
"     Helge Riemann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31381/contributors\">",
"     Whitney A High, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31381/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31381/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31381/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31381/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/41/31381/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1970, Ralph Grover presented a series of six patients with a pruritic papular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    papulovesicular rash upon the trunk that cleared within weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/1\">",
"     1",
"    </a>",
"    ]. Histopathologic analysis revealed a characteristic pattern of acantholysis within the epidermis, and Grover named the disease \"transient acantholytic dermatosis\". Subsequent reports described an often chronic course, but essentially identical histologic findings and the term \"transient and persistent acantholytic dermatosis\" was proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, the eponym, \"Grover's disease,\" remains in wide use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence and incidence of Grover's disease have not been firmly established. In a study from Switzerland, Grover's disease was diagnosed in just 24 of more than 30,000 skin biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is thought that Grover's disease affects chiefly white adults in the fifth decade or later, and appears to be around 1.6 to 2.1 times more common in men than in women [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Grover's disease appears less common in darker-skinned individuals, but has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of Grover's disease is unknown. Suspected triggers of disease activity include heat and sweating, sunlight, ionizing irradiation, end-stage renal",
"    <span class=\"nowrap\">",
"     disease/hemodialysis,",
"    </span>",
"    and mechanical irritation or prolonged bed rest [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some cases of Grover's disease have been associated with medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , and interleukin-4 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/1,8-15\">",
"     1,8-15",
"    </a>",
"    ]. One series of 300 patients with Grover's disease reported an association with other coexisting dermatoses including atopic dermatitis, contact dermatitis, and xerosis cutis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/5\">",
"     5",
"    </a>",
"    ]. Finally, smaller series have detailed an association with pyoderma gangrenosum, bacterial and viral infections, and occasionally malignancies were described [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/5,16\">",
"     5,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although Grover's disease may show histological similarities to Darier's disease, it does not appear to be caused by the same mutations in the ATP2A2 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/17\">",
"     17",
"    </a>",
"    ]. Grover's disease is frequently seen in association with increased sweating, whether caused by heat or bedrest. Some investigators believe the condition may be precipitated by occlusion of eccrine sweat glands, a process that may lead to miliaria as well.",
"   </p>",
"   <p>",
"    In support of this hypothesis, one study used electron microscopy to identify occlusion of the acrosyringia in three patients whose disease had definitive temporal relationship to increased perspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/18\">",
"     18",
"    </a>",
"    ]. However, in a conflicting study, occlusion of eccrine duct was noted in just 2 of 11 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/19\">",
"     19",
"    </a>",
"    ]. It is unclear if this disparity can be attributed to differences in methodology or patient selection.",
"   </p>",
"   <p>",
"    In contrast to an association with sweating, a review of biopsies read at a dermatopathology center in New York City found that Grover's disease was diagnosed four times more often in the winter months than in the summer [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/6\">",
"     6",
"    </a>",
"    ]. The authors suggested that Grover's disease might be promoted when xerotic skin is exposed to cold, dry air.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases Grover's disease affects the trunk, especially the central area of chest and back. Typically, the eruption consists of intensely pruritic, erythematous papules (",
"    <a class=\"graphic graphic_picture graphicRef76504 \" href=\"UTD.htm?37/5/37983\">",
"     picture 1",
"    </a>",
"    ). Truncal prominence is a common feature, although the limbs (particularly the proximal limbs) may be affected as well. Involvement of the face, palms, or soles is unlikely to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Often the disease is first noticed after a period of fever, or after a hospitalization with prolonged bed rest. This has prompted speculation about an etiology involving sweating or dysfunction of sweat ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Keratotic papules, papulovesicles, vesicles, and papulosquamous plaques reminiscent of psoriasis or parapsoriasis have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/5\">",
"     5",
"    </a>",
"    ]. The lesions of Grover's disease are frequently eroded and crusted.",
"   </p>",
"   <p>",
"    As would be expected, given the name \"transient and persistent acantholytic dermatosis\", the temporal course of the disease is highly variable. Patients may present with a self-limited eruption, a waxing and waning course, or a persistent recalcitrant pattern. In Colorado, a semi-arid environment, it is not uncommon to see a flare in disease activity during the drier winter months.",
"   </p>",
"   <p>",
"    Although Grover's disease is a benign condition, the associated pruritus may be severe and can have a significant impact quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Grover's disease is typically made on skin biopsy in the appropriate clinical setting. The key histopathologic feature of Grover's disease is acantholysis (",
"    <a class=\"graphic graphic_picture graphicRef56584 \" href=\"UTD.htm?10/62/11239\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]; acantholysis is the dissociation of keratinocytes from one another in the epidermis.",
"   </p>",
"   <p>",
"    A number of histologic subtypes have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Different histologic subtypes may be observed within a single biopsy specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Darier's disease is a genodermatosis caused by mutations in the keratinocyte calcium transporter gene ATP2A2. It may demonstrate clinical and histological similarities to Grover's disease. Unlike Grover's disease, Darier's disease usually presents first during puberty. Darier's disease favors intertriginous areas, and is associated with concomitant nail changes, palmar pits, and mucosal manifestations; all features lacking in Grover's disease. Darier's disease is inherited in autosomal dominant fashion and a family history of similar illness may suggest Darier's disease rather than Grover's disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H11#H11\">",
"       \"The genodermatoses\", section on 'Darier disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hailey-Hailey disease is also an autosomal dominant condition. It is caused by a mutation in the ATP2C1 gene that encodes for a membrane-bound transporter protein present on keratinocytes. Hailey-Hailey disease is characterized by recurrent blisters and crusted, vegetating erosions in intertriginous areas. As with Darier's disease, a positive family history suggests this inherited disorder rather than Grover's disease.",
"     </li>",
"     <li>",
"      Pemphigus is an autoimmune vesiculobullous disorder that may be distinguished from Grover's disease by positive direct immunofluorescence studies performed on involved skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Galli-Galli disease, the acantholytic variant of Dowling-Degos disease, is characterized by reticulated hyperpigmentation of major flexures and intertriginous areas [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published randomized clinical trials of therapies for Grover's disease. Nearly all evidence for therapies comes from case series, case reports, and clinical experience.",
"   </p>",
"   <p>",
"    Since heat and sweating may be triggers for Grover's disease, patients should be advised to avoid activities that expose them to such triggers whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/5,8,11\">",
"     5,8,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High potency topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ), moisturizers, and emollients are typically recommended as first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Limited data suggest topical corticosteroids improve the condition in approximately 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/4\">",
"     4",
"    </a>",
"    ]. Antihistamines may be helpful for symptomatic relief of itching [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/3\">",
"     3",
"    </a>",
"    ]. Many dermatologists believe sedating and semisedating antihistamines, if tolerated, possess superior antipruritic activity, however the evidence supporting this is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=see_link&amp;anchor=H8354417#H8354417\">",
"     \"Pruritus: Overview of management\", section on 'Antihistamines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional treatment options described in the literature include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic corticosteroids&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/23\">",
"       23",
"      </a>",
"      ]. Relapse appears to be common upon withdrawal.",
"     </li>",
"     <li>",
"      Topical vitamin D analogs [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/24-26\">",
"       24-26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic retinoids [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phototherapy and photochemotherapy (PUVA) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. PUVA may cause an initial exacerbation of symptoms before producing benefit.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      has been described as an effective treatment for refractory Grover&rsquo;s disease in a case report [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31381/abstract/31\">",
"       31",
"      </a>",
"      ]].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of stronger evidence for therapies, we suggest a sequential approach starting with safer, cheaper, and more readily available therapies. Patients who fail such therapies can then undergo trials of other therapies. Such a strategy is presented below (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Summary and recommendations'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Appearance and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grover's disease (transient and persistent acantholytic dermatosis) is an uncommon pruritic papular",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      papulovesicular rash that most commonly affects the trunk. The etiology is unknown but there appears to be an association with heat and sweating (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The diagnosis of Grover's disease is typically made on skin biopsy in the appropriate clinical setting (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published randomized clinical trials of therapies for Grover's disease. Nearly all evidence for therapies comes from case series, case reports, and clinical experience.",
"   </p>",
"   <p>",
"    In the absence of stronger evidence for therapies, we suggest a sequential approach starting with safer, cheaper, and more readily available therapies (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). Patients who fail such therapies can then undergo trials of other therapies (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Treatment'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First line:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Avoidance of triggering factors (eg, heat, sweating)",
"     </li>",
"     <li>",
"      Moisturizers, emollients",
"     </li>",
"     <li>",
"      Topical corticosteroids (high potency fluorinated compounds) (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Second line",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Topical vitamin D-analogs (calcipotriene 0.005 percent twice daily); treat for three to four weeks before assessing clinical response",
"     </li>",
"     <li>",
"      Oral antihistamines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Third line:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Systemic corticosteroids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      starting at 20 to 40 mg daily and tapering over two to three weeks)",
"     </li>",
"     <li>",
"      Systemic retinoids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      40 mg daily for 2 to 12 weeks; taper to as little as 10 mg daily for prolonged control)",
"     </li>",
"     <li>",
"      Phototherapy or photochemotherapy (PUVA); may initially exacerbate disease before producing benefit",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/1\">",
"      Grover RW. Transient acantholytic dermatosis. Arch Dermatol 1970; 101:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/2\">",
"      Simon RS, Bloom D, Ackerman AB. Persistent acantholytic dermatosis. A variant of transient acantholytic dermatosis (Grover disease). Arch Dermatol 1976; 112:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/3\">",
"      Heenan PJ, Quirk CJ. Transient acantholytic dermatosis. Br J Dermatol 1980; 102:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/4\">",
"      Streit M, Paredes BE, Braathen LR, Brand CU. [Transitory acantholytic dermatosis (Grover disease). An analysis of the clinical spectrum based on 21 histologically assessed cases]. Hautarzt 2000; 51:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/5\">",
"      Parsons JM. Transient acantholytic dermatosis (Grover's disease): a global perspective. J Am Acad Dermatol 1996; 35:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/6\">",
"      Scheinfeld N, Mones J. Seasonal variation of transient acantholytic dyskeratosis (Grover's disease). J Am Acad Dermatol 2006; 55:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/7\">",
"      Quirk CJ, Heenan PJ. Grover's disease: 34 years on. Australas J Dermatol 2004; 45:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/8\">",
"      Hu CH, Michel B, Farber EM. Transient acantholytic dermatosis (Grover's disease). A skin disorder related to heat and sweating. Arch Dermatol 1985; 121:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/9\">",
"      Guana AL, Cohen PR. Transient acantholytic dermatosis in oncology patients. J Clin Oncol 1994; 12:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/10\">",
"      Casanova JM, Pujol RM, Taberner R, et al. Grover's disease in patients with chronic renal failure receiving hemodialysis: clinicopathologic review of 4 cases. J Am Acad Dermatol 1999; 41:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/11\">",
"      French LE, Piletta PA, Etienne A, et al. Incidence of transient acantholytic dermatosis (Grover's disease) in a hospital setting. Dermatology 1999; 198:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/12\">",
"      Ott, A. Persistent acantholytic dermatosis in a patient with increased sensitivity to light. Zeitschrift fuer Hautkrankheiten 1993; 62:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/13\">",
"      Antunes I, Azevedo F, Mesquita-Guimar&atilde;es J, et al. Grover's disease secondary to ribavirin. Br J Dermatol 2000; 142:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/14\">",
"      Mahler SJ, De Villez RL, Pulitzer DR. Transient acantholytic dermatosis induced by recombinant human interleukin 4. J Am Acad Dermatol 1993; 29:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/15\">",
"      Tscharner GG, B&uuml;hler S, Borner M, Hunziker T. Grover's disease induced by cetuximab. Dermatology 2006; 213:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/16\">",
"      Andersen BL. Pyoderma gangrenosum associated with transient acantholytic dermatosis (pemphigus erythematosus-like) and paraproteinemia. Acta Derm Venereol 1981; 61:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/17\">",
"      Powell J, Sakuntabhai A, James M, et al. Grover's disease, despite histological similarity to Darier's disease, does not share an abnormality in the ATP2A2 gene. Br J Dermatol 2000; 143:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/18\">",
"      Hashimoto K, Moiin A, Chang MW, Tada J. Sudoriferous acrosyringeal acantholytic disease. A subset of Grover's disease. J Cutan Pathol 1996; 23:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/19\">",
"      Antley CM, Carrington PR, Mrak RE, Smoller BR. Grover's disease (transient acantholytic dermatosis): relationship of acantholysis to acrosyringia. J Cutan Pathol 1998; 25:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/20\">",
"      Davis MD, Dinneen AM, Landa N, Gibson LE. Grover's disease: clinicopathologic review of 72 cases. Mayo Clin Proc 1999; 74:229.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. Skin Pathology, Churchill Livingstone, London 2002. p.297.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/22\">",
"      Gilchrist H, Jackson S, Morse L, et al. Galli-Galli disease: A case report with review of the literature. J Am Acad Dermatol 2008; 58:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/23\">",
"      Er&ouml;s N, Kov&aacute;cs A, K&aacute;rolyi Z. Successful treatment of transient acantholytic dermatosis with systemic steroids. J Dermatol 1998; 25:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/24\">",
"      Keohane SG, Cork MJ. Treatment of Grover's disease with calcipotriol (Dovonex). Br J Dermatol 1995; 132:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/25\">",
"      Mota AV, Correia TM, Lopes JM, Guimar&atilde;es JM. Successful treatment of Grover's disease with calcipotriol. Eur J Dermatol 1998; 8:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/26\">",
"      Hayashi H, Yokota K, Koizumi H, Shimizu H. Treatment of Grover's disease with tacalcitol. Clin Exp Dermatol 2002; 27:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/27\">",
"      Dodd HJ, Sarkany I. Persistent acantholytic dermatosis. Clin Exp Dermatol 1984; 9:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/28\">",
"      Helfman RJ. Grover's disease treated with isotretinoin. Report of four cases. J Am Acad Dermatol 1985; 12:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/29\">",
"      Breuckmann F, Appelhans C, Altmeyer P, Kreuter A. Medium-dose ultraviolet A1 phototherapy in transient acantholytic dermatosis (Grover's disease). J Am Acad Dermatol 2005; 52:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/30\">",
"      Paul BS, Arndt KA. Response of transient acantholytic dermatosis to photochemotherapy. Arch Dermatol 1984; 120:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31381/abstract/31\">",
"      Norman R, Chau V. Use of etanercept in treating pruritus and preventing new lesions in Grover disease. J Am Acad Dermatol 2011; 64:796.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5566 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31381=[""].join("\n");
var outline_f30_41_31381=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Appearance and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5566\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5566|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/5/37983\" title=\"picture 1\">",
"      Grovers disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/62/11239\" title=\"picture 2\">",
"      Grovers histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5566|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=related_link\">",
"      Pruritus: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_41_31382="Imaging of pleural plaques, thickening, and tumors";
var content_f30_41_31382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Imaging of pleural plaques, thickening, and tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31382/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31382/contributors\">",
"     Paul Stark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31382/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31382/contributors\">",
"     Nestor L Muller, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31382/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31382/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31382/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/41/31382/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging procedures are commonly used in the diagnostic evaluation of pleural abnormalities. The imaging of pleural plaques, diffuse pleural thickening, and pleural tumors will be reviewed here. The imaging of pleural effusions and pneumothorax are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link\">",
"     \"Imaging of pleural effusions in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=see_link\">",
"     \"Imaging of pneumothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PLEURAL PLAQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural plaques are deposits of hyalinized collagen fibers in the parietal pleura. They are indicative of asbestos exposure and typically become visible twenty or more years after the inhalation of asbestos fibers, although latency periods of less than ten years have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleural plaques are presumed to be the result of pleural inflammation caused by asbestos fibers that are transported to the pleural surface along lymphatic channels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    direct penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The former may explain why pleural plaques tend to be located near the stomata where asbestos fibers are resorbed by lymphatic flow (ie, Kampmeier's foci) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=see_link\">",
"     \"Asbestosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural plaques preferentially involve the parietal pleura adjacent to ribs, particularly the sixth through ninth ribs. They are also common along the diaphragm. Pleural plaques are less extensive in the intercostal spaces, only rarely occur in the visceral pleura, and are conspicuously absent in the region of the costophrenic sulci and the lung apices.",
"   </p>",
"   <p>",
"    Calcifications within pleural plaques are identified by chest radiography in 20 percent of patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55085 \" href=\"UTD.htm?6/13/6352\">",
"     image 1",
"    </a>",
"    ), by computed tomography (CT) in 50 percent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61458 graphicRef69952 \" href=\"UTD.htm?19/51/20278\">",
"     image 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56120 \" href=\"UTD.htm?42/20/43330\">",
"     image 3",
"    </a>",
"    ), and by morphological examination in 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/2,6-8\">",
"     2,6-8",
"    </a>",
"    ]. Morphological examination refers to the examination of autopsy specimens and pleural biopsy specimens.",
"   </p>",
"   <p>",
"    On chest radiographs, pleural plaques appear as focal areas of pleural thickening when they are viewed tangentially (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55085 \" href=\"UTD.htm?6/13/6352\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52721 \" href=\"UTD.htm?24/36/25157\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64308 \" href=\"UTD.htm?1/8/1158\">",
"     image 5",
"    </a>",
"    ). They can have a nodular, stippled, sunburst, irregular, leaf-like, or geographic appearance. When calcified, pleural plaques may also look like a dripping candle or display rolled margins. Several site-specific manifestations have to be highlighted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjacent to the diaphragm, pleural plaques can appear as curvilinear calcifications or as serrations, flat-topped focal areas of pleural thickening, or scalloping",
"     </li>",
"     <li>",
"      Within fissures, pleural plaques can rarely mimic solitary pulmonary nodules",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On CT, pleural plaques appear as focal pleural thickening (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61458 graphicRef69952 \" href=\"UTD.htm?19/51/20278\">",
"     image 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56120 \" href=\"UTD.htm?42/20/43330\">",
"     image 3",
"    </a>",
"    ). They can have a linear, band-like, or nodular appearance and may impinge slightly on the adjacent lung parenchyma. This impingement may occasionally cause a pulmonary subpleural curvilinear line adjacent to the plaque.",
"   </p>",
"   <p>",
"    CT clearly distinguishes pleural plaques from extrapleural fat and endothoracic fascia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/7\">",
"     7",
"    </a>",
"    ]. This is valuable because extrapleural fat may mimic a pleural plaque on a chest radiograph, but a subsequent CT will reveal the true nature of the abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. A large body-mass index can be an important factor that influences the over-reading of pleural plaques and leads to false-positive diagnosis of pleural plaques on chest radiographs. This finding can be clarified with CT scanning that demonstrates the fatty nature of those presumed pleural plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleural plaques do not have further disease potential and, therefore, do not need to be followed radiologically. However, clinicians should be aware that pleural plaques are markers of asbestos exposure and asbestos exposure is a risk factor for malignant mesothelioma, lung cancer, and asbestosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFUSE PLEURAL THICKENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse pleural thickening typically begins as fibrosis of the visceral pleura with secondary thickening of the parietal pleura. The visceral and parietal pleura may become inseparable, leading to obliteration of the costophrenic sulci. In addition, fatty tissue deposition external to the parietal pleura is probably due to adipose tissue being drawn inward during pleural retraction and cicatrization (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55881 \" href=\"UTD.htm?38/44/39616\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Radiologically, diffuse pleural thickening forms a smooth, uninterrupted pleural opacity. It characteristically extends over at least 25 percent of the chest wall and obliterates the costophrenic sulci. Computed tomography (CT) criteria that define diffuse pleural thickening include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/10,14,15\">",
"     10,14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pleural thickening extends more than 8 cm in the craniocaudal direction",
"     </li>",
"     <li>",
"      The pleural thickening extends along more than 5 cm of the chest wall when visualized in cross-section",
"     </li>",
"     <li>",
"      The pleural thickness exceeds 3 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calcification of the inner aspect of the thickened pleura is common and facilitates accurate measurement of the pleural thickness (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70716 \" href=\"UTD.htm?21/45/22227\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Diffuse pleural thickening is usually a consequence of intense pleural inflammation, such as that which occurs during infection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75166 \" href=\"UTD.htm?2/19/2358\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57875 \" href=\"UTD.htm?5/11/5302\">",
"     image 9",
"    </a>",
"    ). It can also be a response to other types of injuries, such as prior empyema, pleural hemorrhage, prior pneumothorax therapy for tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/16\">",
"     16",
"    </a>",
"    ], occupational exposure, trauma, radiation, pulmonary embolism, medication, a benign asbestos-related pleural effusion, or a neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/2,9,17\">",
"     2,9,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleural thickening can occur in the lung apices, but this is usually not caused by tuberculosis, unless accompanying adjacent scarring of the lung parenchyma is present. It has been hypothesized that pleural thickening in the lung apices may be related to apical ischemia and gravitational stress due to the upright posture (especially since its frequency increases with age) or extrapleural fat deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with diffuse pleural thickening should be followed for the progression of restrictive disease. This generally includes serial assessment by physical examination, chest imaging, and pulmonary function testing. The frequency of these assessments should be individualized according to the suspected rate of progression of restrictive physiology. Patients who report progressive symptoms warrant more frequent follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PLEURAL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of pleural tumors are malignant. Among malignant pleural tumors, most are due to metastatic disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61913 graphicRef79085 \" href=\"UTD.htm?7/0/7174\">",
"     image 10A-B",
"    </a>",
"    ) rather than a primary pleural malignancy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52053 graphicRef70651 \" href=\"UTD.htm?40/60/41925\">",
"     image 11A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mainstay for imaging of pleural tumors remains multislice, multidetector row, volumetric CT scanning with intravenous, iodinated contrast-material enhancement; it provides exquisite spatial resolution and allows for near-isotropic multiplanar reformatting. Several radiological features identified by computed tomography (CT) are helpful in distinguishing malignant from benign pleural disease. Features associated with malignant disease include circumferential thickening, nodular thickening, thickness greater than 1 cm, and involvement of the mediastinal pleura [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/14,16\">",
"     14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance imaging with gadolinium-based contrast has a high sensitivity and specificity for pleural malignancy, but is usually not performed due to greater expense and potential side-effects of gadolinium [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/16\">",
"     16",
"    </a>",
"    ]. Positron emission tomography computed tomography (PET-CT) with 18-fluorodeoxyglucose (FDG) also has a high sensitivity for pleural malignancy, but is not generally necessary for diagnosis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease can spread from a distant primary malignancy to the pleura in several ways: hematogenous dissemination, direct invasion from an adjacent carcinoma, subpleural tumor plaques (eg, lymphoma, (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59966 \" href=\"UTD.htm?17/58/18336\">",
"     image 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81106 \" href=\"UTD.htm?21/61/22481\">",
"     image 13",
"    </a>",
"    )), and pleural seeding (eg, thymoma or bronchogenic carcinoma, (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67739 \" href=\"UTD.htm?12/25/12703\">",
"     image 14",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/18\">",
"     18",
"    </a>",
"    ]. Pleural seeding is sometimes referred to as drop metastases.",
"   </p>",
"   <p>",
"    These mechanisms may have radiological consequences, which serve as clues that the pleural thickening is due to metastatic disease. As an example, pleural puckering indicates metastatic pleural disease because it is the result of the internal elastic lamina being breached by an invading tumor.",
"   </p>",
"   <p>",
"    The radiographic appearance of the metastatic pleural disease cannot be used to determine the histological type of malignancy. Nevertheless, the detection of metastatic pleural disease is important because it may have implications for prognosis and management. As examples, in patients with non-small cell lung cancer, the infiltration of extrapleural fat with malignant disease identifies a T3 lesion (stage IIB or more advanced disease), while the presence of pleural nodules or a malignant pleural effusion identifies M1a or stage IV disease (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/19\">",
"     19",
"    </a>",
"    ]. Dry pleural dissemination can manifest with subtle beading or nodularity in the interlobar fissures without an accompanying pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Primary tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary pleural lesions arise directly from the pleural membranes. Chest radiographic findings of pleural and extrapleural tumors include the incomplete border sign: the border of the lesion is indistinct towards the chest wall or the mediastinum, but sharp towards the adjacent lung.",
"   </p>",
"   <p>",
"    Pleural and chest wall tumors have tapered borders and obtuse angles of interface with the chest wall or mediastinum. In contrast, pulmonary masses are circumferentially surrounded by lung parenchyma and have acute angles of interface with the chest wall or the lung parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Malignant mesothelioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common CT findings associated with malignant mesothelioma are pleural thickening (92 percent), involvement of the fissure (86 percent), pleural effusion (74 percent), contraction of a hemithorax (42 percent), midline mediastinum (44 percent), contralateral shift of the mediastinum (14 percent), chest wall involvement (18 percent), and rib destruction (10 percent) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52053 graphicRef70651 \" href=\"UTD.htm?40/60/41925\">",
"     image 11A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79374 \" href=\"UTD.htm?20/41/21136\">",
"     image 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64863 \" href=\"UTD.htm?7/35/7730\">",
"     image 16",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50710 graphicRef61332 \" href=\"UTD.htm?14/12/14536\">",
"     image 17A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging features of malignant mesothelioma can be mimicked by metastatic adenocarcinoma and rarely by benign, inflammatory pleural disease. However, once malignant mesothelioma is diagnosed by tissue sampling, CT imaging is helpful in evaluating features that characterize the severity of disease: chest wall invasion, mediastinal invasion, and transdiaphragmatic growth of tumor into the abdomen. The addition of magnetic resonance imaging (MRI) may improve the evaluation of chest wall and apical involvement, as well as transdiaphragmatic tumor growth (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59885 graphicRef74112 \" href=\"UTD.htm?6/17/6422\">",
"     image 18A-B",
"    </a>",
"    ). Multiplanar, near-isotropic imaging with multislice, multidetector-row volumetric CT scanning can display these features as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3910?source=see_link\">",
"     \"Magnetic resonance imaging of the thorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The non-radiological aspects of malignant mesothelioma are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link\">",
"     \"Epidemiology of malignant mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=see_link\">",
"     \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other primary pleural tumors include lipomas, fibrous tumors, and neurogenic tumors (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59318 \" href=\"UTD.htm?8/54/9056\">",
"     image 19",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75098 \" href=\"UTD.htm?6/54/7013\">",
"     image 20",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lipomas are pleural or extrapleural masses with homogeneous fatty content. They tend to occur in the upper chest along the second or third ribs. Their diagnosis is facilitated by CT, which can reliably distinguish fat from other tissues, due to fat&rsquo;s low attenuation coefficient of -50HU to -100HU (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81351 \" href=\"UTD.htm?36/14/37090\">",
"     image 21",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Solitary fibrous tumors of the pleura typically appear on CT as a mass with a diameter of 5 to 30 cm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63307 \" href=\"UTD.htm?2/6/2144\">",
"     image 22",
"    </a>",
"    ). A pedicle is present in 40 percent of cases, resulting in marked tumor mobility (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65286 \" href=\"UTD.htm?3/60/4032\">",
"     image 23",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53533 \" href=\"UTD.htm?33/54/34656\">",
"     image 24",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31382/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Solitary fibrous tumors can have cystic components and may enhance after intravenous contrast material administration. Occasionally, they may simulate mediastinal, paravertebral, or intrapulmonary masses, depending upon their exact location within the pleural cavity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77119 graphicRef54568 \" href=\"UTD.htm?31/2/31784\">",
"     image 25A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52030 \" href=\"UTD.htm?22/47/23295\">",
"     image 26",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\", section on 'Solitary fibrous tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pleural plaques appear as focal areas of pleural thickening on both chest radiography and computed tomography (CT). They preferentially involve the parietal pleura adjacent to ribs, particularly the sixth through ninth ribs. Pleural plaques are common along the diaphragm and are often calcified. Pleural plaques can be simulated by extrapleural fat deposits, particularly in persons with large body-mass index. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pleural plaques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diffuse pleural thickening forms a smooth, uninterrupted pleural peel. When visualized by CT, it extends more than 8 cm in the craniocaudal direction, encompasses more than 5 cm of the chest wall when visualized in cross-section, and has a thickness that exceeds 3 mm. In addition, chest radiography reveals ipsilateral blunting of the costophrenic sulcus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diffuse pleural thickening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most pleural tumors are malignant. CT features that may be helpful in distinguishing malignant from benign pleural disease include circumferential thickening, nodular thickening, thickness exceeding 1 cm, and involvement of the mediastinal pleura. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pleural tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/1\">",
"      Larson TC, Meyer CA, Kapil V, et al. Workers with Libby amphibole exposure: retrospective identification and progression of radiographic changes. Radiology 2010; 255:924.",
"     </a>",
"    </li>",
"    <li>",
"     Light RW. Pleural diseases, Lea &amp; Febiger, Philadelphia 1983.",
"    </li>",
"    <li>",
"     Gottschall EB, Newman L. Benign asbestos-related pleural disease. In: Lung Biology in Health and Disease: Pleural Disease, 2nd, Bouros D.  (Ed), Informa Healthcare, New York 2010. p.504.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/4\">",
"      Sargent EN, Jacobson G, Gordonson JS. Pleural plaques: a signpost of asbestos dust inhalation. Semin Roentgenol 1977; 12:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/5\">",
"      American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/6\">",
"      M&uuml;ller NL. Imaging of the pleura. Radiology 1993; 186:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/7\">",
"      Aberle DR, Balmes JR. Computed tomography of asbestos-related pulmonary parenchymal and pleural diseases. Clin Chest Med 1991; 12:115.",
"     </a>",
"    </li>",
"    <li>",
"     Stark P. The Pleura. In: Radiology: Diagnosis, Imaging, Intervention, Taveras, Ferrucci (Eds), Lippincott, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/9\">",
"      Sargent EN, Boswell WD Jr, Ralls PW, Markovitz A. Subpleural fat pads in patients exposed to asbestos: distinction from non-calcified pleural plaques. Radiology 1984; 152:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/10\">",
"      McLoud TC. CT and MR in pleural disease. Clin Chest Med 1998; 19:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/11\">",
"      Vix VA. Extrapleural costal fat. Radiology 1974; 112:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/12\">",
"      Lee YC, Runnion CK, Pang SC, et al. Increased body mass index is related to apparent circumscribed pleural thickening on plain chest radiographs. Am J Ind Med 2001; 39:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/13\">",
"      Pairon JC, Laurent F, Rinaldo M, et al. Pleural plaques and the risk of pleural mesothelioma. J Natl Cancer Inst 2013; 105:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/14\">",
"      Leung AN, M&uuml;ller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 1990; 154:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/15\">",
"      Aberle DR, Gamsu G, Ray CS. High-resolution CT of benign asbestos-related diseases: clinical and radiographic correlation. AJR Am J Roentgenol 1988; 151:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/16\">",
"      Downer NJ, Ali NJ, Au-Yong IT. Investigating pleural thickening. BMJ 2013; 346:e8376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/17\">",
"      Schwartz DA, Fuortes LJ, Galvin JR, et al. Asbestos-induced pleural fibrosis and impaired lung function. Am Rev Respir Dis 1990; 141:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/18\">",
"      Shuman LS, Libshitz HI. Solid pleural manifestations of lymphoma. AJR Am J Roentgenol 1984; 142:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/19\">",
"      Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007; 2:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/20\">",
"      Kim YK, Lee HY, Lee KS, et al. Dry pleural dissemination in non-small cell lung cancer: prognostic and diagnostic implications. Radiology 2011; 260:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/21\">",
"      Schiffman SR, Datta V, Wandtke J, Hobbs SK. Imaging features of chest wall tumors. Contemporary disgnostic radiology (CDR) 2012; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/22\">",
"      Alexander E, Clark RA, Colley DP, Mitchell SE. CT of malignant pleural mesothelioma. AJR Am J Roentgenol 1981; 137:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/23\">",
"      Grant DC, Seltzer SE, Antman KH, et al. Computed tomography of malignant pleural mesothelioma. J Comput Assist Tomogr 1983; 7:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/24\">",
"      Mirvis S, Dutcher JP, Haney PJ, et al. CT of malignant pleural mesothelioma. AJR Am J Roentgenol 1983; 140:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/25\">",
"      Wang ZJ, Reddy GP, Gotway MB, et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 2004; 24:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/26\">",
"      Stark P. [Fibrous pleural mesothelioma (pleura fibroma) -- a contribution to the differential diagnosis of pleural tumours (author's transl)]. Rofo 1981; 134:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31382/abstract/27\">",
"      Desser TS, Stark P. Pictorial essay: solitary fibrous tumor of the pleura. J Thorac Imaging 1998; 13:27.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4399 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.196.66.12-1617F87D8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31382=[""].join("\n");
var outline_f30_41_31382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PLEURAL PLAQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFUSE PLEURAL THICKENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PLEURAL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Primary tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Malignant mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4399|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/13/6352\" title=\"diagnostic image 1\">",
"      Calcified pleural plaques PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/34/21024\" title=\"diagnostic image 2A\">",
"      Pleural plaques CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/20/40257\" title=\"diagnostic image 2B\">",
"      Calcified pleural plaque CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/20/43330\" title=\"diagnostic image 3\">",
"      Nodular pleural plaques CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/36/25157\" title=\"diagnostic image 4\">",
"      Pleural plaques asbestos PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/8/1158\" title=\"diagnostic image 5\">",
"      Calcified apical caps PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/44/39616\" title=\"diagnostic image 6\">",
"      Proliferation extrapleural CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/45/22227\" title=\"diagnostic image 7\">",
"      Post pneumonectomy CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/19/2358\" title=\"diagnostic image 8\">",
"      Tuberculous pleurisy I PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/11/5302\" title=\"diagnostic image 9\">",
"      Tuberculosis pleurisy II PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/9/22673\" title=\"diagnostic image 10A\">",
"      Metastatic ca to pleura I CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/17/17680\" title=\"diagnostic image 10B\">",
"      Metastatic ca to pleura II CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/52/20288\" title=\"diagnostic image 11A\">",
"      Malignant mesothelioma I CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/31/2545\" title=\"diagnostic image 11B\">",
"      Malignant mesothelioma II CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/58/18336\" title=\"diagnostic image 12\">",
"      Pleural lymphoma I CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/61/22481\" title=\"diagnostic image 13\">",
"      Pleural lymphoma II CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/25/12703\" title=\"diagnostic image 14\">",
"      Malignant thymoma pleural CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/41/21136\" title=\"diagnostic image 15\">",
"      Malignant mesothelioma III CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/35/7730\" title=\"diagnostic image 16\">",
"      Malignant mesothelioma I MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/4/30787\" title=\"diagnostic image 17A\">",
"      Malignant mesothelioma II MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/3/32818\" title=\"diagnostic image 17B\">",
"      Malignant mesothelioma IV CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/16/3330\" title=\"diagnostic image 18A\">",
"      Malignant mesothelioma III MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/5/42079\" title=\"diagnostic image 18B\">",
"      Malignant mesothelioma IV MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/54/9056\" title=\"diagnostic image 19\">",
"      Intercostal neurofibroma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/54/7013\" title=\"diagnostic image 20\">",
"      Fibrous pleural tumor I PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/14/37090\" title=\"diagnostic image 21\">",
"      Pleural lipoma I CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/6/2144\" title=\"diagnostic image 22\">",
"      Fibrous pleural tumor I CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/60/4032\" title=\"diagnostic image 23\">",
"      Fibrous pleural tumor II CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/54/34656\" title=\"diagnostic image 24\">",
"      Fibrous pleural tumor III CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/17/44308\" title=\"diagnostic image 25A\">",
"      Fibrous pleural tumor II PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/9/16530\" title=\"diagnostic image 25B\">",
"      Fibrous pleural tumor Lateral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/47/23295\" title=\"diagnostic image 26\">",
"      Fibrous pleural tumor IV CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4399|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=related_link\">",
"      Asbestosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=related_link\">",
"      Epidemiology of malignant mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=related_link\">",
"      Imaging of pleural effusions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=related_link\">",
"      Imaging of pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3910?source=related_link\">",
"      Magnetic resonance imaging of the thorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=related_link\">",
"      Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_41_31383="MAZE III procedure";
var content_f30_41_31383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    MAZE III procedure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Modification of the posterior incisions to the vena cava and placement of the septal incision posterior to the orifice of the superior vena cava (SVC) are noted.",
"    <div class=\"footnotes\">",
"     CS: coronary sinus; FO: foramen ovale; IVC: inferior vena cava; LAA: left atrial appendage; MV: mitral valve; RAA: right atrial appendage; SAN: sinoatrial node; TV: tricuspid valve.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Cheng A, Shah A, Hogue CW. Cardiac electrophysiology: Diagnosis and treatment. In: Kaplan's Cardiac Anesthesia, 6th ed, Kaplan JA, Reich DL, Lake CL, Konstadt SN (Eds), Saunders, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31383=[""].join("\n");
var outline_f30_41_31383=null;
var title_f30_41_31384="Paroxysmal atrial fibrillation";
var content_f30_41_31384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paroxysmal atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31384/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31384/contributors\">",
"     Alan Cheng, MD, FACC, FAHA, FHRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31384/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31384/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31384/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31384/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31384/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/41/31384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H356405846\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is the most common arrhythmia lasting for more than 30 seconds. Its prevalence in the population increases with age, and it is estimated to affect over 4 percent of the population above the age of 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paroxysmal atrial fibrillation (PAF), also termed intermittent AF, is defined as recurrent (two or more) episodes of AF that terminate spontaneously in less than seven days, usually less than 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. &ldquo;Persistent&rdquo; (AF that continues until reverted chemically or electrically), &ldquo;longstanding persistent&rdquo;, and &ldquo;permanent&rdquo; (AF continued as the underlying rhythm of choice) are the other types of AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This definition applies to recurrent intermittent episodes of AF that are unrelated to a reversible cause. If the AF is secondary to cardiac surgery, pericarditis, myocardial infarction (MI), hyperthyroidism, pulmonary embolism, pulmonary disease, or other reversible causes, therapy is directed toward the underlying disease as well as the AF.(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of paroxysmal AF (PAF) is uncertain, because up to 90 percent of episodes are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], including some that last more than 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address the ways in which patients with PAF differ from the broad population of patients with AF. However, in many instances, patients with PAF are managed in a manner similar to those with more sustained forms of AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1696500\">",
"    <span class=\"h1\">",
"     SIGNS AND SYMPTOMS OF AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms secondary to AF are broad. The most common complaints include irregular palpitations often in the setting of worsening shortness of breath, dyspnea on exertion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a sensation of lightheadedness. Other symptoms include more general complaints such as fatigue, weakness, or generalized malaise. The severity and extent of symptoms are often dictated by the patient&rsquo;s underlying cardiac condition, age, and rapidity and regularity of the ventricular response. In patients with co-existing congestive heart failure, worsening heart failure may result from loss of atrial contraction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link&amp;anchor=H4#H4\">",
"     \"Atrial fibrillation in patients with heart failure\", section on 'Effect on cardiac function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On physical examination, there may be a slight variation in the intensity of the first heart sound in the setting of an irregularly irregular pulse. Since atrial contraction is lost, S4 sounds are not heard and jugular venous a waves are absent. Variations in cuff blood pressure readings are also common during atrial fibrillation due to changes in the beat-to-beat cadence. It is often necessary to measure the blood pressure multiple times and average these values to obtain a more accurate blood pressure reading. Lastly, an apical-radial pulse deficit can be observed in patients in AF. When one assesses the apical pulse rate and the radial pulse rate simultaneously, one will appreciate that the radial heart rate is less than the apical heart rate. Since the heart rate is irregular, some ventricular contractions will occur preceded by shorter periods of diastole. This will necessarily result in episodes where there is insufficient stroke volume to transmit the pressure wave to the arm.",
"   </p>",
"   <p>",
"    The relationship between subclinical AF and cryptogenic stroke is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link&amp;anchor=H19246582#H19246582\">",
"     \"Cryptogenic stroke\", section on 'Subclinical atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for developing PAF are similar to those associated with sustained AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    .) The most common ones include: [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertension &mdash; 16 to 34 percent",
"     </li>",
"     <li>",
"      Coronary artery disease &mdash; 6 to 24 percent",
"     </li>",
"     <li>",
"      Rheumatic heart disease &mdash; 3 to 14 percent",
"     </li>",
"     <li>",
"      Hyperthyroidism &mdash; 2 percent",
"     </li>",
"     <li>",
"      Miscellaneous &mdash; 12 to 16 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors that precipitate PAF, particularly in patients without apparent structural heart disease, are incompletely understood but are thought to be secondary to the presence of atrial premature beats (APBs) and alterations in autonomic nervous system dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Atrial premature beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies in which Holter monitoring was performed have shown that the majority of episodes of PAF are triggered by APBs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. A small number of PAF episodes are preceded by typical atrial flutter, atrial tachycardia, or even paroxysmal supraventricular tachycardias [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. APBs most often originate from near the ostia of the pulmonary veins, occurring in 89 and 94 percent of cases in two series [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Less commonly, foci have also been described to occur in the",
"    <span class=\"nowrap\">",
"     right/left",
"    </span>",
"    atria, the vein of Marshall, and the superior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/13,16,17\">",
"     13,16,17",
"    </a>",
"    ]. The importance of the pulmonary veins in the genesis of PAF is further illustrated by the beneficial effect of pulmonary vein isolation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    APBs appear to be most important as a trigger in patients with PAF who have structurally normal or near-normal hearts. The relative importance of APBs or other triggers versus an abnormal substrate is much less clear in patients with significant structural heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autonomic nervous system may be involved, as both increased vagal (parasympathetic) and sympathetic tone can promote the development of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/18\">",
"     18",
"    </a>",
"    ]. Increased sympathetic tone has been referred to as the adrenergic form of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vagal tone is predominant in normal hearts, which may explain why vagally-mediated AF is often seen in athletic young men without apparent heart disease who have slow heart rates during rest or sleep; such patients may also have an ECG pattern of common atrial flutter alternating with AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/18,20\">",
"     18,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vagal innervation of the atria is heterogeneous. As a result, the induction of AF by vagal stimulation may result from shortening of the atrial refractory period in only some areas of the atrial myocardium, thus producing heterogeneity of atrial refractoriness [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/21\">",
"     21",
"    </a>",
"    ]. Vagal stimulation and the associated hypotension may on occasion contribute to the development of syncope in association with episodes of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased sympathetic tone may be associated with AF occurring in patients with underlying heart disease and during exercise or other activity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/18\">",
"     18",
"    </a>",
"    ]. However, AF during exercise is a rare event; in a retrospective review of 3000 exercise tests, there were only four episodes of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sympathetic stimulation has also been suggested as the cause for AF associated with hyperthyroidism and coronary artery bypass graft surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link\">",
"     \"Cardiovascular effects of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of autonomic dysfunction as a trigger for paroxysmal AF in these patients has not been well studied. In a report from the European Heart Survey on AF, 1517 patients with paroxysmal AF were categorized according to trigger pattern: adrenergic, vagal, or both (6, 15, and 12 percent of the total group, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/24\">",
"     24",
"    </a>",
"    ]. The was no significant difference in the prevalence of the different kinds of underlying heart disease (heart failure, coronary artery disease, valvular heart disease, or hypertension) among groups.",
"   </p>",
"   <p>",
"    The adrenergic trigger pattern was defined as follows: initiated by exercise or emotion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    present mainly during daytime without reported vagal triggers. Patients were classified in the vagal group if AF occurred postprandially",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    was present during the night only without presence of any adrenergic triggers. Patients were classified in the mixed AF group when a combination of at least one adrenergic and one vagal trigger was present.",
"   </p>",
"   <p>",
"    In a report of patients referred for radiofrequency ablation due to symptomatic drug refractory PAF, the prevalence of vagal, adrenergic, or other AF was found 27, 7, and 66 percent of the time, respectively",
"   </p>",
"   <p>",
"    In a report of patients referred for radiofrequency ablation due to symptomatic drug refractory PAF, the prevalence of vagal, adrenergic, or other AF was found 27, 7, and 66 percent of the time, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence, except in CABG patients in the perioperative period, that selection of therapy based upon the type of autonomic dysfunction improves outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Recurrence of AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of patients with PAF suggests that episodes will continue but with variable frequency. The incidence in different reports has ranged from 70 percent at one year (without antiarrhythmic therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/26\">",
"     26",
"    </a>",
"    ] to 90 percent at four years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/27\">",
"     27",
"    </a>",
"    ] to 60 to 65 percent at five to six years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/9,28,29\">",
"     9,28,29",
"    </a>",
"    ]. These estimates almost certainly represent an underestimate, since up to 90 percent of episodes are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], including some that last more than 48 hours; such prolonged asymptomatic episodes occurred in 17 percent of patients in a report using continuous monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/7\">",
"     7",
"    </a>",
"    ]. The latter study also showed that 40 percent of patients had episodes of AF-like symptoms in the absence of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Stroke Prevention in Atrial Fibrillation (SPAF) trial evaluated 341 patients with intermittent AF who were followed for 26 months [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/30\">",
"     30",
"    </a>",
"    ]. During this time, 49 percent had recurrent AF documented on at least one electrocardiogram. There were 104 additional patients who underwent cardioversion (electric or pharmacologic); the recurrence rate during follow-up was 54 percent in this group.",
"   </p>",
"   <p>",
"    The report from SPAF also provided insight into clinical and echocardiographic factors that predict recurrence of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/30\">",
"     30",
"    </a>",
"    ]. When compared to patients without a recurrence of AF, patients with any AF recurrence were more likely to have heart failure (17 versus 8 percent) or a prior myocardial infarction (15 versus 5 percent). Echocardiographic factors associated with AF recurrence included moderate to severe left ventricular dysfunction (12 versus 3 percent in those without recurrence) and larger left atrial diameter. Compared to a normal left atrial diameter of less than 4.0 cm, the relative risk of recurrent AF was 1.6 with a left atrial diameter between 4.1 and 5.0 cm and 4.5 above 5.0 cm.",
"   </p>",
"   <p>",
"    These risk factors are similar to those for recurrence after cardioversion to sinus rhythm in patients with permanent AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Progression to permanent AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, PAF spontaneously reverts to sinus rhythm within seven days of onset. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The percent of patients with PAF who progress to persistent or permanent AF increases with time. In different reports, the rate of progression to permanent AF was 8, 12, 18, and 25 percent at one, two, four, and five years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have attempted to identify predictors of progression to persistent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In the report from SPAF cited above, the following differences were noted between the patients with paroxysmal and persistent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with PAF were less likely to have hypertension or heart failure.",
"     </li>",
"     <li>",
"      On echocardiography, patients with PAF had a smaller left atrial diameter (4.3 versus 4.8 cm), were less likely to have a diameter greater than 5.0 cm (11 versus 34 percent), and were less likely to have moderate to severe left ventricular dysfunction (6 versus 18 percent). For every 1 cm increase in left ventricular systolic dimension, there was a 1.8 fold greater risk of developing persistent AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The transition from PAF to persistent AF also depends upon the underlying etiology for the arrhythmia. Progression has been reported in approximately 66 percent of patients with rheumatic mitral stenosis, 40 percent with hypertension, and 27 percent with ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. On the other hand, as few as 5 percent of patients with paroxysmal AF progress to persistent AF over a six-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing age also predicts increased risk for the development of persistent AF. The hazard ratio for progression in two reports was 1.41 to 1.82 for each 10-year increase in age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/29,31\">",
"     29,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk of embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the risk of embolization is well established in persistent AF, the evidence presented below highlights the uncertainty as to whether the risk is lower in patients with documented PAF. Some but not all of our experts believe in the absence of further evidence to support a claim of lower risk, that the approach to anticoagulation in patients with PAF should be similar to that of patients with persistent AF. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Anticoagulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A number of studies noted a lower risk in patients with PAF compared to those with persistent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. In the Framingham Heart Study, for example, the annual incidence of stroke in patients with PAF was 1.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these data, several large trials have reported",
"    <strong>",
"     no difference",
"    </strong>",
"    in the risk of stroke between those with PAF and permanent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The following are two examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients not on anticoagulation in SPAF, the yearly stroke rate was the same in PAF and sustained AF (5.6 versus 5.9 percent with no",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and 3.2 versus 3.3 percent on aspirin) in the different risk groups (",
"      <a class=\"graphic graphic_figure graphicRef82291 \" href=\"UTD.htm?2/1/2078\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/36\">",
"       36",
"      </a>",
"      ]. Among the 24 percent of patients with PAF predicted to be at high risk, the rate of ischemic stroke was 7.8 percent per year.",
"     </li>",
"     <li>",
"      The Boston Area Anticoagulation Trial in Atrial Fibrillation (BAATAF) found a similar incidence of stroke in the two groups (13 versus 17 percent) for a yearly incidence of 2.5 and 2.8 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar lack of difference in embolic risk was noted in a pooled analysis from the five randomized control trials of anticoagulation in AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/38\">",
"     38",
"    </a>",
"    ]. Furthermore, a subset meta-analysis found that the reduction in ischemic stroke with oral anticoagulation in patients with PAF (1.5 versus 4.7 events per 100 patient-years, hazard ratio 0.32) was similar to that in patients with persistent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One concern is that these trials were not designed to specifically evaluate patients with PAF, who constituted approximately 12 percent of the patients. There were also problems with the definition of PAF as well as documentation of the frequency and duration of AF. Embolic events can occur in patients with acute AF for as little as 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence of the embolic risk associated with PAF comes from AFFIRM and RACE trials that compared rhythm to rate control in patients with paroxysmal or permanent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Embolization occurred with equal frequency whether a rhythm control or a rate control strategy was adopted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are at least two reasons for the risk of embolization even when sinus rhythm appears to be maintained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent episodes of paroxysmal AF are common and most often asymptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients have other reasons for embolic risk such as complex aortic plaque or left ventricular systolic dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"       \"Indications for antithrombotic therapy in heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=see_link\">",
"       \"Embolism from aortic plaque: Thromboembolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although periods of sinus rhythm should reduce stroke risk, this may be counterbalanced by an increase in risk during the transition from AF to sinus rhythm as occurs after cardioversion. This is especially important for episodes that are longer lasting, ie, &gt;48 hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in persistent AF, increasing age, hypertension, and prior stroke best correlate with stroke probability in PAF. In the SPAF trial of 460 patients with PAF treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , the stroke rate was highest (7.8 percent per year) in the 24 percent of patients with PAF who met criteria for being at high risk (",
"    <a class=\"graphic graphic_figure graphicRef82291 \" href=\"UTD.htm?2/1/2078\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/36\">",
"     36",
"    </a>",
"    ]. As a result, the commonly used tool for risk stratification (eg, CHADS2) of stroke development does not take into account the frequency or type AF documented. Rather, it assesses existing comorbidities that increase stroke risk (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ). A modification of the CHADS2 risk score has been published and takes into account other risk factors known to be associated with a stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H621956777#H621956777\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Prevention approach by CHA2DS2-VASc score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is the rate of embolization during and after electrical or pharmacological cardioversion in patients with AF of less than 48 hours duration. The risk of cardioversion-associated embolization is very low in such patients, even without anticoagulation (four episodes among 573 patients in two series) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Therefore, this further complicates issues about the role of anticoagulation in patients with PAF who have episodes that last for a few minutes or hours to less than 48 hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link&amp;anchor=H16#H16\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\", section on 'AF of less than 48 hours duration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H124273315\">",
"    <span class=\"h3\">",
"     Duration and frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with PAF, it is not known whether the risk of embolization is influenced by either the duration or frequency. There are few studies that address this issue. In the TRENDS study, 2486 patients with and without known PAF (CHADS2 score &ge;1) and a pacemaker or defibrillator with atrial arrhythmia monitoring capability were evaluated for a mean duration of 1.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients were categorized into zero, low (&lt;5.5 hours), and high (&ge;5.5 hours) atrial",
"    <span class=\"nowrap\">",
"     tachycardia/atrial",
"    </span>",
"    fibrillation",
"    <span class=\"nowrap\">",
"     (AT/AF)",
"    </span>",
"    burden groups, with burden defined as the maximum number of hours of",
"    <span class=\"nowrap\">",
"     AT/AF",
"    </span>",
"    burden on any day during the antecedent 30 days. The annualized thromboembolic risk was 1.1, 1.1, and 2.4 percent in patients with zero, low, and high burden findings on monitoring, but the relative risk between the high and zero burden groups did not achieve statistical significance. The approach to anticoagulation in these patients is discussed below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Anticoagulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether patients with paroxysmal AF have worse survival than the general population has not been well studied. In the best available study, 888 patients from the Stockholm cohort study of atrial fibrillation (SCAF) were followed for a mean of 4.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/46\">",
"     46",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean annual all-cause mortality was 7 percent and the standardized mortality ratio (compared with the general population) was significantly increased at 1.6 percent (95% CI 1.4-1.8).",
"     </li>",
"     <li>",
"      This excess mortality was principally from cardiovascular causes.",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      appeared to do better than those not treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE ARRHYTHMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the arrhythmia in patients with PAF is similar to that for the general population of patients with AF. Important considerations are the duration and the presence or absence of symptoms during an episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two components to the management of the abnormal rhythm in patients with PAF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute control of the heart rate, usually with a beta blocker or calcium channel blocker (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ) or, if the patient has heart failure or hypotension,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"       \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unless PAF reverts spontaneously, electrical cardioversion in patients who are hemodynamically unstable and either electrical or pharmacologic cardioversion in patients who are hemodynamically stable but have unacceptable symptoms and in patients with a first-detected episode of AF&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prevention of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no data suggesting that preventing episodes of AF with any intervention reduces mortality, including the subset of patients with PAF. Thus, the decision to start antiarrhythmic drug therapy in patients with PAF is similar to that in the general population of patients with AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with frequent or highly symptomatic PAF may require pharmacologic or nonpharmacologic therapy to prevent recurrence. The choice of therapy is often determined by the clinical setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Catheter-based pulmonary vein isolation (PVI) is generally viewed as being more effective than antiarrhythmic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/47\">",
"     47",
"    </a>",
"    ]. It has been increasingly used for prevention of PAF episodes and adopted as second-line therapy when antiarrhythmics have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/4\">",
"     4",
"    </a>",
"    ]. Whether PVI should be considered first line therapy has been a subject of much debate and evaluated in small randomized study. Catheter-based PVI is most commonly performed with radiofrequency. Alternative energy sources have also been developed, including cryoballoon and balloon-based laser ablation. Surgical-based techniques such as the MAZE procedure are still being used and are often performed in conjunction with other cardiac surgical procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential value of yoga for reducing the frequency of episodes (lasting more than 30 seconds) of AF was evaluated in a study of 49 individuals with PAF in whom symptomatic and asymptomatic episodes were evaluated before and after three months of twice-weekly yoga training for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/48\">",
"     48",
"    </a>",
"    ]. Yoga training significantly reduced the number of symptomatic episodes, symptomatic non-AF episodes, and asymptomatic episodes (3.8 versus 2.1, 2.9 versus 1.4, and 0.12 versus 0.04, respectively). Given limitations of this study, including its small size, we believe that further support for the use of yoga is necessary before we recommend its use to reduce the frequency of AF episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily use of a rate controlling agent such as a beta blocker, calcium channel blocker, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is generally not needed in PAF. However, such drugs may be considered in patients with highly symptomatic episodes and can be used for an acute episode. Some patients are maintained on one of these drugs to control the ventricular rate when PAF occurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a group, patients with PAF have a risk for embolic events that appears to be similar to that in patients with persistent AF, although the data are not conclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31384/abstract/36-39,49\">",
"     36-39,49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Risk of embolization'",
"    </a>",
"    above.) Thus, the approach to antithrombotic therapy in patients with PAF is felt by some experts to be similar to that in patients with persistent or permanent AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, it is not known whether patients with infrequent episodes or episodes of short duration are at the same level of risk as those with longer or more frequent episodes. There are no good data to establish a threshold of duration or frequency of AF for the initiation of antithrombotic therapy. We suggest that the decision to anticoagulate be dictated on an individual&rsquo;s CHADS2 risk score and not be based on the frequency or duration of PAF. We recognize that this approach may have its limitations, but until more data are available, we believe that every effort should be made to minimize an individual&rsquo;s risk for stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100913677\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal (ie, self-terminating or intermittent) atrial fibrillation (PAF) is defined as AF that terminates spontaneously in less than seven days, usually less than 24 hours. This classification applies to recurrent episodes of AF that last more than 30 seconds and that are unrelated to a reversible cause. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If the AF is secondary to cardiac surgery, pericarditis, myocardial infarction (MI), hyperthyroidism, pulmonary embolism, pulmonary disease, or other reversible causes, therapy is directed toward the underlying disease as well as the AF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The recurrence rate of AF is high in patients who present with PAF. The incidence in different reports has ranged from 70 percent at one year (without antiarrhythmic therapy) to 90 percent at four years to 60 to 65 percent at five to six years. These estimates almost certainly represent an underestimation of the true incidence. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The percent of patients with PAF who progress to persistent or permanent AF increases with time. In different reports, the rate of progression to permanent AF was 8, 12, 18, and 25 percent at one, two, four, and five years, respectively. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Progression to permanent AF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of embolization with frequent and prolonged episodes of PAF may be similar to the risk in patients with persistent or permanent AF. However, data are not conclusive. We suggest an approach to antithrombotic therapy similar to that in the broad group of patients with AF, although recommendations should be individualized to the specific patient.(See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk of embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of the arrhythmia in patients with PAF is similar to that for the general population of patients with AF. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prevention of recurrence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/1\">",
"      Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke 1988; 19:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/2\">",
"      Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/3\">",
"      Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/4\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 57:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/5\">",
"      European Heart Rhythm Association (EHRA), European Cardiac Arrhythmia Scoiety (ECAS), American College of Cardiology (ACC), et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/6\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/7\">",
"      Israel CW, Gr&ouml;nefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/8\">",
"      Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/9\">",
"      Takahashi N, Seki A, Imataka K, Fujii J. Clinical features of paroxysmal atrial fibrillation. An observation of 94 patients. Jpn Heart J 1981; 22:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/10\">",
"      Suttorp MJ, Kingma JH, Koomen EM, et al. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 1993; 71:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/11\">",
"      Clementy J, Dulhoste MN, Laiter C, et al. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol 1992; 70:44A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/12\">",
"      Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999; 100:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/13\">",
"      Ha&iuml;ssaguerre M, Ja&iuml;s P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/14\">",
"      Kolb C, N&uuml;rnberger S, Ndrepepa G, et al. Modes of initiation of paroxysmal atrial fibrillation from analysis of spontaneously occurring episodes using a 12-lead Holter monitoring system. Am J Cardiol 2001; 88:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/15\">",
"      Sauer WH, Alonso C, Zado E, et al. Atrioventricular nodal reentrant tachycardia in patients referred for atrial fibrillation ablation: response to ablation that incorporates slow-pathway modification. Circulation 2006; 114:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/16\">",
"      Hwang C, Wu TJ, Doshi RN, et al. Vein of marshall cannulation for the analysis of electrical activity in patients with focal atrial fibrillation. Circulation 2000; 101:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/17\">",
"      Lin WS, Tai CT, Hsieh MH, et al. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. Circulation 2003; 107:3176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/18\">",
"      Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996; 7:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/19\">",
"      Coumel P. Cardiac arrhythmias and the autonomic nervous system. J Cardiovasc Electrophysiol 1993; 4:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/20\">",
"      Herweg B, Dalal P, Nagy B, Schweitzer P. Power spectral analysis of heart period variability of preceding sinus rhythm before initiation of paroxysmal atrial fibrillation. Am J Cardiol 1998; 82:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/21\">",
"      Elvan A, Pride HP, Eble JN, Zipes DP. Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs. Circulation 1995; 91:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/22\">",
"      Brignole M, Gianfranchi L, Menozzi C, et al. Role of autonomic reflexes in syncope associated with paroxysmal atrial fibrillation. J Am Coll Cardiol 1993; 22:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/23\">",
"      Graboys TB, Wright RF. Provocation of supraventricular tachycardia during exercise stress testing. Cardiovasc Rev Rep 1980; 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/24\">",
"      de Vos CB, Nieuwlaat R, Crijns HJ, et al. Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J 2008; 29:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/25\">",
"      Rosso R, Sparks PB, Morton JB, et al. Vagal paroxysmal atrial fibrillation: prevalence and ablation outcome in patients without structural heart disease. J Cardiovasc Electrophysiol 2010; 21:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/26\">",
"      Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/27\">",
"      Rostagno C, Bacci F, Martelli M, et al. Clinical course of lone atrial fibrillation since first symptomatic arrhythmic episode. Am J Cardiol 1995; 76:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/28\">",
"      Davidson E, Weinberger I, Rotenberg Z, et al. Atrial fibrillation. Cause and time of onset. Arch Intern Med 1989; 149:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/29\">",
"      Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/30\">",
"      Flaker GC, Fletcher KA, Rothbart RM, et al. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Am J Cardiol 1995; 76:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/31\">",
"      Al-Khatib SM, Wilkinson WE, Sanders LL, et al. Observations on the transition from intermittent to permanent atrial fibrillation. Am Heart J 2000; 140:142.",
"     </a>",
"    </li>",
"    <li>",
"     Godtfredsen J. Atrial fibrillation &mdash; Etiology, course and prognosis: A followup of 1212 patients, University of Denmark, Copenhagen 1975.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/33\">",
"      Aboaf AP, Wolf PS. Paroxysmal atrial fibrillation. A common but neglected entity. Arch Intern Med 1996; 156:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/34\">",
"      Petersen P, Godtfredsen J. Atrial fibrillation--a review of course and prognosis. Acta Med Scand 1984; 216:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/35\">",
"      Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke 1986; 17:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/36\">",
"      Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/37\">",
"      The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/38\">",
"      Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/39\">",
"      van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/40\">",
"      Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995; 25:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/41\">",
"      Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/42\">",
"      Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/43\">",
"      Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/44\">",
"      Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 2002; 40:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/45\">",
"      Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009; 2:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/46\">",
"      Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J 2007; 28:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/47\">",
"      Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/48\">",
"      Lakkireddy D, Atkins D, Pillarisetti J, et al. Effect of Yoga on Arrhythmia Burden, Anxiety, Depression, and Quality of Life in Paroxysmal Atrial Fibrillation: The YOGA My Heart Study. J Am Coll Cardiol 2013; 61:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31384/abstract/49\">",
"      Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 956 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-201.211.0.116-9C65E8D14A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31384=[""].join("\n");
var outline_f30_41_31384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H100913677\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H356405846\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1696500\">",
"      SIGNS AND SYMPTOMS OF AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Atrial premature beats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Recurrence of AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Progression to permanent AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk of embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H124273315\">",
"      - Duration and frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT OF THE ARRHYTHMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Rate control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100913677\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/956|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/1/2078\" title=\"figure 1\">",
"      Stroke rates AF risk category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/956|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/45/40668\" title=\"table 1\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=related_link\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_41_31385="Etiology and evaluation of cyanosis in children";
var content_f30_41_31385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and evaluation of cyanosis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31385/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31385/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31385/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31385/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/41/31385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanosis, a bluish purple discoloration of the tissues due to an increased concentration of deoxygenated hemoglobin in the capillary bed, results from a variety of conditions, many of which are life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/1\">",
"     1",
"    </a>",
"    ]. It is most easily appreciated in the lips, nail beds, earlobes, mucous membranes, and locations where the skin is thin. It may be enhanced or obscured by lighting conditions and skin pigmentation. In children, life-threatening cyanosis most often results from respiratory disorders.",
"   </p>",
"   <p>",
"    This topic will review the differential diagnosis and approach to the child with cyanosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two mechanisms result in cyanosis: systemic arterial oxygen desaturation and increased oxygen extraction by the tissues. Based upon these mechanisms, two types of cyanosis are described: central and peripheral. In addition, dermatologic conditions may result in blue skin color that mimics cyanosis in the absence of increased levels of deoxygenated blood in the capillary beds. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Dermatologic conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Central cyanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central cyanosis is evident when systemic arterial concentration of deoxygenated hemoglobin (Hb) in the blood exceeds 5",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    (3.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (oxygen saturation &le;85 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/2\">",
"     2",
"    </a>",
"    ]. Of note, cyanosis cannot be detected by observation in patients with severe anemia (Hb &lt;5",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    [3.1",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Peripheral cyanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients",
"    with peripheral cyanosis have a normal systemic arterial oxygen saturation. However, increased oxygen extraction results in a wide systemic arteriovenous oxygen difference and increased deoxygenated blood on the venous side of the capillary beds. The increased extraction of oxygen results from sluggish movement of blood through the capillary circulation. Causes include vasomotor instability, vasoconstriction caused by exposure to cold, venous obstruction, elevated venous pressure, polycythemia, and low cardiac output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LIFE-THREATENING CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanosis may be caused by a wide range of disorders, but it usually stems from one of several common disorders of childhood and adolescence. Respiratory causes are most often to blame in previously healthy children with the new onset of central cyanosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/1\">",
"     1",
"    </a>",
"    ]. Vascular causes, including cardiac and pulmonary vascular etiologies, are also important etiologies of both central and peripheral cyanosis, particularly in young infants (",
"    <a class=\"graphic graphic_table graphicRef82520 \" href=\"UTD.htm?12/20/12621\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other serious conditions produce central cyanosis through disordered breathing caused by neurologic disease or decreased ability for hemoglobin to carry oxygen (eg, methemoglobinemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Respiratory causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any condition that inhibits oxygen from reaching the alveoli or disrupts its movement across the alveolar interface can cause life-threatening cyanosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Decreased inspired oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to an environment where the concentration of inspired oxygen (FiO2) is decreased can lead to cyanosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/4\">",
"     4",
"    </a>",
"    ]. In children, the most common scenario is smoke inhalation from house fires. With this exposure, hypoxia from the diminished ambient FiO2 is frequently compounded by toxicity from carbon monoxide exposure (which primarily affects O2 delivery and to a lesser extent O2 utilization), and cyanide poisoning (which primarily affects O2 utilization). In addition, lower airway obstruction from smoke particles and upper airway obstruction from direct thermal injury are common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"     \"Carbon monoxide poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=see_link\">",
"     \"Cyanide poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, children experience environments with diminished FiO2 through unintentional exposure to asphyxiating gases (eg, hydrogen sulfide [\"sewer gas\"], methane [common in peat bogs]) or intentional inhalation of hydrocarbons (eg, propane, butane, trichloroethane). Initial treatment consists of removal from the asphyxiating environment and immediate administration of 100 percent oxygen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33753?source=see_link\">",
"     \"Inhalant abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Upper airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe upper airway obstruction, as with a foreign body, croup, thermal injury, epiglottitis, bacterial tracheitis,",
"    <span class=\"nowrap\">",
"     tracheal/bronchial",
"    </span>",
"    disruption, or congenital airway abnormalities, quickly leads to decreased alveolar ventilation and hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/3\">",
"     3",
"    </a>",
"    ]. Physical findings include stridor, voice changes or aphonia, drooling, suprasternal retractions, and prolonged inspiratory time.",
"   </p>",
"   <p>",
"    The initial approach to the child with severe symptoms includes a rapid assessment of respiratory function and identification of key clinical features (such as history of injury, fever, and onset of symptoms) that suggest the diagnosis and guide therapeutic interventions (",
"    <a class=\"graphic graphic_algorithm graphicRef54996 \" href=\"UTD.htm?9/37/9810\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link&amp;anchor=H39#H39\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Severe upper airway obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Central cyanosis indicates severe airway obstruction and is an ominous finding. The child's condition will rapidly deteriorate if the airway obstruction is not relieved. Treatment must be initiated immediately by the most expert clinician available (",
"    <a class=\"graphic graphic_algorithm graphicRef55990 \" href=\"UTD.htm?22/48/23296\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link&amp;anchor=H36#H36\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\", section on 'No airway, complete obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Impairment of chest wall or lung expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanosis ensues rapidly when chest wall movement or lung inflation is impeded. This condition is often a result of major trauma (eg, motor vehicle collisions) and includes external chest compression (eg, victims of building collapse or mudslides), flail chest, open pneumothorax, tension pneumothorax, or hemothorax (",
"    <a class=\"graphic graphic_table graphicRef79921 \" href=\"UTD.htm?31/3/31803\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12807?source=see_link\">",
"     \"Chest wall injuries in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features include abnormal chest wall movement (as may occur with splinting from pain or with a flail segment), chest wall ecchymosis or abrasions, deformity of the chest wall, subcutaneous air with crepitus, open sucking chest wound, tracheal deviation, abnormal breath sounds, or focal tenderness to palpation over ribs, sternum, or scapula.",
"   </p>",
"   <p>",
"    Immediately life-threatening injuries must be identified and treated during the initial rapid assessment. Interventions may include assisted ventilation (flail chest), needle or tube thoracostomy (tension pneumothorax, hemothorax), application of an occlusive dressing secured on three of four sides (open pneumothorax), or (rarely) emergency thoracotomy (hemothorax unresponsive to tube thoracostomy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intrinsic lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary pulmonary conditions such as severe asthma, bronchiolitis, pertussis, pneumonia, empyema, cystic fibrosis, noncardiogenic pulmonary edema, and, in the premature infant, hyaline membrane disease, comprise the most common life-threatening conditions that cause cyanosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/1\">",
"     1",
"    </a>",
"    ]. These etiologies can be broadly described as causing small airway obstruction (eg, asthma, bronchiolitis), parenchymal disease (eg, pneumonia), or disruption of oxygen exchange in the alveoli (eg, pulmonary edema, hyaline membrane disease).",
"   </p>",
"   <p>",
"    The work of breathing is often increased in such patients and may be associated with retractions, nasal flaring,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    grunting. The auscultatory abnormalities vary by etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expiratory wheezing typically occurs in diseases that cause small airway obstruction (eg, asthma, bronchiolitis). Children with bronchiolitis also frequently have coarse or fine rales. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=see_link&amp;anchor=H9#H9\">",
"       \"Bronchiolitis in infants and children: Clinical features and diagnosis\", section on 'Examination'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute asthma exacerbations in children: Outpatient management\", section on 'Assessment of severity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inspiratory rales are prominent in patients with parenchymal lung disease or alveolar disruption. In addition, patients with pneumonia may have lung findings of consolidation, such as decreased breath sounds, bronchial breath sounds, or dullness to percussion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Lung examination'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=see_link&amp;anchor=H18#H18\">",
"       \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In infants and young children with pertussis at the paroxysmal stage, coughing persists and severity increases, occurring in paroxysmal attacks. The classic cough of pertussis is distinctive. The paroxysm is a long series of coughs during which the child may develop gagging and cyanosis and appear to be struggling for breath (",
"      <a class=\"graphic graphic_movie graphicRef80861 \" href=\"UTD.htm?33/32/34304\">",
"       movie 1",
"      </a>",
"      ). Whooping, which is characterized by the noise of the forced inspiratory effort, may be observed following a coughing attack during the paroxysmal phase (",
"      <a class=\"graphic graphic_movie graphicRef57822 \" href=\"UTD.htm?10/7/10352\">",
"       movie 2",
"      </a>",
"      ), but is not always present (",
"      <a class=\"graphic graphic_movie graphicRef55250 \" href=\"UTD.htm?10/22/10592\">",
"       movie 3",
"      </a>",
"      ). Post-tussive emesis occurs frequently. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\", section on 'Paroxysmal'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with severe lung disease and poor air entry may not have lung findings that easily distinguish among the possible causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Circulatory causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulatory conditions may cause cyanosis by mixing oxygenated and deoxygenated blood (eg, intracardiac or vascular shunts), structural or vascular alteration in pulmonary blood flow, cardiac decompensation with pulmonary edema, or shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanotic congenital heart disease (CHD) is a common cause of central cyanosis in newborns (",
"    <a class=\"graphic graphic_table graphicRef50161 \" href=\"UTD.htm?18/6/18540\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Although most newborns with cyanotic congenital heart disease are discovered either in utero or while still in the newborn nursery, occasionally infants with cyanosis from undiagnosed CHD will present to an emergency department or a primary care office. Specifically, those infants with lesions dependent upon a patent ductus arteriosus for pulmonary blood flow (eg, coarctation of the aorta, hypoplastic left heart syndrome, pulmonary atresia) can have profound cyanosis when the ductus closes, usually one to two weeks after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hyperoxia test is useful in distinguishing cardiac from pulmonary causes of cyanosis in some infants. In the hyperoxia test, arterial oxygen tension (PaO2) is measured in the right radial artery (preductal) while the patient breathes 100 percent oxygen concentration for 10 minutes. Oxygen can be administered via an oxyhood or an endotracheal tube if the patient is already intubated.",
"   </p>",
"   <p>",
"    In CHD associated with intracardiac right-to-left shunting, blood in the pulmonary veins is fully saturated with oxygen in ambient air. Administering higher concentrations of inspired oxygen increases the amount of dissolved oxygen, but has minimal effect on oxygen tension levels. In contrast, patients with nonvascular pulmonary disease have pulmonary venous desaturation. Supplemental oxygen administration in pulmonary disease typically increases pulmonary venous oxygen levels and improves systemic oxygenation (",
"    <a class=\"graphic graphic_table graphicRef54070 \" href=\"UTD.htm?16/41/17053\">",
"     table 4",
"    </a>",
"    ). However, neonates with persistent pulmonary hypertension of the newborn do not increase systemic oxygenation in response to the hyperoxia test, although a difference between preductal and postductal pO2 may be detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnosis and initial management of cyanotic heart disease in the newborn\", section on 'Hyperoxia test'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link&amp;anchor=H13#H13\">",
"     \"Persistent pulmonary hypertension of the newborn\", section on 'Arterial blood gas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once CHD has been identified as the cause of cyanosis, findings on physical examination, chest radiograph, and electrocardiogram vary depending on the cardiac lesion (",
"    <a class=\"graphic graphic_table graphicRef79941 \" href=\"UTD.htm?26/1/26653\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=see_link\">",
"     \"Cardiac causes of cyanosis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with suspected cyanotic congenital heart disease warrant urgent pediatric cardiology consultation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12409?source=see_link\">",
"     \"Suspected heart disease in infants and children: Criteria for referral\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary edema may result from cardiac and noncardiac causes and diminishes arterial oxygenation by limiting diffusion of O2 across the alveoli into the pulmonary capillaries [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiogenic &ndash; Cardiogenic pulmonary edema occurs as a result of pulmonary congestion in association with heart failure or congenital cardiac lesions that shunt blood from the systemic to the pulmonary circulation (eg, ventricular septal defect, persistent patent ductus arteriosus, total anomalous pulmonary venous connection). Myocarditis is one of the most important causes of acquired heart failure in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=see_link&amp;anchor=H18#H18\">",
"       \"Cardiac causes of cyanosis in the newborn\", section on 'Increased pulmonary blood flow'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=see_link\">",
"       \"Pathophysiology of left to right shunts\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Children with cardiogenic pulmonary edema usually have inspiratory rales on lung auscultation and a gallop rhythm with or without a murmur on cardiac examination. Patients with congenital heart lesions often have electrocardiograms that show age-specific increased voltage, and the heart is often enlarged on chest radiograph. In children with myocarditis, the EKG may show decreased voltage and the heart size may either be normal or increased on x-ray. Echocardiography by a pediatric cardiologist helps identify the degree of failure and the underlying cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12409?source=see_link\">",
"       \"Suspected heart disease in infants and children: Criteria for referral\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Noncardiogenic &ndash; Permeability pulmonary edema due to acute respiratory distress syndrome (ARDS) is the most common form of noncardiogenic pulmonary edema. It presents with severe respiratory distress (dyspnea) in association with the acute appearance of diffuse chest radiographic infiltrates and hypoxemia. The onset of ARDS is often within the first two hours after an inciting event, although this can be delayed as long as one to three days. Chest radiographs usually progress to a bilateral alveolar filling pattern.",
"      <br/>",
"      <br/>",
"      The diagnosis of permeability pulmonary edema requires distinction from cardiogenic pulmonary edema and from other causes of lung disease and is usually associated with a normal cardiac examination and pulmonary capillary wedge pressure. Therapy is primarily supportive and includes fluid restriction, diuretic administration, and mechanical ventilation in concert with treatment of the underlying cause. Specific pharmacologic therapies such as inhaled vasodilators, anti-inflammatory agents, exogenous surfactant,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      novel ventilation strategies have NOT shown consistent and unequivocal clinical benefit. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link&amp;anchor=H4#H4\">",
"       \"Noncardiogenic pulmonary edema\", section on 'Permeability pulmonary edema due to ARDS'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Noncardiogenic pulmonary edema may also occur in association with rapid high altitude exposure, neurologic insults (eg, head trauma, intracranial surgery, intracranial bleeding), reexpansion of a pneumothorax, and viral infections (eg, hantavirus, enterovirus). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link&amp;anchor=H10#H10\">",
"       \"Noncardiogenic pulmonary edema\", section on 'Other noncardiogenic forms of pulmonary edema'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27769?source=see_link&amp;anchor=H13205892#H13205892\">",
"       \"High altitude disease: Unique pediatric considerations\", section on 'High altitude pulmonary edema'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary vascular abnormalities (eg, persistent pulmonary hypertension of the newborn (PPHN)) can lead to central cyanosis because of high pulmonary pressures that shunt blood from the pulmonary to the systemic circulation through a patent ductus arteriosus or open foramen ovale away from the lungs and cause hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonates with PPHN may have a hyperdynamic precordium and a harsh murmur of tricuspid regurgitation. The definitive diagnosis of PPHN requires echocardiography although it is suggested by a difference in pO2 between a preductal (right radial) and postductal (umbilical or lower extremity) arterial blood gas or a difference between pulse oximetry obtained in the right thumb or finger and either great toe. Initial treatment includes oxygen, assisted ventilation, artificial surfactant administration, inhaled nitric oxide, circulatory support, and correction of acidosis. Patients that do not respond to these measures are candidates for extracorporeal membrane oxygenation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link&amp;anchor=H15#H15\">",
"     \"Persistent pulmonary hypertension of the newborn\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, pulmonary hypertension may be idiopathic or may occur secondary to unrepaired congenital heart disease, left-sided heart failure from acquired heart disease (eg, myocarditis, rheumatic heart disease), or obesity with obstructive sleep apnea. On cardiac examination, the clinician may note a systolic ejection murmur with a single or narrowly split S2 and, in severely affected patients, a diastolic murmur of tricuspid regurgitation. Prominent jugular venous pulse and a gallop may also be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link&amp;anchor=H17914993#H17914993\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary embolism (PE) is rarely diagnosed in children but occurs not uncommonly in adolescents, particularly females. Risk factors in the pediatric patient include hypercoagulable states (eg, protein C deficiency, protein S deficiency, sickle cell disease, nephrotic syndrome), indwelling central venous catheters, solid tumors, heart disease, use of oral contraceptives, and pregnancy termination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\", section on 'Pulmonary embolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in adults, PE can manifest with pleuritic chest pain, tachypnea, cough, tachycardia, acute dyspnea, and sudden collapse. Most commonly, however, the clinical manifestations of PE in children, especially younger ones, are not specific and often mimic the clinical symptoms of the underlying disease. For this reason and because younger children cannot verbalize their symptoms, the diagnosis of PE should be remembered in critically ill children with sudden, unexplained cardiorespiratory deterioration. Children with proven pulmonary embolism warrant anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27241?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to chest pain in children\", section on 'Pulmonary embolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link&amp;anchor=H3409167#H3409167\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\", section on 'Secondary venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pulmonary hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hemorrhage sufficient to cause cyanosis is very rare in children. Potential causes include acute histoplasmosis, exposure to Stachybotrys chartarum, Goodpasture syndrome, Wegener's granulomatosis, idiopathic pulmonary hemosiderosis, bronchiectasis (especially children with cystic fibrosis), lupus pneumonitis, and pulmonary arteriovenous malformations (Osler-Weber-Rendu syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37896?source=see_link&amp;anchor=H3#H3\">",
"     \"Hemoptysis in children\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in septic or cardiogenic shock have a low perfusion state. When transit time for red cells across capillary beds is lengthened, there is greater time for unloading of oxygen to the tissues, and perfusion related peripheral cyanosis occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/3\">",
"     3",
"    </a>",
"    ]. The type and cause of shock can generally be determined from a focused history, thorough physical examination, and selected diagnostic studies (",
"    <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"UTD.htm?1/61/2000\">",
"     algorithm 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"     \"Initial evaluation of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Severe methemoglobinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methemoglobin is an altered state of hemoglobin in which the ferrous (Fe2+) irons of heme are oxidized to the ferric (Fe3+) state. The ferric hemes of methemoglobin are UNABLE to bind oxygen. In addition, the oxygen affinity of any remaining ferrous hemes in the hemoglobin tetramer is increased. The net effect is an impaired delivery of oxygen to the tissues and central cyanosis.",
"   </p>",
"   <p>",
"    Methemoglobinemia can be either congenital or acquired. Congenital methemoglobinemia results from a genetically determined deficiency in hemoglobin structure (eg, hemoglobin M) or in key enzyme systems that normally participate in reducing naturally occurring methemoglobin (",
"    <a class=\"graphic graphic_figure graphicRef53599 \" href=\"UTD.htm?24/8/24718\">",
"     figure 1",
"    </a>",
"    ). The main complaint of subjects with congenital methemoglobinemia is \"cyanosis\" or a slate-blue color of the skin and mucous membranes, a finding that is due to the different absorbance spectrum of methemoglobin compared with oxyhemoglobin.",
"   </p>",
"   <p>",
"    Acquired methemoglobinemia results from oxidative stress either from endogenous (eg, severe dehydration) or exogenous causes (eg, drugs, environmental exposures) (",
"    <a class=\"graphic graphic_table graphicRef51406 \" href=\"UTD.htm?38/28/39372\">",
"     table 6",
"    </a>",
"    ). Infants are particularly susceptible to this stress because of immature enzyme systems required to reduce hemoglobin. Symptoms in patients with acquired methemoglobinemia tend to be more severe than in patients with congenital methemoglobinemia because they result from an acute impairment in oxygen delivery to tissues that does not allow sufficient time for compensatory mechanisms to take place. Early symptoms include headache, fatigue, dyspnea, and lethargy. At higher methemoglobin levels, respiratory depression, altered consciousness, shock, seizures, and death may occur. Acquired methemoglobinemia is life-threatening when methemoglobin comprises more than 40 percent of total hemoglobin.",
"   </p>",
"   <p>",
"    Methemoglobinemia may be clinically suspected by the presence of clinical \"cyanosis\" in the presence of a normal arterial pO2 (PaO2) as obtained by arterial blood gases. The blood in methemoglobinemia usually appears normal at the time of venipuncture but with observation over time may turn a color that has been variously described as dark-red, chocolate, or brownish to blue in color, and, unlike deoxyhemoglobin, the color does not change with the addition of oxygen (",
"    <a class=\"graphic graphic_figure graphicRef58540 \" href=\"UTD.htm?16/60/17344\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78013 \" href=\"UTD.htm?4/20/4418\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Routine pulse oximetry may be INACCURATE in monitoring oxygen saturation in the presence of methemoglobinemia, and may not be used to make the diagnosis of this disorder. However, the presence of methemoglobin can be suspected when the oxygen saturation as measured by pulse oximetry is significantly different from the oxygen saturation calculated from arterial blood gas analysis (\"saturation gap\"). Often the oxygen saturation is mildly depressed, but rarely to a level below 85 percent. Direct measurement of methemoglobin concentration confirms the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\", section on 'Laboratory diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link&amp;anchor=H8#H8\">",
"     \"Pulse oximetry\", section on 'Abnormal hemoglobins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic conditions that result in disordered breathing comprise an important cause of central cyanosis in children. Common etiologies include major head trauma, poisoning, and seizures. However, any neurologic disease that results in altered mental status or weakness can lead to hypoventilation and cyanosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=see_link\">",
"     \"Evaluation of stupor and coma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/54/24425?source=see_link\">",
"     \"Etiology and evaluation of the child with muscle weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OTHER CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other etiologies of cyanosis include acrocyanosis, cold exposure, or polycythemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Acrocyanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acrocyanosis refers to bluish color in the hands and feet and around the mouth (circumoral cyanosis). The mucus membranes generally remain pink. Acrocyanosis is a form of peripheral cyanosis that usually reflects benign vasomotor changes in the affected extremities. It does not indicate pathology unless cardiac output is extremely low, resulting in cutaneous vasoconstriction (eg, myocarditis).",
"   </p>",
"   <p>",
"    Acrocyanosis of the newborn is an impressive example of cyanosis arising from intense peripheral vasoconstriction and variable perfusion in the extremities compared with the central circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/7\">",
"     7",
"    </a>",
"    ]. It is seen in well babies and resolves within the first few days of life.",
"   </p>",
"   <p>",
"    Acrocyanosis may also occur in infants when they cry, regurgitate, vomit, cough, or hold their breath. This finding is often very alarming to the caregiver who witnesses the event and requires careful questioning and observation to differentiate from serious underlying pathology (eg, seizure, apneic episode, cardiac arrhythmia). The child with acrocyanosis typically does not have major changes in mental status during the event and appears well on physical examination.",
"   </p>",
"   <p>",
"    Occasionally, children with significant gastroesophageal reflux will have paroxysmal acrocyanosis (especially perioral cyanosis) in association with brief episodes of limpness, stereotypical positioning or tonic clonic motions suggestive of a seizure, or apnea. This constellation of features is called Sandifer syndrome and typically responds to treatment of the gastroesophageal reflux. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link&amp;anchor=H15#H15\">",
"     \"Nonepileptic paroxysmal disorders in infancy\", section on 'Sandifer syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Raynaud phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raynaud phenomenon (RP) is a specific type of acrocyanosis that causes white, blue, and red discoloration of the fingers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the toes after exposure to changes in temperature (cold or hot) or emotional events. Skin discoloration occurs because an abnormal spasm of the blood vessels causes a diminished blood supply to the local tissues. Initially, the",
"    <span class=\"nowrap\">",
"     fingers/toes",
"    </span>",
"    turn white because of the diminished blood supply. The",
"    <span class=\"nowrap\">",
"     fingers/toes",
"    </span>",
"    then turn blue because of lack of oxygen&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/8\">",
"     8",
"    </a>",
"    ]. RP is considered primary if these symptoms occur alone without evidence of any associated disorder. By comparison, secondary RP refers to the presence of the disorder in association with a related illness, such as systemic lupus erythematosus and scleroderma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cold exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate cold exposure slows the transit times through capillary beds and allows for increased unloading of oxygen from the blood to the tissues in infants and young children, leading to cyanosis, especially in the lips and perioral region [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/7\">",
"     7",
"    </a>",
"    ]. This form of peripheral cyanosis rapidly resolves with patient warming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia can cause cyanosis due to the increased red blood cell mass and relatively increased amount of deoxygenated hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/1,3,7\">",
"     1,3,7",
"    </a>",
"    ]. Causes of polycythemia in children vary by age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Neonatal polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In term neonates, polycythemia is typically due to erythrocyte autotransfusion, most commonly caused by delayed clamping of the umbilical cord with increased transfer of placental blood to the infant. This can occur intentionally or unintentionally (eg, at an unattended delivery), and may be exaggerated if the baby is held at a level below the mother immediately following birth for an extended period of time before the cord is clamped. Intrauterine erythropoiesis is an important etiology when infants are small for gestational age and in infants of mothers with preeclampsia, cardiac disease, pulmonary disease, or other causes of placental insufficiency and chronic intrauterine hypoxia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=see_link&amp;anchor=H5#H5\">",
"     \"Neonatal polycythemia\", section on 'Causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When term neonates have a peripheral venous hematocrit that exceeds 65 percent (hemoglobin &gt;22",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    [13.7",
"    <span class=\"nowrap\">",
"     mmol/liter]),",
"    </span>",
"    changes in blood viscosity may lead to symptoms including cyanosis, respiratory distress, persistent pulmonary hypertension of the newborn, acute decompensated heart failure, and altered mental status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Polycythemia outside of the neonatal period",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hypoxia due to lung or heart disease is the most common cause of polycythemia in children outside of the neonatal period. Sleep apnea secondary to obesity and high altitude exposure are other important etiologies. Genetic causes or erythropoietin secreting tumors rarely occur in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link\">",
"     \"Diagnostic approach to the patient with polycythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cyanotic breath-holding spells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with cyanotic breath-holding spells manifests with a history of crying, typically followed by sudden breath-holding in forced expiration with apnea and cyanosis. These features may progress to limpness and loss of consciousness. Cyanosis can appear faster than anticipated with simple breath-holding, and the loss of tone is often striking. As the child resumes normal breathing, the cyanosis resolves. Cyanotic breath-holding spells most commonly occur around one year of age with a range of six months to four years. Up to 15 percent of cases may have an initial episode below the age of six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link&amp;anchor=H8#H8\">",
"     \"Nonepileptic paroxysmal disorders in infancy\", section on 'Breath-holding spells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Dermatologic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain conditions may uncommonly cause blue skin in children that may rarely be mistaken for cyanosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pigmentary lesions (eg, Mongolian spots or large birthmarks) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Drug therapy (eg, gray-blue skin discoloration from",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      administration, use of products containing silver) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/10,12\">",
"       10,12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Large and extensive tattoos [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Blue clothing dye",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several historical features help determine the cause of cyanosis in children (",
"    <a class=\"graphic graphic_table graphicRef82520 \" href=\"UTD.htm?12/20/12621\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &ndash; Although respiratory disorders predominate as the cause of central cyanosis in all children, cyanotic congenital heart disease and polycythemia are much more common etiologies for life-threatening central cyanosis in neonates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Methemoglobinemia is more likely in young infants, especially those with gastroenteritis or oxidant toxin exposure. Acrocyanosis and cold exposure are common causes of peripheral cyanosis in otherwise healthy neonates and young infants.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever &ndash; Fever may be present in children with infectious causes of cyanosis secondary to upper airway obstruction (eg, croup), lower airway disease (eg, pneumonia), or shock (eg, septic shock).",
"     </li>",
"     <li>",
"      Trauma &ndash; Chest wall or upper airway trauma may cause central cyanosis due to lung injury or upper airway obstruction.",
"     </li>",
"     <li>",
"      Exposures &ndash; Smoke inhalation or exposure to other low oxygen environments suggests central cyanosis from decreased inspired oxygen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oxidant toxin exposure may lead to methemoglobinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/13\">",
"     13",
"    </a>",
"    ]. Domestic and environmental substances implicated in methemoglobinemia include foods or well water contaminated with nitrates or nitrites, aniline dyes, naphthalene, and certain industrial compounds (nitrobenzenes, nitrous gases and organic amines) (",
"    <a class=\"graphic graphic_table graphicRef51406 \" href=\"UTD.htm?38/28/39372\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications &ndash; Blue skin color may occur in patients undergoing treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      . Colloidal silver use can cause argyria, an irreversible blue-gray tinting of the skin [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prior lung disease &ndash; Exacerbation of pre-existing lung disease (eg, asthma, bronchopulmonary dysplasia) is a common cause of respiratory distress and central cyanosis in children.",
"     </li>",
"     <li>",
"      Congenital heart disease &ndash; Cyanotic congenital heart disease may explain profound central cyanosis in an otherwise well-appearing child or underlie pulmonary edema or shock in the ill-appearing child.",
"     </li>",
"     <li>",
"      Neurologic&nbsp;disease &ndash; Any neurologic condition that results in decreased respiratory effort can lead to cyanosis. A history of drug or toxin-related respiratory depression, CNS lesions, seizures, breath holding spells, and neuromuscular disease should be pursued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanosis is always a concerning finding and is often less apparent in the skin of patients with darker pigmentation. For this reason, examination should include the nail beds, tongue, and mucous membranes, which are less affected by pigmentation. Patients with peripheral cyanosis typically have cyanotic nail beds, decreased peripheral perfusion, and cold extremities in conjunction with a pink tongue and oral mucous membranes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever &ndash; Fever is often present in cyanotic children with intrinsic pulmonary conditions (eg, pneumonia, bronchiolitis), infectious upper airway obstruction (eg, croup), and septic shock.",
"     </li>",
"     <li>",
"      Lung examination &ndash; Tachypnea is seen in patients with either respiratory or circulatory causes of cyanosis. Similarly, flaring, grunting, and retractions are nonspecific indicators of respiratory distress in the child with cyanosis.",
"      <br/>",
"      <br/>",
"      Stridor and suprasternal retractions identify upper airway obstruction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Upper airway obstruction'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Rales",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wheezing suggest lower airway disease or pulmonary edema. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Intrinsic lung disease'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Clear lung sounds may be present in patients with cyanotic congenital heart disease, early myocarditis, methemoglobinemia, or neurologic conditions associated with hypoventilation (eg, coma, seizures, muscle weakness).",
"      <br/>",
"      <br/>",
"      Traumatic lung injury may have multiple findings including (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Impairment of chest wall or lung expansion'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abnormal chest wall movement (eg, a flail segment)",
"     </li>",
"     <li>",
"      Open, sucking chest wound",
"     </li>",
"     <li>",
"      Chest wall ecchymosis or abrasions",
"     </li>",
"     <li>",
"      Subcutaneous air with crepitus",
"     </li>",
"     <li>",
"      Tracheal deviation",
"     </li>",
"     <li>",
"      Abnormal breath sounds",
"     </li>",
"     <li>",
"      Focal tenderness to palpation over ribs, sternum, or scapula",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac examination - Tachycardia frequently accompanies cyanosis in children. Bradycardia is an ominous sign of impending cardiorespiratory collapse.",
"      <br/>",
"      <br/>",
"      A cardiac murmur and a second heart sound that is loud or single is heard in many patients with cyanotic structural heart disease (",
"      <a class=\"graphic graphic_table graphicRef79941 \" href=\"UTD.htm?26/1/26653\">",
"       table 5",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=see_link\">",
"       \"Cardiac causes of cyanosis in the newborn\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Myocardial dysfunction with pulmonary edema is suggested by the presence of a gallop rhythm, palpable cardiac thrill,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laterally displaced point of maximal impulse.",
"     </li>",
"     <li>",
"      Skin examination &ndash; Peripheral vasoconstriction with cool extremities is found in children with peripheral cyanosis caused by cold exposure.",
"      <br/>",
"      <br/>",
"      Central cyanosis with a slate gray appearance to the skin is characteristic of methemoglobinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Dermatologic conditions that may mimic cyanosis are often well demarcated (eg, Mongolian spot, tattoo) or are present at sites of external exposures (eg, blue clothing dye, finger paints).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional testing in the cyanotic child is frequently necessary to identify the presence and degree of systemic arterial oxygen desaturation and to determine the underlying etiology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial blood gas &ndash; Cyanotic patients with abnormalities in respiration, control of breathing, or circulation have a decreased partial pressure of oxygen (PaO2) in arterial blood.",
"      <br/>",
"      <br/>",
"      If the patient has a normal PaO2 and is well-appearing despite central cyanosis, possible etiologies include mild methemoglobinemia, acrocyanosis, polycythemia, cold exposure, or dermatologic etiologies. If the patient is ill-appearing with a normal PaO2, one must evaluate for septic or cardiogenic shock, polycythemia, or severe methemoglobinemia.",
"      <br/>",
"      <br/>",
"      In many cases of peripheral cyanosis, central oxygenation is obvious on physical examination, and arterial blood gas determination is unnecessary.",
"     </li>",
"     <li>",
"      Hematocrit &ndash; The hematocrit should be measured in neonates who appear plethoric or who have signs or symptoms that may be due to polycythemia. The hematocrit may be measured initially on a capillary blood sample, usually taken from a warmed heel. If the capillary hematocrit is &gt;65 percent, the hematocrit should be repeated on a sample of venous blood. The venous hematocrit usually will be 5 to 15 percent lower than the capillary hematocrit. The diagnosis of polycythemia is made if the venous hematocrit is &gt;65 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=see_link&amp;anchor=H14#H14\">",
"       \"Neonatal polycythemia\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperoxia test &ndash; The hyperoxia test is useful in distinguishing cardiac from pulmonary causes of cyanosis in the neonate. In this test, arterial oxygen tension (PaO2) is measured in the right radial artery (preductal) while breathing room air and after breathing 100 percent oxygen for 10 minutes. The findings vary with etiology (",
"      <a class=\"graphic graphic_table graphicRef54070 \" href=\"UTD.htm?16/41/17053\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link&amp;anchor=H21#H21\">",
"       \"Diagnosis and initial management of cyanotic heart disease in the newborn\", section on 'Hyperoxia test'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest radiograph &ndash; An abnormal chest radiograph can lead directly to the diagnosis of traumatic lung inflation conditions, intrinsic pulmonary conditions, pulmonary edema, or congenital heart disease (",
"      <a class=\"graphic graphic_table graphicRef79941 \" href=\"UTD.htm?26/1/26653\">",
"       table 5",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary hypertension.",
"     </li>",
"     <li>",
"      EKG &ndash; In cyanotic patients with abnormal findings on cardiac examination, EKG can be very helpful in solidifying a diagnosis of heart disease (",
"      <a class=\"graphic graphic_table graphicRef79941 \" href=\"UTD.htm?26/1/26653\">",
"       table 5",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary hypertension. However, echocardiography is necessary to more specifically identify the cardiac lesion and function.",
"     </li>",
"     <li>",
"      Methemoglobin level &ndash; Direct measurement of methemoglobin should be performed in cyanotic patients with a normal PaO2 in whom cardiac disease has been excluded. Methemoglobinemia is also indirectly suggested by a difference between the calculated oxygen saturation on an arterial blood gas and direct measurement by cooximetry. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical features, diagnosis, and treatment of methemoglobinemia\", section on 'Laboratory diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the cyanotic child focuses on physical examination, the presence of decreased oxygen saturation, and the results of electrocardiogram and chest radiograph (",
"    <a class=\"graphic graphic_algorithm graphicRef77813 \" href=\"UTD.htm?4/18/4386\">",
"     algorithm 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31385/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Peripheral cyanosis, well-appearing",
"      </strong>",
"      &ndash; Peripheral cyanosis in the well-appearing neonate is typically due to acrocyanosis and mild to moderate cold exposure. In the older child, Raynaud phenomenon (RP) is a specific type of acrocyanosis that causes white, blue, and red discoloration of the fingers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the toes after exposure to changes in temperature (cold or hot) or emotional events.",
"     </li>",
"     <li>",
"      <strong>",
"       Normal oxygen saturation, well-appearing",
"      </strong>",
"      &ndash; Infants with polycythemia and mild methemoglobinemia (&lt;20 percent methemoglobin) have central cyanosis and normal or near normal oxygen saturation. The pulse oximetry declines approximately 1 percent for every 2 percent increase in methemoglobin up to 30 percent methemoglobin and then provides a persistent reading of 85 percent at higher levels of methemoglobin.",
"      <br/>",
"      <br/>",
"      Children with certain dermatologic conditions may also appear cyanotic but will be well-appearing with a normal oxygen saturation.",
"     </li>",
"     <li>",
"      <strong>",
"       Normal oxygen saturation, ill-appearing",
"      </strong>",
"      &ndash; Ill-appearing children with normal oxygen saturation warrant additional evaluation for septic or cardiogenic shock. In addition, neonates may uncommonly appear ill because of polycythemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"       \"Initial evaluation of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decreased oxygen saturation, abnormal heart sounds &ndash; A centrally cyanotic patient with an abnormal cardiac examination warrants an electrocardiogram (EKG) and a chest radiograph. An abnormal EKG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chest radiograph suggests congenital heart disease or heart failure. However, a normal EKG does not exclude certain lesions such as tetralogy of Fallot, truncus arteriosus, and transposition of the great arteries. In addition, patients with marked pulmonary hypertension (eg, persistent pulmonary hypertension of the neonate) may also have an abnormal cardiac examination with severe cyanosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Decreased oxygen saturation, abnormal pulmonary findings",
"      </strong>",
"      &ndash; If there is no murmur present and the patient is cyanotic, attention is turned primarily to the respiratory system, although cardiac and pulmonary vascular problems cannot be entirely dismissed. Children with respiratory distress or an abnormal examination of the lung should undergo chest radiography:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abnormal chest radiographs are seen with a variety of pulmonary diseases. In addition, patients with the rare condition of total anomalous pulmonary venous return with obstruction of the pulmonary veins, may display congested lung fields and a large heart on radiograph.",
"     </li>",
"     <li>",
"      If the chest radiograph is normal, assessment for methemoglobinemia should occur (see",
"      <a class=\"local\" href=\"#H32\">",
"       'Ancillary studies'",
"      </a>",
"      above). Other possible etiologies include airway obstruction, mechanical chest wall dysfunction, pulmonary hypertension or possibly pulmonary embolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Decreased oxygen saturation, normal pulmonary findings",
"      </strong>",
"      &ndash; Patients in whom the arterial oxygen tension is decreased without respiratory distress typically have central nervous system etiologies or neuromuscular weakness causing respiratory depression. In addition, transient central cyanosis is a common feature of breath-holding spells and seizures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the cyanotic child is summarized in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef77813 \" href=\"UTD.htm?4/18/4386\">",
"     algorithm 4",
"    </a>",
"    ). Assessment should focus on appearance, differentiation between central and peripheral cyanosis, and physical findings suggestive of heart or lung disease. The table lists the causes of cyanosis in children, highlighting the most common and most life-threatening etiologies (",
"    <a class=\"graphic graphic_table graphicRef82520 \" href=\"UTD.htm?12/20/12621\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/1\">",
"      Driscoll DJ. Evaluation of the cyanotic newborn. Pediatr Clin North Am 1990; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     Grant JB, Saltzman AR. Respiratory functions of the lung. In: Textbook of Pulmonary Diseases, 5th, Baum GL, Wolinsky E.  (Eds), Little, Brown, Boston 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/3\">",
"      DiMaio AM, Singh J. The infant with cyanosis in the emergency room. Pediatr Clin North Am 1992; 39:987.",
"     </a>",
"    </li>",
"    <li>",
"     West JB. Pulmonary gas exchange. In: Physiological Basis of Medical Practice, 12th, West JB.  (Ed), Williams &amp; Wilkins, Baltimore 1990. p.546.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/5\">",
"      Woods WA, McCulloch MA. Cardiovascular emergencies in the pediatric patient. Emerg Med Clin North Am 2005; 23:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/6\">",
"      Berger S, Konduri GG. Pulmonary hypertension in children: the twenty-first century. Pediatr Clin North Am 2006; 53:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/7\">",
"      Sasidharan P. An approach to diagnosis and management of cyanosis and tachypnea in term infants. Pediatr Clin North Am 2004; 51:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/8\">",
"      Cooke JP, Marshall JM. Mechanisms of Raynaud's disease. Vasc Med 2005; 10:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/9\">",
"      Conlon JD, Drolet BA. Skin lesions in the neonate. Pediatr Clin North Am 2004; 51:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/10\">",
"      Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001; 2:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/11\">",
"      Sweeney SM. Tattoos: a review of tattoo practices and potential treatment options for removal. Curr Opin Pediatr 2006; 18:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/12\">",
"      Fung MC, Bowen DL. Silver products for medical indications: risk-benefit assessment. J Toxicol Clin Toxicol 1996; 34:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/13\">",
"      Dahshan A, Donovan GK. Severe methemoglobinemia complicating topical benzocaine use during endoscopy in a toddler: a case report and review of the literature. Pediatrics 2006; 117:e806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31385/abstract/14\">",
"      Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med 1999; 34:646.",
"     </a>",
"    </li>",
"    <li>",
"     Stack AM. Cyanosis. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Willaims &amp; Wilkins, Philadelphia 2006. p.223.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6437 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31385=[""].join("\n");
var outline_f30_41_31385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Central cyanosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Peripheral cyanosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LIFE-THREATENING CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Respiratory causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Decreased inspired oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Impairment of chest wall or lung expansion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intrinsic lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Circulatory causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pulmonary hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Severe methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OTHER CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Acrocyanosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cold exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Polycythemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Polycythemia outside of the neonatal period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cyanotic breath-holding spells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Dermatologic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6437\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6437|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/37/9810\" title=\"algorithm 1\">",
"      Severe upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/48/23296\" title=\"algorithm 2\">",
"      Complete airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/61/2000\" title=\"algorithm 3\">",
"      Undifferentiated pediatric shock algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?4/18/4386\" title=\"algorithm 4\">",
"      Cyanosis algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6437|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/8/24718\" title=\"figure 1\">",
"      Methemoglobin reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/60/17344\" title=\"figure 2\">",
"      Acquired methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6437|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/20/4418\" title=\"picture 1\">",
"      Methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6437|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?33/32/34304\" title=\"movie 1\">",
"      Pertussis infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/7/10352\" title=\"movie 2\">",
"      Classical whooping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?10/22/10592\" title=\"movie 3\">",
"      Whooping cough no whoop",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6437|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/20/12621\" title=\"table 1\">",
"      Causes of cyanosis child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/3/31803\" title=\"table 2\">",
"      Pediatric thoracic injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/6/18540\" title=\"table 3\">",
"      Causes central cyanosis newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/41/17053\" title=\"table 4\">",
"      Interpretation neonatal hyperoxia test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/1/26653\" title=\"table 5\">",
"      Findings cyanotic heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/28/39372\" title=\"table 6\">",
"      Agents causing methemoglobinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27241?source=related_link\">",
"      Approach to chest pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16074?source=related_link\">",
"      Bronchiolitis in infants and children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=related_link\">",
"      Cardiac causes of cyanosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12807?source=related_link\">",
"      Chest wall injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/18/7466?source=related_link\">",
"      Cyanide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=related_link\">",
"      Diagnosis and initial management of cyanotic heart disease in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=related_link\">",
"      Diagnostic approach to the patient with polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/54/24425?source=related_link\">",
"      Etiology and evaluation of the child with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=related_link\">",
"      Evaluation of stupor and coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37896?source=related_link\">",
"      Hemoptysis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/7/27769?source=related_link\">",
"      High altitude disease: Unique pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33753?source=related_link\">",
"      Inhalant abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=related_link\">",
"      Neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=related_link\">",
"      Nonepileptic paroxysmal disorders in infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=related_link\">",
"      Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=related_link\">",
"      Pathophysiology of left to right shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12409?source=related_link\">",
"      Suspected heart disease in infants and children: Criteria for referral",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_41_31386="Overview of hepatitis B virus infection in children";
var content_f30_41_31386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hepatitis B virus infection in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31386/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31386/contributors\">",
"     Annemarie Broderick, MB, BCh, MMedSc, FRCPI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31386/contributors\">",
"     Maureen M Jonas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31386/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31386/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31386/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/41/31386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/41/31386/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/41/31386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus (HBV) infection remains a global public health problem despite the availability of an effective vaccine.",
"   </p>",
"   <p>",
"    An overview of HBV infection in children will be presented here. More detailed discussions of the microbiology, pathogenesis, clinical manifestations, and diagnosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=see_link\">",
"     \"Characteristics of the hepatitis B virus and pathogenesis of infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the incidence of acute hepatitis B in children (&lt;19 years) has decreased from approximately 13.8 cases per 100,000 population (10 to 19 years) in the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/1\">",
"     1",
"    </a>",
"    ] to 3.03 and 0.34 cases per 100,000 population in 1990 and 2002, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/2\">",
"     2",
"    </a>",
"    ]. Declines have been greatest among children who were born after 1991 when recommendations for universal hepatitis B vaccination of infants were implemented. By 2007, the incidence of acute hepatitis B in children &lt;15 years had fallen to 0.02 cases per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of acute hepatitis B infection in the United States, and in several other non-endemic countries, develop in patients from high-risk groups such as intravenous drug users, homosexual men, in those living in communities with a large proportion of immigrants from regions where HBV is endemic, and in certain groups where HBV is endemic, such as Native Americans in Alaska [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/5\">",
"     5",
"    </a>",
"    ]. The majority of children with chronic HBV infections are immigrants, have immigrant parents, or became exposed through other household contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In countries where HBV is endemic, perinatal transmission remains the most important cause of chronic infection because of high rates of disease in pregnant women. Perinatal transmission also occurs in non-endemic countries, including the United States, mostly in children of HBV-infected mothers who do not receive appropriate HBV immunoprophylaxis at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WHO SHOULD BE SCREENED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for HBV infection should be performed by testing for HBsAg and anti-HBs. Patients who are negative for these markers should be vaccinated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following groups should be screened for HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adolescents who engage in high-risk behaviors. This includes those who use intravenous or intranasal drugs, have unprotected sex with an infected partner or more than one partner, men who have sex with men, and those with a history of sexually transmitted disease [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All internationally adopted children",
"     </li>",
"     <li>",
"      Immigrants from high prevalence areas (regions in which the HBsAg prevalence is more than 2 percent). These include all of Africa and Asia, the Cape Verde islands, most of Eastern and Mediterranean Europe, the Caribbean, and parts of South America (",
"      <a class=\"graphic graphic_figure graphicRef62806 \" href=\"UTD.htm?6/43/6838\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link&amp;anchor=H2#H2\">",
"       \"Epidemiology, transmission, and prevention of hepatitis B virus infection\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children living in communities where HBV is endemic (including children born to immigrant parents from endemic areas)",
"     </li>",
"     <li>",
"      Household contacts of individuals with HBV infection",
"     </li>",
"     <li>",
"      Infants born to women with HBV infection (HBeAg positive or negative). Infants who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/39/24181?source=see_link\">",
"       hepatitis B immune globulin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/17/15639?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      at birth, followed by two additional immunizations, should be tested for anti-HBs and HBsAg at 9 to 18 months of age. This is important because about 5 percent of such infants develop chronic HBV infection even after optimal immunoprophylaxis. Those infants who were not immunized should be tested as soon as identified. Infants born to mothers who were not tested for HBsAg during pregnancy should also receive hepatitis B vaccine before hospital discharge (as is recommended for infants born to HBsAg-positive mothers), and the maternal HBsAg status should be determined as soon as possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37881?source=see_link&amp;anchor=H7#H7\">",
"       \"Hepatitis viruses and the newborn: Clinical manifestations and treatment\", section on 'Hepatitis B'",
"      </a>",
"      .) &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with HBV is associated with characteristic changes in the serum levels of hepatitis B antigens and antibodies (",
"    <a class=\"graphic graphic_table graphicRef60627 graphicRef60827 \" href=\"UTD.htm?7/35/7742\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69344 \" href=\"UTD.htm?41/25/42398\">",
"     figure 2",
"    </a>",
"    ). These markers are used to define different clinical states. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acute HBV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute hepatitis B is based upon the detection of HBsAg (hepatitis B surface antigen) and IgM anti-HBc (IgM antibody to hepatitis B core antigen). HBeAg (hepatitis B e antigen) is positive in the early phase, then converts to negative as anti-HBe (antibody to hepatitis B e antigen) appears (",
"    <a class=\"graphic graphic_figure graphicRef69344 \" href=\"UTD.htm?41/25/42398\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Acute HBV infection in children has a variable course ranging from asymptomatic infection to fulminant hepatitis. Universal HBV vaccination has substantially reduced the frequency of fulminant hepatitis. As an example, mortality in Taiwan decreased from 5.36 to 1.71 per 100,000 during the last two decades of the 20th century [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations in children who develop symptoms are similar to those in adults. The incubation period lasts one to four months. A serum sickness-like syndrome may develop during the prodromal period, followed by constitutional symptoms, anorexia, nausea, jaundice and right-upper-quadrant discomfort. The symptoms and jaundice generally disappear after one to three months, but some patients have prolonged fatigue even after normalization of serum aminotransferase concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some features are seen more commonly in certain age groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of patients progressing to chronic infection is much higher in neonates (up to 90 percent) compared with 1 to 5 percent in adults and intermediate values in young children.",
"     </li>",
"     <li>",
"      Most older children and adolescents have mild constitutional symptoms during acute HBV infection. Fulminant hepatitis is rare, but can also be seen, particularly in infants born to mothers who are HBsAg-positive and HBeAg-negative [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/12\">",
"       12",
"      </a>",
"      ]. Hepatitis B vaccination does not consistently protect against the development of fulminant hepatitis B in infants or older children.",
"     </li>",
"     <li>",
"      Gianotti-Crosti syndrome (characterized by papular acrodermatitis of the face, extremities, and trunk accompanied by lymphadenopathy) is seen in infants and young children with acute HBV infection in whom it may be the only clinical manifestation. The syndrome is not specific to HBV infection, since it can be seen with other forms of viral infection as well. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23097?source=see_link\">",
"       \"Gianotti-Crosti syndrome (papular acrodermatitis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic HBV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chronic HBV infection is based on persistence of HBsAg for more than six months; IgG anti-HBc is positive, while IgM anti-HBc is negative (",
"    <a class=\"graphic graphic_table graphicRef60627 graphicRef60827 \" href=\"UTD.htm?7/35/7742\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69344 \" href=\"UTD.htm?41/25/42398\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most children with chronic HBV infection are asymptomatic and grow and develop normally. Some children note vague right upper quadrant discomfort and fatigue.",
"   </p>",
"   <p>",
"    Chronic HBV infection is occasionally associated with extrahepatic manifestations including polyarteritis nodosa and glomerulonephropathy; the latter is observed principally in children. HBV infection can induce both membranous nephropathy and, less often, membranoproliferative glomerulonephritis. The typical presentation is with nephrotic range proteinuria. Approximately 30 to 60 percent of children with HBV-related membranous nephropathy undergo spontaneous remission, usually in association with HBeAg to anti-HBe seroconversion (ie, conversion from HBeAg positive to negative, and from anti-HBe negative to positive). The incidence of HBV associated membranous nephropathy is falling as rates of HBV vaccination increase [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link\">",
"     \"Renal disease associated with hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of chronic HBV infection in children is variable, depending upon age, mode of acquisition, and ethnicity. These differences are likely due to immune tolerance that develops when infection occurs at an early age. The exact mechanisms through which immune tolerance develops are unknown.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children from endemic countries in whom HBV was acquired perinatally usually remain HBeAg-positive and have high levels of viral replication, although histologic injury is typically mild [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. In an illustrative report from Taiwan, which followed a cohort of children with HBV infection born before the implementation of universal HBV immunization, approximately 66 percent of children remained HBeAg positive at 10 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/16\">",
"       16",
"      </a>",
"      ]. Rates of spontaneous seroconversion are less than 2 percent per year in children younger than three years of age, and 4 to 5 percent after age three. The frequency of spontaneous seroconversion increases during puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. In boys, the rate of seroconversion is associated with testosterone levels and earlier onset of puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/19\">",
"       19",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      By contrast, children in non-endemic countries are less likely to have acquired the disease perinatally. In this case, they frequently clear HBeAg and HBV DNA from serum during the first two decades of life [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/20\">",
"       20",
"      </a>",
"      ]. In a 29-year longitudinal study of Italian children with chronic HBV who underwent HBeAg seroconversion, 95 percent",
"      <span class=\"nowrap\">",
"       (81/85)",
"      </span>",
"      of those without cirrhosis had inactive HBV infection at most recent follow-up, and 15 percent",
"      <span class=\"nowrap\">",
"       (13/89)",
"      </span>",
"      cleared HBsAg [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/21\">",
"       21",
"      </a>",
"      ]. Children who seroconvert spontaneously tend to have higher alanine aminotransferase (ALT) levels early in life as compared with those who do not seroconvert spontaneously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Phases of chronic HBV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with perinatally acquired chronic HBV infection typically enter an immune tolerant phase, from which they eventually move on to an immune active phase and thence to spontaneous clearance of the infection or to an inactive carrier state. The timing of this progression varies between individuals, and the severity of liver injury may depend on the length of the immune active phase (",
"    <a class=\"graphic graphic_figure graphicRef64996 graphicRef76907 \" href=\"UTD.htm?26/48/27396\">",
"     figure 3A-B",
"    </a>",
"    ). Some patients may progress rapidly through one or more of these phases, so each step may not be clinically apparent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Immune tolerant",
"    </span>",
"    &nbsp;&mdash;&nbsp;This phase is characterized by normal or mildly elevated serum aminotransferase activity (ALT &lt;2 times the upper limit of normal) and evidence of active HBV replication (HBV DNA &gt;20,000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    or 10(5)",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    HBsAg and HBeAg are positive. Young children with vertically transmitted disease typically enter this phase, which continues for months, years, or even decades before entering the immune-active phase. Treatment of patients in this phase is not recommended because patients are unlikely to respond, and treatment with nucleoside or nucleotide analogs may induce drug resistance and even cross-resistance to newer medications. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Selection of patients for treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Immune active (clearance)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This phase is characterized by elevated serum aminotransferase activity (ALT&gt;1.5 to 2 times the upper limit of normal) and active HBV replication (HBV DNA is typically &gt;20,000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    or 10(5)",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    HBsAg and HBeAg are positive. Patients in this phase are more likely to clear HBeAg spontaneously or to respond to treatment than those in the immune tolerant phase. Spontaneous clearance of HBeAg early in life is less likely for patients with genotype C as compared with other genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/22\">",
"     22",
"    </a>",
"    ]. There is increasing evidence that individuals with prolonged immune active phase of HBV are at high risk for progressive liver disease, prompting a more proactive approach to treatment of children in this phase. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Selection of patients for treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Inactive carrier",
"    </span>",
"    &nbsp;&mdash;&nbsp;This phase (also known as the nonreplicative or latent phase) is characterized by normal levels of serum aminotransferase activity and low or undetectable levels of HBV replication. HBsAg is positive but HBeAg is negative. Up to 20 percent of patients have one or more reversions to the immune active phase, and 20 to 30 percent reactivate into HBeAg-negative HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/23\">",
"     23",
"    </a>",
"    ]. These conversions may occur at any time, so regular monitoring is necessary. These patients also remain at risk for complications of HBV such as hepatocellular carcinoma. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Monitoring of patients'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Hepatocellular carcinoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Resolution of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients who clear HBeAg also go on to clear the HBV infection, heralded by clearance of HBsAg and appearance of anti-HBs. With rare exceptions, these individuals will not revert to active HBV infection, but they remain at risk for hepatocellular carcinoma. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Hepatocellular carcinoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;20 to 30 percent of patients progress to a reactivation phase, also known as HBeAg-negative chronic HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/9\">",
"     9",
"    </a>",
"    ]. Viral DNA levels increase, and ALT is normal or elevated, but HBeAg remains undetectable. Patients in this phase tend to have more virulent liver disease. Antiviral therapy (interferon, and sometimes",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"     adefovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ) may be indicated to minimize liver damage, although long-term clearance of HBV is rare. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Hepatocellular carcinoma'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Prediction of response in HBeAg negative patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Progression to cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis appears to be an infrequent complication of HBV infection during childhood. One of the largest studies included 292 consecutive children who were HBsAg positive and had elevated serum ALT levels [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/24\">",
"     24",
"    </a>",
"    ]. Cirrhosis was found in 10 patients (3 percent) at a mean age 4.0 &plusmn;3.3 years. However, children with cirrhosis had a higher prevalence of Hepatitis D virus (HDV) infection and were more likely to have had blood transfusions suggesting that coinfection with HDV or Hepatitis C virus (HCV) may have contributed to disease progression in some children. No child developed cirrhosis during follow-up (ranging from 1 to 10 years).",
"   </p>",
"   <p>",
"    Although frank cirrhosis is unusual during childhood, development of moderate or severe fibrosis is relatively common. In a series of 76 children with chronic HBe-Ag-positive HBV and elevated ALT, at least half had moderate to severe fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/25\">",
"     25",
"    </a>",
"    ]. These findings suggest that many individuals with perinatally acquired chronic HBV are at risk for developing cirrhosis in the long term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Sequelae and prognosis of chronic HBV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of progression to cirrhosis among adults diagnosed with chronic HBV infection is discussed separately. The risk is higher among individuals from areas endemic for HBV infection, most of whom acquire the disease perinatally, and individuals who abuse alcohol probably have accelerated disease progression. Males also have higher risk for exacerbations of HBV, cirrhosis, and hepatocellular carcinoma as compared to females. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Sequelae and prognosis of chronic HBV infection'",
"    </a>",
"    .) In transgenic mice, hepatitis B virus acts as a sex hormone responsive virus, which may explain the lower rates of hepatocellular carcinoma (HCC) and HBV viral load seen in women compared with men; human correlation is awaited [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) in children and adults with HBV infection has been described in both Asian and Western populations [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. Adults with perinatally acquired HBV develop HCC at a rate of about 5 percent per decade [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/33\">",
"     33",
"    </a>",
"    ]. The risk is related to the duration of disease, the degree of histologic injury, and the replicative state of the virus (HBV DNA levels). The risk is higher in patients who are HBeAg positive for extended periods of time and for those with precore mutants. The risk is increased further in the presence of cirrhosis or concomitant infection with HCV or HIV. However, HCC has been described in children who had undergone early HBeAg seroconversion, indicating that there is still a risk for HCC even after viral replication ceases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/34\">",
"     34",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Hepatitis B'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these risks, we suggest surveillance for HCC in individuals in all phases of HBV infection, including those who have undergone seroconversion (converted to HBeAg negative), either spontaneously or after successful treatment. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Monitoring of patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    HBV genotype may influence HCC development in children differently than in young adults. In Taiwan, the majority of children with HCC and chronic HBV infection have HBV genotype B [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast, most studies in young adults report an association between HBV genotype C and HCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical significance of hepatitis B virus genotypes\", section on 'Hepatocellular carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Universal childhood vaccination has led to a major decline in the incidence of HCC in endemic countries. In Taiwan, for example, the average annual incidence in children six to nine years of age has decreased from 0.7 to 0.57 to 0.36 per 100,000 between the years 1981 to 1986, 1986 to 1990, and 1990 to 1994, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/36\">",
"     36",
"    </a>",
"    ]. Long-term studies have substantiated this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF CHRONIC HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of children with chronic HBV infection involves general measures such as counseling of the patient and family, surveillance for disease progression and development of complications, and consideration for treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef78464 \" href=\"UTD.htm?0/61/976\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/9,38\">",
"     9,38",
"    </a>",
"    ]. Guidelines for the management of chronic HBV infection in adults have been proposed by the American Association for the Study of Liver Disease (AASLD) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/39\">",
"     39",
"    </a>",
"    ]; some elements are applicable to children and are reflected in the discussion below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation of patients with chronic HBV infection should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history emphasizing risk factors for coinfection with HCV",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HIV, use of alcohol, and family history of HBV infection, liver disease, and liver cancer. Physical examination should assess signs of chronic liver disease (such as spider telangiectasias, palmar erythema, hepatosplenomegaly, jaundice, ascites, edema, wasting, and gynecomastia in boys) as well as growth parameters.",
"     </li>",
"     <li>",
"      Laboratory tests: complete blood count with platelets, liver biochemical tests (AST, ALT, total bilirubin, alkaline phosphatase), albumin, prothrombin time, and tests for HBV replication (HBeAg, anti-HBe, HBV DNA). Testing for immunity to hepatitis A virus (HAV) with a serum HAV IgG should be considered in patients from high-endemicity areas who are not known to be immune.",
"     </li>",
"     <li>",
"      Evaluation for other causes of liver disease (such as hepatitis C) can be considered in children with risk factors, particularly if a pre-treatment liver biopsy suggests additional causes of chronic liver disease. We do not routinely test for other causes if there is no heightened clinical suspicion for these disorders.",
"     </li>",
"     <li>",
"      Screening for hepatocellular carcinoma with a right upper quadrant ultrasound and serum alpha fetoprotein. Ongoing monitoring for hepatocellular carcinoma is also recommended for patients in any phase of HBV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Monitoring of patients'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Liver biopsy for patients who meet criteria for chronic hepatitis (ie, HBsAg positive for &gt;6 months, serum HBV DNA &gt;10(5)",
"      <span class=\"nowrap\">",
"       copies/mL,",
"      </span>",
"      persistent elevation in",
"      <span class=\"nowrap\">",
"       ALT/AST",
"      </span>",
"      levels) and who are being considered for treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link\">",
"       \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Counseling and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;All pregnant women should be screened for HBV infection and case management procedures put in place to prevent perinatal infection of their infant [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/40\">",
"     40",
"    </a>",
"    ]. HBsAg positive pregnant women should inform their providers so that their infants can receive hepatitis B immunoglobulin and vaccine immediately after delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37881?source=see_link&amp;anchor=H7#H7\">",
"     \"Hepatitis viruses and the newborn: Clinical manifestations and treatment\", section on 'Hepatitis B'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Household members of children with chronic HBV should be vaccinated if they test negative for HBV serologic markers. The children and their families should be counseled regarding the risk of transmission to others, including perinatal transmission and risk of environmental exposure from blood. Household members should not share utensils such as toothbrushes or razors, which may become contaminated with blood. Although HBV DNA has been detected in various bodily secretions of hepatitis B carriers, there is no firm evidence of HBV transmission via body fluids. Adolescents should be advised regarding prevention of sexual transmission (ie, vaccination of sex partners in individuals with monogamous partners and safe sex practice including use of condoms in subjects with multiple partners). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\", section on 'Modes of transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with chronic HBV infection should be allowed to participate in all regular activities and should not be excluded from regular school and participation in sports [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/41\">",
"     41",
"    </a>",
"    ]. No special arrangements need to be made other than practicing universal precautions in daycare centers, schools, sports clubs and camps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adolescents with chronic HBV infection should be advised that heavy use of alcohol (&gt;40",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    and drug abuse has been associated with worsening liver disease and an increased risk of HCC. Patients who are not immune to hepatitis A should be vaccinated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Monitoring of patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expert panels suggest regular monitoring of children in all phases of HBV infection, to evaluate for hepatic decompensation and disease progression, and for surveillance of hepatocellular carcinoma (HCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/9\">",
"     9",
"    </a>",
"    ]. Guidelines for adults suggest monitoring of liver biochemical tests every three to six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H41#H41\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Monitoring of patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because children generally have milder disease activity, somewhat less frequent monitoring is reasonable unless specific risk factors are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Disease activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are in the immune tolerant phase of HBV infection (ie, HBsAg positive, HBeAg positive, serum HBV DNA&gt;20,000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    should undergo monitoring of liver biochemical tests every 6 to 12 months. If the ALT becomes elevated, biochemical tests and serologies should be measured more frequently. In this case, the patient is probably entering an immune active phase, and may undergo spontaneous seroconversion, or become eligible for treatment; such patients are also at risk for hepatic decompensation.",
"   </p>",
"   <p>",
"    Patients who are in the inactive carrier phase of hepatitis B infection (ie, HBsAg positive, HBeAg negative, anti HBe positive, persistently normal",
"    <span class=\"nowrap\">",
"     ALT/AST",
"    </span>",
"    levels, serum HBV DNA &lt;10(5)",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    should undergo monitoring of liver biochemical tests every 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/42\">",
"     42",
"    </a>",
"    ]. If the ALT becomes elevated, HBV serologies and HBV DNA should be measured. The disease may reactivate even after years of quiescence; 4 to 20 percent of inactive carriers have one or more reversions back to HBeAg [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     HCC surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic measurements of hepatic ultrasounds have been recommended in adults, or serum alpha-fetoprotein levels if ultrasound is not available. The benefit of surveillance for HCC has not been well established, and these recommendations are based upon observational data and expert opinion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal monitoring protocol for HCC and the benefit of monitoring in children have not been established. However, we generally monitor liver ultrasound and serum alpha fetoprotein (AFP) every 12 months. For patients with elevated AFP, cirrhosis, or a family history of hepatocellular carcinoma, we monitor more closely. Because the risk for HCC increases with age, it is reasonable to screen somewhat less frequently (eg, every two to three years) in young patients in the immune tolerant phase, if baseline AFP and ultrasound are normal.",
"   </p>",
"   <p>",
"    HCC can develop in patients with HBV infection, regardless of whether the virus is actively replicating. Therefore, we continue surveillance for HCC in individuals in all phases of HBV infection, including those who have undergone seroconversion (converted to HBeAg negative), either spontaneously or after successful treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Selection of patients for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few large trials in children to guide treatment decisions for chronic HBV. To date, the efficacy of treatment has only been measured through intermediate outcomes such as changes in short-term virologic, biochemical, and histologic parameters.",
"   </p>",
"   <p>",
"    The ultimate goal of treatment is to reduce the risks of progression to cirrhosis and hepatocellular carcinoma (HCC). Effects of treatment on these long-term outcomes are inferred from the intermediate virologic and biochemical outcomes of treatment trials, but are not clinically proven [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/33\">",
"     33",
"    </a>",
"    ]. Because progression to cirrhosis appears to be associated with the intensity and duration of chronic inflammatory activity, it is reasonable to infer that successful treatment of HBV probably reduces the risk of cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/33\">",
"     33",
"    </a>",
"    ]. It is not clear whether treatment reduces the risk for HCC. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Hepatocellular carcinoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    None of the available treatments is highly efficacious. Furthermore, under some circumstances, prolonged treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    or other nucleoside or nucleotide analogs induces drug resistance in a substantial percentage of patients. Therefore, the choice of whether and when to treat depends on several patient-specific characteristics which predict the efficacy of treatment, including persistently abnormal ALT levels, and active disease shown on liver biopsy (if performed), as well as on the patient's values and preferences (",
"    <a class=\"graphic graphic_algorithm graphicRef78464 \" href=\"UTD.htm?0/61/976\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Trials in adults and children demonstrate that the likelihood of response to any of the currently available drugs depends highly upon the degree of elevation of the serum aminotransferases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/6,44,45\">",
"     6,44,45",
"    </a>",
"    ]. This observation leads to several general recommendations about treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest treatment for most patients with HBV DNA-positive chronic hepatitis who are in the immune active phase (usually defined as ALT &gt;2 x ULN and HBV DNA &gt;20,000",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      or 10(5)",
"      <span class=\"nowrap\">",
"       copies/mL,",
"      </span>",
"      for at least four to six months) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/42\">",
"       42",
"      </a>",
"      ]. Almost all children with chronic HBV are HBeAg positive, but therapy can also be considered for the few in whom HBeAg is negative provided that active HBV infection is documented by demonstration of viremia of &gt;10",
"      <sup>",
"       4",
"      </sup>",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      and ALT is persistently abnormal.",
"     </li>",
"     <li>",
"      We suggest NOT treating patients with ALT levels less than 1.5 to 2 times the upper limit of normal, even if HBV DNA levels are high. These findings generally indicate that the patient is in the immune tolerant phase of HBV infection, and in this phase treatment with any of the currently available drugs does not result in higher rates of HBeAg seroconversion compared with no treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/33,45,46\">",
"       33,45,46",
"      </a>",
"      ]. Moreover, treatment of patients in this phase using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"       lamivudine",
"      </a>",
"      or other nucleoside or nucleotide analogs is associated with development of drug resistance, which could diminish responsiveness to the same or related medications at a later date, when hepatic injury is active.",
"     </li>",
"     <li>",
"      We suggest initial observation for children with ALT values greater than 10 times the upper limit of normal but with concomitant low HBV DNA levels; these children may be in the process of spontaneous seroconversion, and may not require treatment. Instead, these patients should be observed for several months with serial serologic testing. Treatment should then be initiated if the patient has not undergone seroconversion to the inactive carrier state (ie, converted from HBeAg+ to HBeAg-, with undetectable HBV DNA). In this state, HBeAb is usually positive but should be monitored periodically because some individuals have a mutant HBV which is associated with active liver disease despite low levels of HBeAg (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link&amp;anchor=H6#H6\">",
"       \"Serologic diagnosis of hepatitis B virus infection\", section on 'Hepatitis B e antigen and antibody'",
"      </a>",
"      ). If there is evidence of hepatic decompensation, such as jaundice or coagulopathy, treatment should be initiated earlier [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. Interferon cannot be used in patients with decompensated disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other considerations may be relevant to treatment decisions for individual patients, such as those co-infected with HCV, HIV or HDV. A limited course of treatment may also be appropriate in some children who will be undergoing immunosuppression (such as chemotherapy, anti-tumor necrosis factor alpha treatments, or organ transplantation), even if they are in the immune tolerant or inactive carrier phase of HBV infection. In this case,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    or another nucleos(t)ide is often used in an effort to prevent reactivation; these drugs may be discontinued after immune reconstitution and if HBV DNA remains undetectable. Issues related to screening and prophylaxis are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be treated and how'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CHOICE OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several drugs currently are approved for treatment of chronic HBV infection in adults (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    , interferon alfa,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8152?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef63171 \" href=\"UTD.htm?20/47/21245\">",
"     table 2",
"    </a>",
"    ). The first two, lamivudine and interferon (IFN), are licensed for use in children in the United States. Adefovir has been evaluated in a clinical trial in children and is approved for use in those over 12 years of age in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/49\">",
"     49",
"    </a>",
"    ]. IFN is not a good option in children with an underlying autoimmune disorder, organ transplant, or serious neuropsychiatric disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An advantage of IFN over",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    is that it has a finite duration of treatment and is not associated with the development of resistant variants. Development of resistance during lamivudine treatment is particularly likely among patients with minimal disease activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor compliance with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, in our practice we generally use IFN alfa as the first-line treatment for the patients who are most likely to respond (ie, for patients with serum ALT more than twice the upper limit of normal, have positive HBeAg, who are committed to adhering to the treatment, and have no comorbid diseases that might be exacerbated by an immunostimulatory agent). If the patient does not respond to IFN alfa (defined by detectable HBV DNA and elevated serum ALT six months after completion of the course of IFN alfa), there is a contraindication to IFN, or the",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    choose not to receive IFN, a",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analog such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"     adefovir",
"    </a>",
"    can be used if liver disease is significant. However, lamivudine and adefovir are not considered preferred agents, and, unless advanced liver disease is present, it may be prudent to await availability of drugs with high potency and high barrier to development of resistance. In our practice, we enroll these children in clinical trials of agents shown to be more efficacious with lower resistance rates, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    . If lamivudine or adefovir is used, it should be discontinued if there is no virologic response (persistent detectable HBV DNA) after 24 weeks, in order to minimize the risk of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/50\">",
"     50",
"    </a>",
"    ]. If a",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analog is used, it should be continued for at least 12 months after HBeAg seroconversion is documented [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genotype testing is not an established factor for making the choice between IFN and",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    therapy. However, it may be considered for HBeAg-positive patients who are considering IFN therapy, since patients with genotype A and B have a more favorable response to IFN, and those with genotype C generally are less likely to respond. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferons have antiviral, antiproliferative, and immunomodulatory effects. Interferon alfa (IFN alpha) and IFN-beta have predominantly antiviral effects, while IFN-gamma has more marked immunoregulatory but less potent antiviral activity.",
"   </p>",
"   <p>",
"    IFN alfa (Intron-A) was the first treatment approved for chronic HBV infection in most countries. It leads to a beneficial response in 30 to 40 percent of patients with chronic HBV infection. However, it is expensive and may be accompanied by frequent and unpleasant side effects, as described below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For children with HBeAg-positive chronic HBV infection we typically treat with a six month course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/47/40695?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    , six million units (MU) per m(2) (maximum 10 MU) three times a week for 24 weeks, followed by an observation period of 6 to 12 months. A year of treatment may be preferable in those with HBeAg-negative chronic HBV infection, based upon data in adults. Patients should be monitored regularly for hepatitis flares during the first few months after the drug is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pegylated interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The attachment of polyethylene glycol to a protein (pegylation) reduces its rate of absorption following subcutaneous injection, reduces renal and cellular clearance, and decreases the immunogenicity of the protein. All of these effects tend to enhance the half-life of the pegylated versus the native protein. Pegylated interferon (in combination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    ) has become the treatment of choice for patients with chronic hepatitis C virus infection; it is also a therapeutic option for adults with HBV.",
"   </p>",
"   <p>",
"    The efficacy of pegylated interferons in children with chronic HBV infection has not been established, but is under investigation in clinical trials. However, based on its efficacy in adults and experience in using it for treatment of HCV in children, we feel that it is a reasonable choice for children with HBV who are in the immune active phase of HBV infection as described above, in the context of a clinical trial, using a 48 week course of treatment as is recommended for adults. Outside of the context of a clinical trial, pegylated interferon should be used with caution in young children with HBV if at all, because its efficacy has not been established in this age group, and because of potential side effects, which include growth suppression in prepubertal children. Although pegylated interferon not yet licensed for HBV in patients younger than 18 years, it may be acceptable as therapy for post-pubertal children with active hepatic disease, but should be avoided if cirrhosis is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several controlled trials in children have evaluated the efficacy of standard IFN alfa in different regions of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/45,51-57\">",
"     45,51-57",
"    </a>",
"    ]. Response rates (usually defined as HBeAg seroconversion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of HBV DNA) have generally been highest in Western countries (20 to 58 percent of treated patients compared with 8 to 17 percent of controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. Response rates have been much lower in Asian countries (approximately 17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lower response rate in populations from Asian countries is primarily explained by the higher proportion of individuals who were infected at birth and tend to have a prolonged immune tolerant phase of infection. For reasons that are incompletely understood, such patients appear to be less likely to respond to antiviral treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HBV genotype C is more common among Asian populations and appears to be associated with lower rates of seroconversion and response to treatment as compared with HBV genotype B. Whether immune tolerance and genotype exert independent effects on seroconversion has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"     \"Clinical significance of hepatitis B virus genotypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Predictors of response other than immune tolerance were examined in a large multinational study that included Asian and non-Asian patients whose serum ALT was at least 1.5 times the upper limit of normal (indicating that they were in the replicative rather than the immune tolerant phase of infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/55\">",
"     55",
"    </a>",
"    ]. Response rates were similar in Asian and non-Asian patients (22 versus 26 percent), suggesting ethnicity itself is not an independent predictor of response.",
"   </p>",
"   <p>",
"    HBeAg seroconversion is generally associated with histologic improvement in studies of adults. There are relatively few studies showing histologic changes in children, since a repeat liver biopsy after treatment is uncommonly performed. One such study involved 10 paired-biopsy samples, six of which were from responders [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/55\">",
"     55",
"    </a>",
"    ]. The histologic activity index (HAI) improved significantly in all responders. It also improved in two of the non-responders, but worsened in the other two.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with interferon is associated with multiple side effects. Nevertheless, most children are able to complete their course of therapy, although not always with the initial dose.",
"   </p>",
"   <p>",
"    Almost all children experience flu-like symptoms (eg, fever, myalgia, headache, arthralgia and anorexia), which usually remit after a few doses (usually within a week). Flu-like symptoms can be reduced by beginning treatment with a low dose and increasing over a week to the recommended full dose of 6 million",
"    <span class=\"nowrap\">",
"     units/m(2).",
"    </span>",
"    Prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    may be used to mitigate these symptoms.",
"   </p>",
"   <p>",
"    Bone marrow suppression, especially neutropenia, is observed in approximately 20 to 40 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/55,60\">",
"     55,60",
"    </a>",
"    ]. Severe neutropenia resulting in infections is rare. In one of the largest controlled trials, the dose was reduced because of bone marrow suppression or fever in 23 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of other side-effects have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changes in personality (mostly irritability and temper tantrums), which are reversible upon withdrawal of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/55,60\">",
"       55,60",
"      </a>",
"      ]. There are no studies regarding use of antidepressant medications in children receiving IFN. It is prudent to refer children for evaluation if they develop moderate depression or behavioral symptoms. Treatment should be stopped in children who develop severe depression.",
"     </li>",
"     <li>",
"      Fevers are common after the first few doses of IFN-alfa in children [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Weight loss (which is typically regained once IFN is discontinued) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. Long-term effects on growth and growth velocity are not known.",
"     </li>",
"     <li>",
"      Decreased quality of life because of medication side effects and fear of injections [",
"      <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/60\">",
"       60",
"      </a>",
"      ]. Quality of life reverts to baseline within three months of cessation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these side effects, interferon alfa is not a good option for patients with an underlying autoimmune disorder, organ transplant, decompensated liver disease, or serious neuropsychiatric disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Non-responders",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the majority of patients treated with interferon do not achieve seroconversion. The long-term outcome of such patients has not been well-described. Small studies suggest that the disease remains relatively stable in the short-term [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment options for such patients could include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    , or newer agents, when clinical trials involving children are completed. A second course of IFNa therapy does not appear to increase the rates of seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23030?source=see_link\">",
"     \"Investigational treatments of chronic hepatitis B virus infection\"",
"    </a>",
"    .) Peginterferon has not yet been evaluated in any large trial of children with chronic hepatitis B. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Pegylated interferon'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Lamivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     Lamivudine",
"    </a>",
"    (3TC) (Epivir-HBV) is a nucleoside analog, the (-) enantiomer of 2',3'-dideoxy 3'-thiacytidine. It is phosphorylated to the triphosphate (3TC-TP), which competes with dCTP for incorporation into growing DNA chains, causing chain termination. For children, lamivudine is given at a dose of 3 mg per kg of body weight to a maximal dose of 100 mg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The available data indicate that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    is safe and sometimes effective in children, but the benefit must be carefully balanced against the risk of selecting resistant mutants.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     Lamivudine",
"    </a>",
"    is usually a second-line treatment choice. If treatment is necessary in pre-adolescent children (which is not very often), we generally use interferon rather than lamivudine. For this age group, we sometimes use lamivudine in special circumstances in which its use is expected to be short-term (eg, around chemotherapy). For adolescents, options other than lamivudine include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Adefovir dipivoxil'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9979439\">",
"     'Newer agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The largest controlled trial included 288 children who were randomly assigned to receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    or placebo for 52 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/46\">",
"     46",
"    </a>",
"    ]. A virologic response at the end of treatment (loss of HBeAg and reduction in serum HBV DNA to undetectable levels using the branched DNA assay [lower limit of detection 0.7 mEq per mL]) was observed significantly more often in children who received lamivudine (23 versus 13 percent) (",
"    <a class=\"graphic graphic_table graphicRef68345 \" href=\"UTD.htm?29/28/30155\">",
"     table 3",
"    </a>",
"    ). On multivariable analysis, a virologic response was associated with higher baseline ALT values and Histologic Activity Index (HAI). Treatment was well tolerated.",
"   </p>",
"   <p>",
"    After one year, 213 patients who remained HBeAg positive (79 placebo and 134 prior",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    ) were enrolled in a two-year, open-label lamivudine treatment phase [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/66\">",
"     66",
"    </a>",
"    ]. At the end of follow-up, HBeAg seroconversion was observed in 23 of 77 (30 percent) patients who had previously received placebo, and 28 of 133 (21 percent) of those who had previously received lamivudine. These data confirm that some patients who do not have HBeAg seroconversion initially might do so with longer duration of treatment. Among those who received additional lamivudine treatment, lamivudine resistant mutations were detected in 34 of 70 (49 percent) prior placebo and 66 of 103 (64 percent) prior lamivudine patients. Patients who lost HBeAg during year one were followed for an additional two years; 46 of 54 (85 percent) patients who remained in the observation arm had sustained virologic response.",
"   </p>",
"   <p>",
"    Children with higher pretreatment ALT and HAI scores on liver biopsy were more likely to respond to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    . Other factors such as HBV DNA levels, age, gender, race, ethnicity, body weight and body mass index did not appear to significantly influence response to lamivudine treatment in children [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal duration of therapy is unclear.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     Lamivudine",
"    </a>",
"    should be used for at least one year, and probably for at least six months after HBeAg seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/33\">",
"     33",
"    </a>",
"    ]. Longer duration of treatment increases the likelihood of HBeAg seroconversion but also increases the development of resistance. In those children who do not develop resistance, up to three years of continuous therapy is associated with further virologic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/66\">",
"     66",
"    </a>",
"    ]. In addition, responses to lamivudine were at least as durable as natural seroconversions in children followed for up to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/68\">",
"     68",
"    </a>",
"    ]. Prolonged treatment of non-responders is not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of concerns about the development of resistance to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    , children who receive this or any other nucleos(t)ide antiviral therapy should be monitored with serial HBV DNA and ALT levels during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/9\">",
"     9",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link&amp;anchor=H21#H21\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\", section on 'Duration and endpoints of therapy'",
"    </a>",
"    ). An increase of at least one log in HBV DNA during lamivudine treatment suggests that the patient's virus has become resistant. In this case, we usually discontinue lamivudine if the patient has only mild liver disease, or we add a second agent (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil) if the patient has significant liver disease. Newer agents can be considered for older patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link&amp;anchor=H32#H32\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\", section on 'Patients who develop resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial data suggested that continued treatment of patients who develop resistance might be beneficial in those in whom HBV DNA continues to be suppressed. However, long-term follow-up of such patients suggests that the disease continues to progress. Thus, it may be prudent to discontinue",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    in children who develop lamivudine-resistant HBV. Patients should be monitored regularly for hepatitis flares during the first few months after the drug is discontinued. For those who require additional therapy, options are limited at this time. For this reason, initiation of treatment should be reserved for those children with histologic evidence of significant chronic hepatitis or fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link&amp;anchor=H11#H11\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\", section on 'Resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Combination therapy with IFN alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    and interferon seems logical because monotherapy with each agent is effective, and lamivudine and interferon have different mechanisms of action. However, disparate results have been described in controlled trials in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=see_link\">",
"     \"Combination therapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one uncontrolled study, in which 23 immune tolerant children with perinatally acquired HBV were treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    for eight weeks followed by lamivudine and IFNa in combination for 10 months, five patients seroconverted to anti-HBe during treatment or within 18 months of the end of treatment and four of these five became persistently HBsAg negative [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/69\">",
"     69",
"    </a>",
"    ]. However, another study, comparing IFN alone with IFN and lamivudine in two different regimens failed to demonstrate a difference among the groups in long-term response [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Adefovir dipivoxil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"     Adefovir",
"    </a>",
"    dipivoxil (Hepsera) is a nucleotide analog of adenosine monophosphate, which can inhibit reverse transcriptase and DNA polymerase activity levels. In adults it is somewhat less effective than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    in reducing HBV DNA levels and inducing seroconversion, but also is less likely to induce viral resistance. Adefovir has been evaluated as primary monotherapy for adults with chronic hepatitis B and those who developed resistance to lamivudine. Pharmacokinetic studies in children have been completed, and a randomized controlled trial has been completed. In the United States, adefovir dipivoxil is approved for children with chronic HBV infection aged 12 years and older.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"     Adefovir",
"    </a>",
"    dipivoxil was as effective in adolescents as in adults in achieving virologic response (defined as a decrease in HBV DNA to undetectable levels and normalization of ALT) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/49\">",
"     49",
"    </a>",
"    ]. Among adolescents, adefovir was significantly more effective than placebo in achieving the primary efficacy endpoint (23 percent achieved HBV DNA&lt;1,000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    as compared with zero percent of those treated with placebo). This response was not seen clearly in younger children, but some of the younger children had HBeAg seroconversions while taking adefovir dipivoxil.",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil in the treatment of children with chronic HBV has not been established. In our practice, we may use adefovir dipivoxil in patients who are over 12 years of age and who have failed IFN alfa treatment and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    or in those who have developed lamivudine resistance. In the case of lamivudine resistance, treatment is discontinued if the liver disease is mild. If there is significant liver disease or another indication to continue treatment in a patient with lamivudine resistance, adefovir is added to lamivudine, rather than switching from lamivudine to adefovir. The latter practice is supported by a small trial in adolescents who had developed lamivudine resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/71\">",
"     71",
"    </a>",
"    ]. Patients treated with adefovir and ongoing lamivudine had a more rapid decline in HBV-DNA titer and were more likely to have undetectable HBV-DNA levels at 24 weeks, as compared with patients who switched to adefovir alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9979439\">",
"    <span class=\"h2\">",
"     Newer agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/52/36679?source=see_link\">",
"     Tenofovir",
"    </a>",
"    disoproxil fumarate (DF) has demonstrated excellent viral suppression and good safety profile in two years of use, and is licensed by the US Food and Drug Administration (FDA) for use in adolescents 12 years and older. In a randomized trial, adolescents 12 to &lt;18 years of age were treated for 72 weeks with either tenofovir DF or placebo (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00734162?term=tenofovir+adolescents&amp;rank=1\">",
"     NCT00734162",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/72\">",
"     72",
"    </a>",
"    ]. HBV DNA decreased to &lt;400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in 89 percent",
"    <span class=\"nowrap\">",
"     (46/52)",
"    </span>",
"    of patients who received tenofovir DF, as compared with 0 percent",
"    <span class=\"nowrap\">",
"     (0/54)",
"    </span>",
"    of those who received placebo. HBeAg seroconversions were rare. However, data regarding HBeAg seroconversion with longer treatment are lacking, and the optimal duration of therapy has not been defined.&nbsp;Therefore, just as with the other agents, appropriate selection of patients for treatment is still an important factor. A study of tenofovir DF in younger patients is planned. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    is licensed in the United States for adolescents 16 years of age and older. A phase 2 study of the safety and pharmacokinetics of entecavir in children has been completed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/41/31386/abstract/73\">",
"     73",
"    </a>",
"    ] (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00423891?term=entecavir+adolescents&amp;rank=1\">",
"     NCT00423891",
"    </a>",
"    ) and a phase 3 study is underway (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT01079806?term=entecavir+pediatric&amp;rank=1\">",
"     NCT01079806",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ACUTE HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute HBV infection in children is generally treated with supportive management alone. There are no data on treatment of children with acute infection. For those with severe acute hepatitis, treatment with a",
"    <span class=\"nowrap\">",
"     nucleoside/tide",
"    </span>",
"    analog might be considered. However, trials in adults did not show clinical benefit. For individuals with fulminant hepatitis caused by HBV, liver transplant may be necessary. The risk of reinfection with HBV after transplantation for fulminant HBV is relatively low, in contrast to the higher risk for reinfection after liver transplantation for chronic HBV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link&amp;anchor=H3#H3\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\", section on 'Risk factors for reinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     IMMUNOPROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to vaccination, post-exposure prophylaxis, and breast feeding are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H10#H10\">",
"     \"Standard immunizations for children and adolescents\", section on 'Hepatitis B vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, the majority of children with chronic HBV infection are immigrants from areas with endemic HBV infection (",
"      <a class=\"graphic graphic_figure graphicRef62806 \" href=\"UTD.htm?6/43/6838\">",
"       figure 1",
"      </a>",
"      ), have immigrant parents, or became exposed through other household contacts. Perinatal transmission of HBV declined sharply after 1991 when recommendations for universal hepatitis B vaccination of infants were implemented. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of chronic HBV infection in children is variable, depending upon age, mode of acquisition, ethnicity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HBV genotype. Children with perinatally acquired HBV usually remain HBeAg-positive and have high levels of viral replication for prolonged periods, although histologic injury is typically mild (",
"      <a class=\"graphic graphic_figure graphicRef76907 \" href=\"UTD.htm?9/24/9614\">",
"       figure 3B",
"      </a>",
"      ). By contrast, children in non-endemic countries tend to have higher ALT elevations and frequently clear HBeAg and HBV DNA from serum during the first two decades of life. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of hepatitis B is made by serologic testing for HBsAg and anti-HBc. The presence of HBsAg indicates HBV infection, and the presence of IgG anti-HBc (with negative anti-HBc IgM) indicates that the infection is chronic (",
"      <a class=\"graphic graphic_figure graphicRef76907 \" href=\"UTD.htm?9/24/9614\">",
"       figure 3B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60627 \" href=\"UTD.htm?40/60/41932\">",
"       table 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with serologic evidence of HBV should be further evaluated with aminotransferases, HBV DNA, and HBeAg. Other causes of liver disease should be excluded. Patients should be vaccinated against hepatitis A if not already immune. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Initial evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Counseling and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Only carefully selected patients with chronic HBV infection should be treated during childhood",
"      </strong>",
"      . This is because none of the available treatments is highly efficacious. Furthermore, under some circumstances, treatment is associated with a high likelihood of drug resistance. Therefore, the choice of whether to treat depends on several patient-specific characteristics which predict the efficacy of treatment, including persistently abnormal ALT levels, and active disease shown on liver biopsy (if performed), as well as on the patient's values and preferences (",
"      <a class=\"graphic graphic_algorithm graphicRef78464 \" href=\"UTD.htm?0/61/976\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that patients who are in the",
"      <strong>",
"       immune tolerant",
"      </strong>",
"      or",
"      <strong>",
"       inactive",
"      </strong>",
"      phases of chronic hepatitis B",
"      <strong>",
"       NOT",
"      </strong>",
"      be treated (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ); this is defined as HBsAg positive and persistently normal",
"      <span class=\"nowrap\">",
"       ALT/AST",
"      </span>",
"      levels, HBeAg positive or negative, even if the HBV DNA levels are high. Instead, they should undergo monitoring of liver biochemical tests every 6 to 12 months to look for evidence of immune activation or reactivation after HBeAg seroconversion (",
"      <a class=\"graphic graphic_figure graphicRef64996 \" href=\"UTD.htm?27/51/28466\">",
"       figure 3A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Selection of patients for treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Monitoring of patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with chronic hepatitis B in the",
"      <strong>",
"       immune active stage",
"      </strong>",
"      be treated (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ); the immune active stage is usually defined as ALT &gt;2 x the upper limit of normal and HBV DNA &gt;20,000",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      or 10(5)",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef78464 \" href=\"UTD.htm?0/61/976\">",
"       algorithm 1",
"      </a>",
"      ). Most children with this profile will be HBeAg positive (",
"      <a class=\"graphic graphic_figure graphicRef64996 \" href=\"UTD.htm?27/51/28466\">",
"       figure 3A",
"      </a>",
"      ). Children with lower ALT levels are unlikely to respond to treatment. Those with markedly elevated ALT levels (greater than 10 times the upper limit of normal) and low HBV DNA levels may be in the process of spontaneous seroconversion, and thus should be observed for several months before considering treatment. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Selection of patients for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a decision to treat has been made, interferon alfa is the first-line choice for most patients until the newer agents are studied and licensed in children.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"       Lamivudine",
"      </a>",
"      is a second-line choice, because of limited efficacy and because it is likely to induce drug resistance with long-term use. Therefore, lamivudine is generally used only for children with specific short-term risks for HBV exacerbation, such as those undergoing chemotherapy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Choice of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newer agents currently under investigation for children with HBV include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pegylated interferon alfa &ndash; The efficacy of pegylated interferons in children with chronic HBV infection has not been established. Based on its efficacy in adults and experience in using it for treatment of HCV in children, we feel that it is a reasonable choice for children with HBV who are in the immune active phase of HBV infection, in the context of a clinical trial. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Pegylated interferon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"       Adefovir",
"      </a>",
"      dipivoxil &ndash; Licensed in the United States for use in patients 12 years of age and older. It may be used as primary therapy, or to treat those who have become refractory to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/0/36871?source=see_link\">",
"       lamivudine",
"      </a>",
"      treatment by adding adefovir dipivoxil to ongoing lamivudine therapy. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Adefovir dipivoxil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/52/36679?source=see_link\">",
"       Tenofovir",
"      </a>",
"      disoproxil fumarate (DF) &ndash; Licensed in the United States for adolescents 12 years and older, after demonstrating excellent viral suppression and a good safety profile in two years of use. However, data regarding HBeAg seroconversion are lacking, and the optimal duration of therapy has not been defined. (See",
"      <a class=\"local\" href=\"#H9979439\">",
"       'Newer agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       Entecavir",
"      </a>",
"      &ndash; Licensed in the United States for adolescents 16 years of age and older. (See",
"      <a class=\"local\" href=\"#H9979439\">",
"       'Newer agents'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because of limited options with current drugs, it may be appropriate to treat older adolescents with immune active HBV with one of these newer agents using adult protocols, or to enroll children in clinical trials of newer agents, or even withhold treatment until the patient is old enough to be treated as adults (if liver fibrosis is only mild).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that children with chronic hepatitis B be surveyed periodically for development of hepatocellular carcinoma (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This is usually performed with a yearly right upper quadrant ultrasound and alpha-fetoprotein level. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'HCC surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/1\">",
"      Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002; 185:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Acute hepatitis B among children and adolescents--United States, 1990-2002. MMWR Morb Mortal Wkly Rep 2004; 53:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/3\">",
"      Daniels D, Grytdal S, Wasley A, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/4\">",
"      Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010; 202:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/5\">",
"      McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/6\">",
"      Ord&ouml;g K, Szendr&ocirc;i A, Szarka K, et al. Perinatal and intrafamily transmission of hepatitis B virus in three generations of a low-prevalence population. J Med Virol 2003; 70:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Prevention of perinatal hepatitis B through enhanced case management--Connecticut, 1994-95, and the United States, 1994. MMWR Morb Mortal Wkly Rep 1996; 45:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/8\">",
"      Jenkins CN, McPhee SJ, Wong C, et al. Hepatitis B immunization coverage among Vietnamese-American children 3 to 18 years old. Pediatrics 2000; 106:E78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/9\">",
"      Haber BA, Block JM, Jonas MM, et al. Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. Pediatrics 2009; 124:e1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/10\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/11\">",
"      Kao JH, Hsu HM, Shau WY, et al. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001; 139:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/12\">",
"      Chen HL, Chang CJ, Kong MS, et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 2004; 39:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/13\">",
"      Bhimma R, Coovadia HM, Adhikari M, Connolly CA. The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy. Arch Pediatr Adolesc Med 2003; 157:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/14\">",
"      Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988; 8:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/15\">",
"      Lok AS, Lai CL, Wu PC, et al. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liver Dis 1989; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/16\">",
"      Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007; 132:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/17\">",
"      Chang MH, Sung JL, Lee CY, et al. Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. J Pediatr 1989; 115:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/18\">",
"      Liaw YF, Chu CM, Lin DY, et al. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/19\">",
"      Wu JF, Tsai WY, Hsu HY, et al. Effect of puberty onset on spontaneous hepatitis B virus e antigen seroconversion in men. Gastroenterology 2010; 138:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/20\">",
"      Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990; 99:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/21\">",
"      Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006; 43:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/22\">",
"      Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/23\">",
"      Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/24\">",
"      Bortolotti F, Calzia R, Cadrobbi P, et al. Liver cirrhosis associated with chronic hepatitis B virus infection in childhood. J Pediatr 1986; 108:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/25\">",
"      Godra A, Perez-Atayde AR, Jonas MM. Histologic features of chronic hepatitis B in children (abstract). Hepatology 2005; 42(Suppl 1):478A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/26\">",
"      Wang SH, Yeh SH, Lin WH, et al. Estrogen receptor &alpha; represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4&alpha;. Gastroenterology 2012; 142:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/27\">",
"      Tong S. Hepatitis B virus, a sex hormone-responsive virus. Gastroenterology 2012; 142:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/28\">",
"      Tanaka T, Miyamoto H, Hino O, et al. Primary hepatocellular carcinoma with hepatitis B virus-DNA integration in a 4-year-old boy. Hum Pathol 1986; 17:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/29\">",
"      Cheah PL, Looi LM, Lin HP, Yap SF. Childhood primary hepatocellular carcinoma and hepatitis B virus infection. Cancer 1990; 65:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/30\">",
"      Giacchino R, Navone C, Facco F, et al. HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases. Dig Dis Sci 1991; 36:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/31\">",
"      Pontisso P, Basso G, Perilongo G, et al. Does hepatitis B virus play a role in primary liver cancer in children of Western countries? Cancer Detect Prev 1991; 15:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/32\">",
"      Hsu HC, Wu MZ, Chang MH, et al. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. J Hepatol 1987; 5:260.",
"     </a>",
"    </li>",
"    <li>",
"     NIH Consensus Development Conference: Management of Hepatitis B, October 20-22, 2008. Draft statement available at: file://consensus.nih.gov/2008/2008HepatitisBCDC120main.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/34\">",
"      Wen WH, Chang MH, Hsu HY, et al. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr 2004; 144:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/35\">",
"      Ni YH, Chang MH, Wang KJ, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 127:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/36\">",
"      Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/37\">",
"      Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/38\">",
"      Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 2010; 52:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/39\">",
"      Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/40\">",
"      Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Hepatitis B. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/42\">",
"      Murray KF, Shah U, Mohan N, et al. Chronic hepatitis. J Pediatr Gastroenterol Nutr 2008; 47:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/43\">",
"      Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/44\">",
"      Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002; 325:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/45\">",
"      Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996; 23:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/46\">",
"      Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/47\">",
"      Shah U, Kelly D, Chang MH, et al. Management of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr 2009; 48:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/48\">",
"      Nikolaidis N, Vassiliadis T, Giouleme O, et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant 2005; 19:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/49\">",
"      Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to &lt;18 years) with chronic hepatitis B. Hepatology 2008; 47:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/50\">",
"      Jonas MM, Kelly D, Pollack H, et al. Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. Pediatr Infect Dis J 2012; 31:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/51\">",
"      Ruiz-Moreno M, Rua MJ, Molina J, et al. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991; 13:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/52\">",
"      Barbera C, Bortolotti F, Crivellaro C, et al. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994; 20:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/53\">",
"      Narkewicz MR, Smith D, Silverman A, et al. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr 1995; 127:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/54\">",
"      Vajro P, Tedesco M, Fontanella A, et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996; 15:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/55\">",
"      Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/56\">",
"      Giacchino R, Main J, Timitilli A, et al. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver 1995; 15:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/57\">",
"      G&uuml;rakan F, Ko&ccedil;ak N, Ozen H, Y&uuml;ce A. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatr Infect Dis J 2000; 19:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/58\">",
"      Lai CL, Lok AS, Lin HJ, et al. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet 1987; 2:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/59\">",
"      Lai CL, Lin HJ, Lau JN, et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991; 78:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/60\">",
"      Iorio R, Pensati P, Botta S, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997; 16:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/61\">",
"      Liberek A, ï¿½ï¿½uczak G, Korzon M, et al. Tolerance of interferon-alpha therapy in children with chronic hepatitis B. J Paediatr Child Health 2004; 40:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/62\">",
"      Gottrand F, Michaud L, Guimber D, et al. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996; 155:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/63\">",
"      Comanor L, Minor J, Conjeevaram HS, et al. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. J Viral Hepat 2001; 8:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/64\">",
"      Ko&ccedil;ak N, G&uuml;rakan F, Saltik IN, et al. Long-term prognosis of interferon nonresponder children with hepatitis B. Am J Gastroenterol 2000; 95:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/65\">",
"      Ballauff A, Schneider T, Gerner P, et al. Safety and efficacy of interferon retreatment in children with chronic hepatitis B. Eur J Pediatr 1998; 157:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/66\">",
"      Sokal EM, Kelly DA, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006; 43:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/67\">",
"      Hom X, Little NR, Gardner SD, Jonas MM. Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J 2004; 23:441.",
"     </a>",
"    </li>",
"    <li>",
"     Jonas, MM, Little, NR, Gardner, SD. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. J Viral Hepat 2007; In press. Abstract available at: www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2893.2007.00891.x (Accessed on November 19, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/69\">",
"      D'Antiga L, Aw M, Atkins M, et al. Combined lamivudine/interferon-alpha treatment in \"immunotolerant\" children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006; 148:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/70\">",
"      Dikici B, Ozgenc F, Kalayci AG, et al. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study. J Gastroenterol Hepatol 2004; 19:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/71\">",
"      Chu M, Cho SM, Choe BH, et al. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. J Pediatr Gastroenterol Nutr 2012; 55:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/41/31386/abstract/72\">",
"      Murray KF, Szenborn L, Wysocki J, et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56:2018.",
"     </a>",
"    </li>",
"    <li>",
"     Chang M-H, Kelly D, Kerkar N, Jonas M, Rosenthal P, and Bifano M. Entecavir pharmacokinetics among nucleos(t)ide-naive pediatric subjects. Poster presentation at the Fourth World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, 2012; Taipei, Taiwan.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5943 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31386=[""].join("\n");
var outline_f30_41_31386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WHO SHOULD BE SCREENED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acute HBV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic HBV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Phases of chronic HBV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Immune tolerant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Immune active (clearance)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Inactive carrier",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Resolution of infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Reactivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Progression to cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT OF CHRONIC HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Counseling and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Monitoring of patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Disease activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - HCC surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Selection of patients for treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CHOICE OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pegylated interferon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Non-responders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Lamivudine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Combination therapy with IFN alfa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Adefovir dipivoxil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9979439\">",
"      Newer agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      MANAGEMENT OF ACUTE HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      IMMUNOPROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5943\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5943|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/61/976\" title=\"algorithm 1\">",
"      Algorithm treatment HBV children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5943|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/43/6838\" title=\"figure 1\">",
"      HBV risk map",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42398\" title=\"figure 2\">",
"      Serology acute and chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28466\" title=\"figure 3A\">",
"      Phases of perinatally acquired hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/24/9614\" title=\"figure 3B\">",
"      Course perinatal chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5943|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/60/41932\" title=\"table 1A\">",
"      Serologic markers HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/45/2781\" title=\"table 1B\">",
"      Interpretation of the Hepatitis B panel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/47/21245\" title=\"table 2\">",
"      Approach HBV summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/28/30155\" title=\"table 3\">",
"      Lamivudine HBV children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=related_link\">",
"      Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=related_link\">",
"      Characteristics of the hepatitis B virus and pathogenesis of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=related_link\">",
"      Clinical significance of hepatitis B virus genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=related_link\">",
"      Combination therapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23097?source=related_link\">",
"      Gianotti-Crosti syndrome (papular acrodermatitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37881?source=related_link\">",
"      Hepatitis viruses and the newborn: Clinical manifestations and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23030?source=related_link\">",
"      Investigational treatments of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=related_link\">",
"      Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_41_31387="Risk classific exercise class D";
var content_f30_41_31387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk classification for exercise training: class D: unstable disease with activity restriction*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        This classification includes individuals with any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Unstable ischemia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Severe and symptomatic valvular stenosis or regurgitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Congenital heart disease; criteria for risk that would prohibit exercise conditioning in patients with congenital heart disease should be guided by the 27th Bethesda Conference recommendations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Heart failure that is not compensated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Uncontrolled arrhythmias.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Other medical conditions that could be aggravated by exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activity guidelines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. No activity is recommended for conditioning purposes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Attention should be directed to treating the patient and restoring the patient to Class C or better.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Daily activities must be prescribed on the basis of individual assessment by the patient's personal physician.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Exercise for conditioning purposes is not recommended.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31387=[""].join("\n");
var outline_f30_41_31387=null;
var title_f30_41_31388="SNRIs - Doses for treating unipolar depression";
var content_f30_41_31388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F88068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F88068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Serotonin-norepinephrine reuptake inhibitors (SNRIs): Doses for treating unipolar depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual starting dose",
"        <br/>",
"        (mg per day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual daily dose",
"        <br/>",
"        (mg per day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Extreme daily dose*",
"        <br/>",
"        (mg per day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desvenlafaxine",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        50 to 100",
"       </td>",
"       <td class=\"centered\">",
"        50 to 400",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duloxetine",
"       </td>",
"       <td class=\"centered\">",
"        30 to 60",
"       </td>",
"       <td class=\"centered\">",
"        30 to 60",
"       </td>",
"       <td class=\"centered\">",
"        30 to 120",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milnacipran",
"       </td>",
"       <td class=\"centered\">",
"        12.5",
"       </td>",
"       <td class=\"centered\">",
"        100 to 200",
"       </td>",
"       <td class=\"centered\">",
"        50 to 300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Venlafaxine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immediate release",
"       </td>",
"       <td class=\"centered\">",
"        37.5 to 75",
"       </td>",
"       <td class=\"centered\">",
"        75 to 375",
"       </td>",
"       <td class=\"centered\">",
"        75 to 450",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extended release",
"       </td>",
"       <td class=\"centered\">",
"        37.5",
"       </td>",
"       <td class=\"centered\">",
"        75 to 225",
"       </td>",
"       <td class=\"centered\">",
"        75 to 225",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Lower doses are often used for elderly, medically compromised (eg, renal or hepatic illness), or drug sensitive patients, as well as patients with a low body mass index. High doses may be used for medications that are well tolerated but ineffective at lower doses.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Although doses up to 400 mg per day have been studied, there is no evidence that doses &gt;50 mg per day provide any additional benefit.",
"     <br/>",
"     &Delta; Although doses up to 120 mg per day have been used, there is no evidence that doses &gt;60 mg per day provide any additional benefit.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <ol>",
"        <li>",
"         DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007; 68:677",
"        </li>",
"        <li>",
"         Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"        </li>",
"        <li>",
"         Labbate LA, Fava M, Rosenbaum JF, Arana GW. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams and Wilkins, Philadelphia 2010. p.54.",
"        </li>",
"       </ol>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31388=[""].join("\n");
var outline_f30_41_31388=null;
var title_f30_41_31389="Compliance bias";
var content_f30_41_31389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Effect of patient compliance on the results of a screening program",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 268px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The control group of patients has a lower standardized mortality ratio (observed: expected deaths, standardized for age) than the study group offered screening; but the control group included only patients who requested screening, whereas the study group included all patients offered screening, both those who wanted it and those who did not.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Originally redrawn from Friedman GD, Collen MP, Fireman BH. Multiphasic health checkup evaluation: A 16-year follow-up. J Chron Dis 1986; 39:453. Reproduced with permission from: Fletcher RF, Fletcher SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed, Lippincott Williams &amp; Wilkins, Baltimore, 2005.&nbsp;Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31389=[""].join("\n");
var outline_f30_41_31389=null;
var title_f30_41_31390="Diarrhea chronic child";
var content_f30_41_31390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Diarrhea: Chronic in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <span style=\"color:#ff0000\">",
"     Red:",
"    </span>",
"    life-threatening cause.",
"    <br>",
"     <span style=\"color:#008000\">",
"      Green:",
"     </span>",
"     common cause.",
"     <div class=\"footnotes\">",
"      * Symptoms typically &gt;1 month in duration.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       More likely in older children and adolescents.",
"       <br>",
"        &Delta; Only in infants.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         More likely in infants and young children.",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31390=[""].join("\n");
var outline_f30_41_31390=null;
var title_f30_41_31391="Airway in hyperextension";
var content_f30_41_31391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Airway changes with hyperextension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During the chin lift procedure, care must be taken to avoid hyperextending the neck, which may cause airway obstruction (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_41_31391=[""].join("\n");
var outline_f30_41_31391=null;
